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Note to the reader 
 
As far as possible, I have written this thesis in the active voice. Using the 
active voice raised the issue of whether to use the first-person singular – ‘I’– 
or first-person plural – ’we’, with the former potentially distracting and less 
readable, but the latter seeming out of place in a PhD thesis where the work 
is the product of one person. I have elected to use the less distracting ‘we’ 
when talking about what I have done in the active voice to improve the 
readability of the text. However, for the record, I wish to make it clear that 
the use of ‘we’ in this thesis implies that ‘I’ have done something. 
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Summary 
 
Urinary tract infection (UTI) is a common cause of morbidity, NHS use, and 
antibiotic prescribing in older people. However, few randomised trials or 
observational studies have explored the impact of different antibiotic 
prescribing strategies on UTI-related outcomes in older people. Routinely 
collected healthcare data provides an opportunity to investigate 
associations between different treatment approaches and outcomes 
efficiently and cost-effectively. 
The aim of this thesis was to carry out epidemiological analyses of linked 
general practice, hospital, and mortality data from the Clinical Practice 
Research Datalink, to understand the impact of different antibiotic 
prescribing strategies on outcomes in older people with acute and recurrent 
UTI.  
In chapter 4, we investigate the burden of clinically diagnosed UTI in older 
people in UK primary care and found that in a sample of adults aged ≥65, 
21% present with at least one UTI over a 10-year period. We also found that 
choice and duration of antibiotic therapy improved over time. For example, 
between 2004 and 2014, nitrofurantoin prescribing increased, broad-
spectrum antibiotic prescribing decreased, and there was an increase in the 
proportion of patients prescribed antibiotics for durations recommended by 
clinical guidelines. In chapters 5 and 7, we investigate associations between 
antibiotic choice and risk of treatment failure, hospitalisation and death. We 
xxv 
 
found that broad-spectrum antibiotics offer little benefit over nitrofurantoin, 
and nitrofurantoin is associated with better outcomes than trimethoprim in 
patients with renal impairment. Chapter 6 investigates the impact of short 
versus long course antibiotic treatment on UTI outcomes in older men and 
found that shorter durations of treatment are associated with higher rates of 
treatment failure but lower rates of acute kidney injury. Chapter 8 reports a 
systematic review and meta-analysis of randomised trials and found that the 
evidence for prophylactic antibiotics for recurrent UTI in older people is 
based on three studies of postmenopausal women. In chapter 9, we provide 
the only currently available data on outcomes in older men with recurrent 
UTI prescribed long-term antibiotic prophylaxis. 
This thesis reports new evidence to support more prudent antibiotic 
prescribing for UTI in older people and highlights the need for more robust 
evidence to address challenges in diagnosis and treatment of UTI. 
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1 Introduction  
 
In 2011, the Annual Report of the Chief Medical Officer to the UK 
Government focussed on infections and the rise of antimicrobial resistance 
(1). The report was instrumental in generating political interest in the global 
public health threat of antimicrobial resistance, and led to a National Institute 
of Health Research themed funding call. The research reported in this thesis 
was funded by that call and examines antibiotic prescribing for urinary tract 
infection (UTI) in older people, with the aim of generating new evidence that 
improves antibiotic use and ultimately helps to contain antibiotic resistance.   
1.1 Urinary tract infection in older people 
UTI refers to infection in the bladder, kidneys, or other part of urinary tract, 
most commonly cause by gram-negative bacteria ascending through the 
urethra. It can be classified according to the presence of fever, the 
anatomical location, or presence of factors that increase patients’ 
susceptibility to UTI or UTI-related complications. Prevention and acute 
treatment of UTI is the commonest reason for antibiotic prescribing in older 
people (2, 3). UTIs can present with non-specific symptoms and signs in 
older people and there are concerns that this has led to over-diagnosis and 
over-treatment (4, 5). Urine culture is less useful because it is more difficult 
to get an uncontaminated sample from older people, and because the 
prevalence of asymptomatic bacteriuria increases with age (6). Therefore, 
an older person with acute confusion and significant bacterial growth in their 
urine culture may not have a UTI, but may be diagnosed and treated for a 
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UTI. However, under-treatment of UTI is also problematic and is thought to 
be a contributor to the increasing rates of blood-stream infection observed 
in older people in certain parts of England (7).  UK hospital data suggest 
that the overall burden of UTI in older people has increased. The number of 
emergency admissions of older people with a primary diagnosis of UTI rose 
from 35,800 in 2001 to 107,300 in 2012, an increase of 200% (8). This is a 
substantial increase in burden, even if some of this increase is due to 
changes in coding practices. 
1.2 Antibiotic resistance 
The global threat of antibiotic resistance is well recognised, with an 
estimated 700,000 deaths attributed to antibiotic resistant infections 
annually (9). The estimated economic impact is expected to reach US$100 
trillion by 2050 (9) . The European Antimicrobial Resistance Surveillance 
Network estimated that there were 671,689 antibiotic resistant infections 
across participating European countries between January 1st and 
December 31st 2015. These infections accounted for 33,110 deaths and 
874,541 disability-adjusted life-years. The burden was highest in infants 
(age <1 year) and older people (age >65 years) (10).  
Prior antibiotic exposure is the most widely studied risk factor for antibiotic 
resistance, with most studies reporting a greater than two-fold increase for 
the risk of antibiotic resistant infections in those previously exposed to 
antibiotics versus those unexposed (11). In primary care, prior prescribing 
of antibiotics for UTI increased the risk of antibiotic resistant urinary 
pathogens by four-fold in the subsequent 30 days and by two-fold at six-
months (12).  Therefore, co-ordinated actions to minimise antibiotic 
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resistance include antibiotic stewardship; prescribing antibiotics only when 
absolutely necessary and prescribing the most appropriate antibiotic, at the 
most appropriate dose and for the most appropriate duration (13). The aim 
is for more prudent prescribing to help preserve the effectiveness and value 
of existing antibiotics. 
1.3 Rationale for this thesis 
This thesis presents a series of complementary observational studies 
investigating antibiotic prescribing and subsequent outcomes in older 
people who presented to primary care with a suspected UTI. The 
overarching hypothesis is that variation in the choice and duration of 
antibiotic prescribing for UTI in older people is unwarranted and has little 
impact on their clinical outcomes. This presents an opportunity to improve 
the use of existing antibiotics by generating new evidence that could support 
more standardised and prudent prescribing. 
We chose primary care as the setting as it is responsible for 90% of patient 
contacts and 75% of antibiotic prescribing in the UK NHS (14). We chose to 
study UTI because 75-90% of patients with suspected UTI are prescribed 
an empirical antibiotic without microbiological confirmation of infection or 
results of antibiotic susceptibilities, (15, 16)  therefore presenting an 
opportunity to improve the choice of the initial empirical prescription. 
Furthermore, UTI accounts for about 15% of all antibiotic prescriptions in 
primary care, (17) so small changes in prescribing behaviour could have 
considerable impact at a population level. We chose older people (defined 
as age ≥65 years) for three reasons. First, because of data reporting a rise 
in UTI hospital admissions in this age group (13). Second, because clinical 
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guidelines excluded older people from most recommendations for the 
management of UTI (18, 19). Third, because the Chief Medical Officer’s 
report stated that this age group would present the greatest growth in the 
burden of infectious disease and that, within this group, UTI was one of the 
three most important infection-related morbidities along with healthcare-
associated infection and influenza (1).  
1.4 Thesis outline 
Figure 1.1 outlines the organisation of this thesis. Chapter 2 presents a 
literature review that appraises published studies reporting the incidence, 
diagnosis, clinical management and outcomes of older people with UTI. We 
highlight key evidence gaps and summarise how these informed the aims 
and objectives of this thesis. These are listed at the end of the chapter. 
Chapter 3 describes the research methods. We justify the choice of data 
source and approach to data analysis, including methods used to adjust for 
confounding and other biases inherent in observational research. 
Chapters 4-9 describe the results. We present detailed information 
regarding the background and methods for the results chapters in chapters 
2 and 3. Therefore, we only briefly summarise the key points at the start of 
each results chapter to prevent unnecessary repetition. The discussion for 
each results chapter is presented in full. In chapter 4, we present the 
findings on trends in the incidence of UTI in primary care over a 10-year 
study period. We also report trends in antibiotic prescribing for UTI over this 
period. Chapters 5 and 6 focus on variation in antibiotic prescribing and 
impact on patient outcomes. We report associations between the choice 
5 
 
and duration of empirical antibiotic prescribing and several adverse 
outcomes. Chapter 7 examines if variation is warranted in patients with renal 
impairment, and investigates outcomes in patients prescribed trimethoprim 
versus nitrofurantoin by degree of kidney function. Chapters 8 and 9 focus 
on recurrent UTI and report a systematic review and meta-analysis of 
randomised trials of antibiotic prophylaxis versus non-antibiotic prophylaxis 
or placebo, and an observational study of prophylaxis versus no 
prophylaxis.   
In chapter 10, we summarise the key findings. We appraise our research, 
and reflect on its strengths and weaknesses, and the lessons learnt. We 
also present implications for future research and practice. 
 
Figure 1.1. Organisation of chapters in this thesis. 
6 
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2 Literature review 
 
2.1 Introduction 
This aim of this chapter is to present an overview of published evidence 
relevant to the objectives of this thesis, to highlight evidence gaps, and to 
contextualise the primary research studies presented in later chapters. We 
searched PubMed from January 1980 to April 2018 for English language 
studies reporting on UTI in older people in primary care using relevant 
search terms related to UTI (e.g., Urinary tract infection* OR cystitis) and 
older people (e.g., old* OR elder OR aged). We combined these terms with 
keywords for each specific objective, e.g., to identify studies reporting the 
incidence of UTI in older people, we combined the search terms related to 
UTI and older people with “incidence” OR “prevalence”. We used the same 
method to identify studies on antibiotic prescribing for UTI (search terms 
were “antibiotic* OR antimicrobial*”), diagnosis of UTI (search term was 
“diagnos*”), recurrent UTI (search term was “recurrent”), and renal 
impairment in UTI (search terms were “renal impairment OR acute kidney 
injury”). We screened titles and abstracts and removed studies that were 
not related to the clinical management of UTI in primary care. We reviewed 
full-text papers of the remaining studies to identify those for inclusion in this 
review. We included studies that were either directly relevant to the 
objectives of this thesis, or were important to help contextualise the 
background and rationale for the empirical studies in chapters 4-9. For 
objectives where no studies were identified, we re-searched but without 
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restricting to older people and identified relevant studies that included adults 
of any age. We clarify in the text whether the evidence presented comes 
from studies of older people or from adults of all ages. When reporting the 
studies, we present data from systematic reviews first (if available), then 
randomised trials (if they add additional information), and then observational 
studies (if they add additional information).  
2.2 Definition and classification of UTI 
UTI is an umbrella term that can refer to infection in the bladder (cystitis), 
kidneys (pyelonephritis), or other part of urinary tract. It can be classified 
according to the presence of fever (febrile versus non-febrile UTI), 
anatomical location (lower versus upper UTI), or presence of factors that 
increase patients’ susceptibility to UTI or UTI-related complications 
(complicated versus uncomplicated) (20). The Infectious Disease Society of 
America and European Society for Microbiology and Infectious Diseases 
define uncomplicated lower UTI as cystitis occurring in non-pregnant, pre-
menopausal women with no known relevant anatomical or functional 
abnormalities within the urinary tract, or comorbidities that could pre-
dispose to UTI or UTI-related complications (18).  Complicated lower UTI 
therefore includes UTI in men, pregnant or post-menopausal women, and 
in patients with relevant anatomical or functional abnormalities of the urinary 
tract, indwelling urinary catheters, renal diseases, and/or other concomitant 
immunocompromising diseases.  
In 2011, the European Association of Urology argued that most UTIs are 
uncomplicated and the widely used definition of complicated UTI included 
many individuals with no excess risk of an adverse outcome (21). They 
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proposed a new classification of UTI that defined uncomplicated and 
complicated according to the severity of clinical presentation (from 
asymptomatic bacteriuria to sepsis), and number and severity of host risk 
factors for an adverse outcome (Figure 2.1) (22).  
A consistent and widely accepted classification of UTI is important for 
clinical practice because most clinical guidelines restrict their 
recommendations to uncomplicated UTI. Therefore, clinicians may treat 
patients presenting with what they judge to be complicated UTI outside of 
these guidelines. Based on The Infectious Disease Society of America 
guidelines, this includes all men and all adults aged ≥65 years, and may 
partly explain the observed variation in antibiotic prescribing for UTI seen in 
this population.  
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Figure 2.1. Classification of complicated and uncomplicated UTI as proposed by the 
European Association of Urology. ABU = asymptomatic bacteriuria; CT = computed 
tomography; CY = cystitis;                            IV = intravenous; MSU = midstream sample of 
urine; PN = pyelonephritis; US = urosepsis. Reproduced with permission from Smelov et 
al, European Urology Supplements (22), license number 4450771360815. 
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2.3 Incidence of UTI  
Over a third of a random sample of 2424 females in England reported having 
had at least one UTI in their lifetime, and this varied by age group (16–34 
years, 36%; 35–54 years, 42%; and 55+ years, 33%) (15). Published 
estimates of the incidence of UTI in older people vary in their design and 
methods. The Pittsburgh Good Health Study followed 417 adults aged ≥65 
from July 1986 to June 1988 and estimated UTI incidence to be 10.9 
episodes per 100 person-years in men, and 14.0 episodes per 100 person-
years in women (23). They defined UTI as a presentation with urinary tract 
symptoms that included dysuria and urinary frequency but did not include 
confirmatory urine culture. These estimates are almost 20 years old and do 
not adequately reflect current population demographics or recent trends in 
health service use related to an aging population. However, the estimates 
are similar to those of the more recent Leiden 85-plus study (24). This study 
recruited 479 adults aged ≥85 and followed them for 4 years. UTI was 
defined by physician diagnosis and corroborating urine analysis. UTI 
incidence rates were 7.8 per 100 person-years in men and 12.8 per 100 
person-years in women. The small sample size prevented meaningful 
analysis of trends over time. 
UK based estimates are limited to a study of older patients with type 2 
diabetes mellitus. McDonald and colleagues used the Clinical Practice 
Research Datalink (CPRD) to identify clinically diagnosed infections using 
clinical codes (25). They estimated UTI incidence to range from 2.94 (age 
65-69) to 14.1 (age ≥85) episodes per 100 person-years in men, and 11.0 
(age 65-69) to 22.3 (age ≥85) episodes per 100 person-years in women. 
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However, these estimates are likely to be higher than for the general 
population of older people due to the higher incidence of UTI in people with 
type 2 diabetes mellitus (26). 
In summary, population-based estimates of UTI incidence in older people 
are limited to two studies from the USA and The Netherlands with follow-up 
of 2-4 years, and incidence estimates of 8-11 per 100 person years in older 
men, and 13-14 per 100 person years in older women (23, 24). UK 
estimates are more granular but are limited to older people with type 2 
diabetes mellitus (25). Therefore, we still need reliable current population-
based estimates of the incidence of UTI in older people, in a longitudinal 
sample that is large enough to identify trends over time and is generalisable 
to the UK over-65 population.  These estimates will increase understanding 
of UTI burden, inform health service planning, and allowing prioritisation of 
resources for prevention and management. 
2.4 Pathophysiology 
The pathogenesis of UTI is described in detail in Figure 2.2. Most 
uncomplicated UTIs arise from microorganisms ascending through the 
urethra, although some microorganisms can reach the urinary tract by 
hematogenous or lymphatic spread (20). In adults of all ages, E. coli is the 
causative pathogen in 70–95% of uncomplicated UTIs, Staphylococcus in 
5–10%  and other Enterobacteriaceae, such as Proteus mirabilis and 
Klebsiella, in the remainder. The microbial spectrum of complicated UTIs is 
broader and includes species of Pseudomonas, Enterococcus, 
Staphylococcus, Serratia, and Providencia and fungi (20). 
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The microbiology of UTI in older adults is less well described. A Brazilian 
study of 598 women aged ≥65 presenting to primary care or nephrology 
outpatients with symptoms of UTI identified 99 urine cultures with bacterial 
growth of >100,000 colony-forming units/mL (27). The predominant 
bacterial species were E.coli (75%), Enterococcus (9%), Proteus mirabilis 
(6%), Klebsiela (5%), Staphylococcus (3%) and Citrobacter (1%). In 
contrast, a study of 171 US nursing home residents with suspected UTI 
found that E.coli was isolated in 54%, Proteus in 15%, Klebsiella in 14%, 
other Enterobacteraciaeae in 6%, Enterococcus in 4.5%, and 
Staphylococcus in 4% (28). However, this included samples with bacterial 
growth of a little as 10,000 colony-forming units/mL. 
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Figure 2.2. Pathogenesis of urinary tract infections. 
a | Uncomplicated urinary tract infections (UTIs) begin when uropathogens that reside in 
the gut contaminate the periurethral area (step 1) and are able to colonize the urethra. 
Subsequent migration to the bladder (step 2) and expression of pili and adhesins results in 
colonization and invasion of the superficial umbrella cells (step 3). Host inflammatory 
responses, including neutrophil infiltration (step 4), begin to clear extracellular bacteria. 
Some bacteria evade the immune system, either through host cell invasion or through 
morphological changes that result in resistance to neutrophils, and these bacteria undergo 
multiplication (step 5) and biofilm formation (step 6). These bacteria produce toxins and 
proteases that induce host cell damage (step 7), releasing essential nutrients that promote 
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bacterial survival and ascension to the kidneys (step 8). Kidney colonization (step 9) results 
in bacterial toxin production and host tissue damage (step 10). If left untreated, UTIs can 
ultimately progress to bacteraemia if the pathogen crosses the tubular epithelial barrier in 
the kidneys (step 11). b | Uropathogens that cause complicated UTIs follow the same initial 
steps as those described for uncomplicated infections, including periurethral colonization 
(step 1), progression to the urethra and migration to the bladder (step 2). However, in order 
for the pathogens to cause infection, the bladder must be compromised. The most common 
cause of a compromised bladder is catheterization. Owing to the robust immune response 
induced by catheterization (step 3), fibrinogen accumulates on the catheter, providing an 
ideal environment for the attachment of uropathogens that express fibrinogen-binding 
proteins. Infection induces neutrophil infiltration (step 4), but after their initial attachment to 
the fibrinogen-coated catheters, the bacteria multiply (step 5), form biofilms (step 6), 
promote epithelial damage (step 7) and can seed infection of the kidneys (steps 8 and 9), 
where toxin production induces tissue damage (step 10). If left untreated, uropathogens 
that cause complicated UTIs can also progress to bacteraemia by crossing the tubular 
epithelial cell barrier (step 11). Reproduced with permission from Flores-Mireles et al, 
Nature Reviews Microbiology (20), license number 4450770317355. 
2.5 Clinical guideline recommendations for UTI in older people 
The Scottish Intercollegiate Guidelines Network (SIGN) produced the first 
comprehensive UK clinical guideline for the management of adult bacterial 
UTI in 2006 (29). SIGN presented their guidance as applicable to four 
groups: adult non-pregnant women, pregnant women, adult men, and 
people with indwelling urinary catheters. The guideline specifically stated 
that all adults aged ≥65 presenting with suspected UTI should have a full 
clinical assessment including measurement and recording of vital signs. 
There were no other recommendations specific to older adults but the 
following statements were applicable to this age-group: 
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1. No antibiotic treatment for men and non-pregnant women  with 
asymptomatic bacteriuria, 
2. All adult men (of any age) presenting with a UTI to have urine 
sampled and sent for culture, 
3. All adult men and non-pregnant women with lower UTI to be treated 
with trimethoprim or nitrofurantoin as first-line, 
4. All adult non-pregnant women (of any age) with lower UTI to be 
treated with three-day antibiotic therapy. 
Shortly after publication of the SIGN guidelines, Public Health England (then 
known as the Health Protection Agency) published their first guideline for 
the management of UTI in November 2007 (30). Their guideline focused 
more on UTI diagnosis and discussed the challenges of accurate diagnosis 
of UTI in older people given the less specific symptoms and signs, the 
difficulties around urine sampling, and the prevalence of asymptomatic 
bacteriuria. They encouraged a more criteria-based approach to UTI 
diagnosis in older people. These two guidelines were the main sources of 
UTI management recommendations during the period of study in the 
empirical studies presented later in this thesis. Subsequent iterations of the 
Public Health England guideline increased the detail of the 
recommendations for diagnosing UTI in older adults. The current version 
(published April 2019) contains a comprehensive checklist of symptoms and 
signs needed to satisfy a diagnosis of UTI. There is also clear guidance to 
not use urine dipstick in older adults (to align with a national campaign to 
reduce unnecessary urine dipstick use in the frail elderly), and reminders to 
consider sepsis, delirium and other causes of the clinical presentation (31). 
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Public Health England recommend considering delayed antibiotics for older 
adults with mild symptoms but specific recommendations regarding 
antibiotic treatment are not made as these are presented in the current 
National Institute of Health and Care Excellence (NICE) guidance for 
antimicrobial prescribing for lower UTI. NICE published these guidelines in 
October 2018 and recommend nitrofurantoin or trimethoprim (if risk of 
trimethoprim resistance is low) as first-line antibiotic treatment for adult men 
and non-pregnant adult women (32). Second-line options include 
pivmecillinam and fosfomycin. NICE also produced guidance on the 
treatment of recurrent UTI in October 2018 (33). Key recommendations 
include: 
1. Discussing with patients behavioural and hygiene measures that 
may reduce the risk of UTI recurrence, 
2. Considering vaginal oestrogens for postmenopausal women with 
recurrent UTI in whom behavioural and hygiene measures are not 
effective, 
3. Considering a trial of daily antibiotic prophylaxis in patients where the 
above measures have failed to reduce UTI incidence. 
If prescribing daily antibiotic prophylaxis, NICE recommend trimethoprim or 
nitrofurantoin as first-line with a review of their effect at six months. 
2.6 Diagnosis of UTI 
Accurate diagnosis of UTI is challenging in older adults. One aim of accurate 
diagnosis is to help decide whether a specific treatment is required. In the 
case of UTI, that treatment would be antibiotics +/- additional supportive or 
symptomatic measures such as analgesics. The pathway to UTI diagnosis 
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in primary care usually involves patients consulting with symptoms and 
signs of illness, a clinical decision about whether or not to sample urine, 
perform point-of-care urinalysis, and send urine for laboratory microscopy 
and culture. This is followed by a decision to prescribe (or not prescribe) 
antibiotics, either empirically without microbiological confirmation of 
infecting organism or antibiotic susceptibilities, or following results of urine 
culture.   
Few symptoms or signs are predictive of laboratory confirmed UTI in older 
people. A systematic review of 15 diagnostic studies of people aged ≥65 
investigated the predictive value of 66 different symptoms and signs (34). 
Studies varied in quality, and in their definition of symptoms and signs, 
meaning that only a few symptoms and signs were appropriate for meta-
analysis. Only one study included men. All studies used urine culture, either 
alone or in combination with symptoms and signs as the reference standard. 
Among studies that used urine culture alone as the reference standard, 
there was little discussion about the limitations of their approach given the 
prevalence of asymptomatic bacteriuria in this older population. Among 
studies that used signs or symptoms and urine culture as the reference 
standard, it was not clear how they dealt with the issue of index tests being 
part of the reference test. Almost all studies had missing reference test data 
(i.e. missing urine cultures). Pooled estimates from six studies identified the 
presence of new urinary incontinence (positive likelihood ratio 1.96) and 
dysuria (positive likelihood ratio 1.70) as predictive of the reference test. 
Incontinence, foul smelling urine and haematuria were predictors of the 
reference test in men, but not in women. Acute changes in functional status 
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were strong predictors of the reference test in both genders, but changes in 
cognition were not. Abnormal vital signs (fever, tachycardia and 
hypotension) were of limited value. Overall, the review highlights the 
methodological challenges of diagnostic accuracy studies of UTI in older 
people, especially given the lack of an ideal reference standard, and the 
clinical challenge of using symptoms and signs to select patients who may 
have a UTI and thus require urine sampling or antibiotic treatment. 
In patients with appropriate symptoms, urine sampling and urinalysis +/- 
urine culture may help to support or refute the diagnosis of UTI. Two US 
studies investigated the reason for urine sampling in nursing home residents 
and found that factors most commonly associated with urine sampling 
requests were acute changes in cognition or function, change in the urine 
colour, odour, or sediment, and dysuria (35, 36). The diagnostic accuracy 
of urinalysis in older adults is unclear. A meta-analysis of four studies of 
older people conducted between 1990 and 1999 found that the presence of 
nitrites or leukocyte esterase on urinalysis had sensitivity and specificity for 
UTI of 82% and 71% respectively (37). More recent studies of older patients 
found that the negative predictive value for dipstick testing ranges from 92% 
to 100% (38-40). Given the variable test characteristics in older people, 
current thinking suggests that urinalysis should be performed in the 
community setting primarily to rule out a diagnosis of UTI (41).  
Urine culture is currently used to confirm the presence of bacteriuria in 
patients with symptoms and signs of a UTI and thus support a diagnosis of 
UTI. Urine culture in older adults is less useful because of high rates of 
contaminated samples that may mask true positives and true negatives, and 
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make interpretation difficult. Interpretation of urine culture results is based 
on findings from studies conducted in the 1950s (42). Current guidance from 
Public Health England is that urine cultures with bacterial counts of 
≥100,000 cfu/mL are indicative of infection, and counts below this usually 
indicate contamination. However, in specific patient groups, counts between 
10,000 cfu/mL and 100,000 cfu/mL may also be significant. Furthermore, a 
pure isolate with counts between 10,000-100,000 cfu/mL should be 
evaluated based on clinical information or confirmed by repeat culture (43).  
Urine cultures may be requested in patients without symptoms or signs of 
UTI and may show bacterial growth.  Asymptomatic bacteriuria (ABU) is 
defined as the presence of bacteria in the urine in quantities of >100,000 
cfu/mL in two consecutive urine specimens in women or one urine specimen 
in men, in the absence of clinical signs or symptoms suggestive of a UTI 
(44). The estimated prevalence of ABU is 6-10% in women and 5% in men 
older than 65, increasing to 20% in women and 10% in men over 85 (45). 
The prevalence is higher in institutionalized adults with estimates ranging 
from 25-50% for women and 15-35% for men (6). A systematic review and 
meta-analysis of seven randomised and two quasi-randomised trials (1614 
participants, seven studies only included adults aged ≥65) found no 
difference in the development of symptomatic UTI, UTI-related 
complications or death in adults with ABU treated with antibiotics versus 
placebo or no treatment (46). Antibiotic treatment resulted in greater rates 
of bacteriological cure but with significantly more adverse events and thus 
had no overall clinical benefit. However, an estimated 45% of adults (of all 
ages) with ABU are thought to be treated with antibiotics, with isolation of 
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gram-negative pathogens, pyuria, nitrite positivity and female gender 
associated with greater odds of receiving treatment (47).  
In summary, common reasons for requesting urine sampling in older people 
are acute changes in cognition or function, change in the urine colour, 
odour, or sediment, and dysuria (35, 36). Of these reasons, current 
evidence suggests only change in function and dysuria are associated with 
bacteriuria (36). Existing diagnostic studies are limited by the challenge of 
obtaining an uncontaminated urine sample, and the prevalence of 
asymptomatic bacteriuria in older people, both of which render urine culture 
an imperfect reference standard. 
2.7 Antibiotic treatment of UTI 
Most people with symptoms or signs suggestive of UTI receive antibiotic 
treatment. Analysis of data from the 2010-2011 US National Ambulatory 
Medical Care Survey and National Hospital Ambulatory Medical Care 
Survey found that same-day empirical antibiotics were prescribed to 65% of 
adults aged ≥65 presenting to ambulatory care with a possible UTI (48). 
There are no published UK data reporting empirical antibiotic prescribing 
rates for older adults with UTI. Analysis of UK primary care data for adults 
of all ages from The Health Improvement Network database found that 92% 
of patients presenting with suspected UTI were prescribed same-day 
empirical antibiotics (16). These patients were aged 14 and over and 
patients with co-morbidities were excluded. Lower prescribing rates were 
reported in a household survey of women aged 16 and over. Of those who 
had seen a healthcare professional for a UTI, 75% reported receiving an 
empirical same-day antibiotic prescription (15).  
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Although same-day antibiotic prescribing is the most common treatment 
strategy employed for patients presenting to primary care with suspected 
UTI, current NICE and Public Health England guidance suggests 
consideration of delayed prescribing for those with milder symptoms (32, 
49). We did not identify any studies investigating the effect of delayed 
antibiotic prescribing for UTI in older people. Evidence for delayed 
prescribing in UTI comes from a trial of 309 women aged <75 presenting to 
primary care with suspected UTI who were randomised to receive 
immediate antibiotics, delayed antibiotics, or targeted antibiotics based on 
urine dipstick, culture, or a symptom score (50).  Women in the delayed 
antibiotic group were advised to drink plenty, and offered a back-up 
antibiotic prescription if symptoms did not improve after 48 hours. There 
were no differences in mean symptom severity 2-4 days after presentation 
or mean symptom duration between women receiving immediate versus 
delayed antibiotics. However, there were differences in antibiotic use, with 
97% of women in the immediate group using antibiotics versus 77% in the 
delayed group.  
Despite the relatively high rates of antibiotic prescribing for patients with 
suspected UTI, few studies have quantified their benefits and harms in older 
adults. Only two (51, 52) of five (51-55) double-blind randomised trials of 
antibiotics versus placebo in women with urinary tract symptoms and 
bacteriuria included women over 65, and none included women over 85. We 
found no trials of antibiotics versus placebo for urinary tract infection in older 
men. Meta-analysis of the five trials in women found that antibiotics were 
more likely to result in clinical cure (1062 patients, odds ratio (OR) 4.81, 
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95% confidence interval (CI) 2.51-9.21) and microbiological eradication 
(967 patients, OR 10.67, 95% CI 2.96-38.43) (56). Furthermore, antibiotic 
treatment reduced microbiological reinfection or relapse by 73% (OR 0.27, 
95% CI 0.13-0.55) but increased the odds of an adverse event by 64% (OR 
1.64, 95% CI 1.10-2.44). It is unlikely that the benefits reported in these 
trials are directly generalisable to a primary care population of older people. 
Most primary care patients are prescribed antibiotics without microbiological 
confirmation of UTI and therefore rates of clinical and microbiological cure 
would differ. Also, the older primary care population may have more co-
morbid conditions and long-term medication use than the trial participants 
and thus, may experience more adverse events, potentially shifting the risk-
benefit balance reported in these trials.    
In summary, immediate antibiotic prescribing is commonly used for patients 
presenting to primary care with suspected UTI. Delayed antibiotic 
prescribing may reduce antibiotic consumption without impacting on illness 
severity or duration, but the current evidence base is limited to one trial that 
did not include people aged over 70. Although meta-analysis of five trials 
found that antibiotics were more likely to result in clinical cure than placebo, 
only two of these included older adults and it remains unclear if the benefits 
seen are generalisable to a primary care population of older men and 
women. 
2.8 Empirical antibiotic choice 
Four systematic reviews summarised results from randomised trials 
comparing clinical outcomes in patients prescribed different antibiotics for 
UTI (57-60). Overall, no clinically important differences were found between 
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trimethoprim, nitrofurantoin, flouroquinolones, beta-lactams, and fosfomycin 
(57-59). Rashes were more common with beta-lactams and trimethoprim 
than other agents. Despite documented concerns, hypersensitivity 
reactions such as pulmonary fibrosis and hepatotoxicity were not observed 
in participants randomised to nitrofurantoin in 27 trials (59). One review also 
reported no clinically important differences between different 
flouroquinolones, but participants randomised to ciprofloxacin experienced 
less adverse events than other flouroquinolones (60). Only one further 
relevant trial was published since these reviews, comparing 5-day 
nitrofurantoin with single dose fosfomycin in women (median age 44, 
interquartile range (IQR) 31-64) (61). Women randomised to nitrofurantoin 
were more likely to report clinical cure at 28 days (70% v 50%). Rates of 
adverse events were low and similar between the two groups. However, 
despite 53 trials with over 20,000 participants, only four trials included 
women over 65, and no trials included men over 65. The trials that included 
women over 65 lacked age related sub-group analyses, meaning effects in 
this population remain relatively unknown.    
2.9 Antibiotic treatment duration 
A systematic review and meta-analysis of 15 randomised trials (1644 
participants) compared outcomes in older patients prescribed different 
durations of antibiotic treatment for UTI (62). Single dose treatment was 
mostly inferior to short (3-6 days) and long (7-14 days) course treatment, 
and resulted in greater risk of persistent symptoms and re-infection two 
weeks after onset. Meta-analysis of four trials of 1210 older women showed 
that 3-6 days of treatment was similar to 7-14 days and resulted in no 
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significant differences in symptom duration, re-infection rates, adverse 
events or patient satisfaction (63-66) . None of these four trials included men 
and three had limitations in methodological quality due to inadequate 
reporting of allocation concealment, blinding, and outcome assessment (63, 
64, 66). Overall, this review provides reasonable quality evidence 
supporting three-day antibiotic therapy for UTI in older women. We found 
no relevant trials published after the search dates for this review.  
In contrast, there is far less evidence to guide antibiotic duration in older 
men. The clinical guideline recommendation of seven-day antibiotic therapy 
is largely based on expert consensus (19, 49, 67). Previous randomised 
trials investigating different antibiotic durations for UTI in men have 
focussed on febrile (68, 69) or complicated UTI (70, 71), where some men 
were recruited following hospital admission or diagnosed with prostatitis or 
pyelonephritis. One further study only included men with spinal cord injury 
(72). Therefore, these trials are not generalisable to the majority of older 
men with community-acquired UTI seen and treated in primary or 
ambulatory care settings. Furthermore, the shortest therapy duration 
investigated in these trials was 7-days. We identified only one observational 
study of short versus long course antibiotic therapy in older men with UTI 
(73). This study of US male Veterans found no difference in the rate of 
clinical recurrence between those prescribed >7-day therapy versus those 
prescribed ≤7 day therapy. However, this study used outpatient data only 
and therefore may have missed men where recurrence was diagnosed via 
a subsequent hospital admission. Therefore, the optimal duration of 
antibiotic therapy for UTI in older men remains unclear and there is a need 
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to understand if shorter courses are as safe and effective as 7-day courses 
in a primary care population. 
2.10 Variation in antibiotic prescribing 
There is variation in the choice of empirical antibiotic prescribing for patients 
presenting to primary care with a suspected UTI (74). Differences in clinical 
guideline recommendations for first-line empirical antibiotics may explain 
some of this variation. For example, UK guidelines generally recommend 
nitrofurantoin or trimethoprim for first-line empirical treatment of UTI, but 
Spanish guidelines include fosfomycin and flouroquinolones as acceptable 
first-line options (75). These differences were observed in the POETIC 
prospective observational study. This study described empirical antibiotic 
prescribing for 797 adult women (median age 45 years) presenting to 
primary care with suspected UTI in Wales, England, Spain and The 
Netherlands (74). In Wales, 76% of empirical antibiotic prescriptions were 
for trimethoprim, compared to 46% in England, 10% in The Netherlands and 
0% in Spain. Fosfomycin comprised 75% of empirical prescriptions in Spain 
but was rarely used in the other three countries. Nitrofurantoin comprised 
80% of empirical prescriptions in The Netherlands, 48% in England, 20% in 
Wales, and only 3% in Spain. Use of co-amoxiclav or flouroquinolones was 
low in Wales, England and The Netherlands, but higher in Spain. 
Importantly, the study found that differences in prescribing were not due to 
differences in severity of presentation or prevalence of co-morbidities, and 
had no impact on clinical recovery, suggesting the variation was 
unwarranted. However, this study included only younger women and it is 
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not known if similar variation in older adults with a higher prevalence of co-
morbid conditions would impact on clinical outcomes. 
Prescribing also varies between countries where clinical guidelines are 
similar. For example, UK guidelines are similar to those in the USA. Both 
currently recommend nitrofurantoin or trimethoprim as first-line treatments 
depending on patients’ renal function and local resistance levels, followed 
by pivmecillinam or fosfomycin, with other agents reserved for situations 
where aforementioned antibiotics are inappropriate. However, recent US 
data suggest flouroquinolones account for around 50% of empirical 
prescriptions for UTI, trimethoprim-sulfamethoxazole for around 23%, 
nitrofurantoin for 24% and other antibiotics for the remaining 3% (76). There 
are no data specifically for older people, but age over 65 was associated 
with a 2.5 fold increase in the odds of receiving a flouroquinolone 
prescription (76). These data suggest differences in clinical guidelines are 
not the sole reason for variation in prescribing. Qualitative work suggested 
that primary care clinicians were more likely to consider second-line 
antibiotics for older patients, who were frail, had co-morbidities, and were 
judged to have more severe illness (77). The perceived aim of broad-
spectrum antibiotic prescribing was to prevent treatment failure, worsening 
illness, and hospitalisation, events thought to be more likely if first-line 
antibiotics were prescribed for that clinical scenario. These findings are 
supported by quantitative analyses showing that increasing age and number 
of co-morbidities are associated with increased odds of overall antibiotic 
prescribing (78), and of broad-spectrum antibiotic prescribing (79).  
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In summary, antibiotic prescribing for UTI varies and this variation is not 
completely accounted for by differences in clinical guideline 
recommendations. There is no evidence to suggest that this variation results 
in better outcomes. Some of the variation may be accounted for by clinician 
behaviour and clinical judgement, with clinicians preferring broad-spectrum 
antibiotics in older frailer patients whom they judge to be more severely 
unwell. 
2.11 Antibiotic prescribing for UTI in patients with renal impairment 
Prescribing for UTI in renal impairment warrants additional discussion 
because the two commonly recommended first-line antibiotics, 
nitrofurantoin and trimethoprim, are not always appropriate. Numerous 
large observational studies have found an association between 
trimethoprim prescribing (with and without sulfamethoxazole) and 
hyperkalaemia, hospital admission for acute kidney injury, and sudden 
death (80-84). About 20% of older people in England have chronic kidney 
disease stages 3 to 5 (85) (Table 2.1) and this degree of renal impairment 
is associated with an increased risk of end-stage renal disease (86). 
Therefore, some variation in antibiotic prescribing for older people with UTI 
may be due to necessary avoidance of trimethoprim in patients judged to 
be at risk of a renal-related adverse event.  
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Table 2.1. Staging chronic kidney disease using the estimated glomerular filtration rate. 
Estimated Glomerular Filtration Rate (ml/min/1.73m2) 
chronic kidney disease 
stage 
≥90 
Normal 
1 
60-89 
Mild reduction related to normal range for a young adult 
2 
45-59 
Mild to moderate reduction 
3a 
30-44 
Moderate to severe reduction 
3b 
15-29 
Severe reduction 
4 
<15 
Kidney failure 
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Nitrofurantoin was contraindicated in patients with estimated glomerular 
filtration rates (eGFR) of below 60mls/min/1.73m2 due to concerns about its 
efficacy. In 2014, a systematic review found little evidence to support the 
avoidance of nitrofurantoin in patients with renal impairment (87). The 
review found that the perceived reduced efficacy came from studies that 
had found a reduction in urinary nitrofurantoin excretion in patients with 
renal impairment compared to those with normal renal function, but had not 
assessed or reported the impact of this on clinical outcomes such as 
symptom resolution or microbiological eradication. Furthermore, a 
retrospective cohort study found no difference in treatment failure rates 
among women with renal impairment prescribed nitrofurantoin, versus 
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those with normal renal function (88). These studies prompted the UK 
Medicines and Healthcare products Regulation Authority to lower the 
threshold for nitrofurantoin use to an eGFR≥45 mls/min/1.73m2. Since the 
updated guidance, one further retrospective cohort study compared 
outcomes in older women with a median eGFR of 38mls/min/1.73m2, 
prescribed either nitrofurantoin or trimethoprim, and found no difference in 
risk of treatment failure or UTI hospitalisation.  However, these studies did 
not include men, had a small number of outcome events and therefore wide 
confidence intervals around their effect estimates, did not use clinically 
relevant definitions for the severity of kidney disease, and lacked 
appropriate comparator groups. Therefore, there is still a need to evaluate 
outcomes following nitrofurantoin prescribing in older people with renal 
impairment to understand if avoidance is clinically warranted. 
2.12 Recurrent UTI 
The European Association of Urology define recurrent UTI as repeated UTI 
with a frequency of 2 or more in the last 6 months or 3 or more in the last 
12 months (67) and this definition has been adopted by the upcoming NICE 
clinical guideline (33). Most research on recurrent UTI focusses on younger 
women. The incidence of recurrent UTI in women aged 18-64 in the USA 
between 2003 and 2011 was around 1 in a 1000 (89). The prevalence of 
recurrent UTI in older people is not known but point-prevalence surveys of 
antibiotic use in care homes have consistently found that UTI prevention is 
the most common reason for antibiotic prescribing (2, 3, 90, 91). The current 
NICE clinical guideline for recurrent UTI recommends that recurrence is 
initially managed through behavioural, hygiene and self-care measures 
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(33). Vaginal oestrogens could be considered for postmenopausal women. 
Antibiotic prophylaxis is recommended if the above measures are 
ineffective. Nitrofurantoin and trimethoprim are suggested first-line agents 
and their effect should be reviewed after six months.  
2.13 Antibiotic prophylaxis for prevention of recurrent UTI  
Clinical guidelines recommend long-term low-dose antibiotic prophylaxis for 
prevention of recurrent UTI (67, 92). A Cochrane systematic review and 
meta-analyses found that long-term low-dose antibiotic prophylaxis 
conferred a relative risk reduction of 79% in the proportion of women 
experiencing a microbiologically confirmed UTI, compared to placebo. 
However, these analyses included data from mostly small trials of younger 
women without co-morbidities and there is uncertainty around the 
generalisability of these findings to older adults (93). We identified four trials 
published since this review that assessed the effect of antibiotic prophylaxis 
on UTI recurrence (94-97). Trials only included women. Overall, antibiotic 
prophylaxis was more effective than oral Lactobacilli capsules (94) or 
vaginal oestrogens (95), less effective than oral D-mannose powder (96), 
and similar in effect to oral cranberry capsules (97). Only one trial assessed 
the impact of antibiotic prophylaxis on antibiotic resistance and found that 
after one month of trimethoprim-sulfamethoxazole prophylaxis, resistance 
to trimethoprim-sulfamethoxazole, trimethoprim, and amoxicillin increased 
from 20-40% to 80-95% in the feces and urine of asymptomatic women (94). 
After 12 months of prophylaxis, all urinary E coli isolates of asymptomatic 
women were resistant to trimethoprim-sulfamethoxazole and trimethoprim. 
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In summary, the existing evidence for use of antibiotic prophylaxis for older 
people with recurrent UTI has several gaps and limitations. First, there are 
no robust data to inform prophylactic antibiotic use in men. Second, trial 
findings in women were mixed, making it difficult to provide clear 
recommendations for clinical practice. Third, existing trials often excluded 
those with co-morbidities such as diabetes, thus limiting their 
generalizability. Finally, trials were underpowered to study important but 
rare events such as hospitalisation.  
2.14 Non-antibiotic treatments for prevention and management of UTI 
Given that the increasing threat of antimicrobial resistance is primarily 
driven by antibiotic consumption, non-antibiotic strategies to treat and 
prevent UTI warrant discussion. The most widely trialled non-antibiotic 
agent for treatment of acute uncomplicated UTIs are Non-Steroidal Anti-
inflammatory Drugs (NSAIDs).  A randomised trial of ibuprofen versus 
placebo in women aged 65-70 with suspected acute UTI found that 
ibuprofen had no impact on symptoms but did reduce consumption of 
delayed antibiotics (34.9% versus 51%) (98). Two non-inferiority trials found 
that ibuprofen and diclofenac were inferior to pivmecillinam and norfloxacin 
in terms of symptom severity and resolution and increased the number of 
women who developed pyelonephritis (99, 100). A randomised trial of 
ibuprofen versus fosfomycin also found that women in the ibuprofen arm 
had more severe symptoms for longer and more cases of pyelonephritis 
(101).  
Several non-antibiotic agents have been studied to assess their effect on 
recurrent UTI. Cranberry juice was thought to reduce the number of 
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symptomatic UTIs, but the most recent Cochrane review of 24 studies with 
4473 participants concluded that cranberry products compared to placebo 
provide no benefit in most population groups, and the benefit in some 
subgroups is likely to be very small (102). Vaginal oestrogens reduced the 
risk of UTI recurrence in postmenopausal women compared to placebo in 
two randomized trials with relative risks of 0.25 (95% CI, 0.13-0.50) and 0.64 
(95% CI, 0.47-0.86), but increased the number of adverse events including 
vaginal bleeding (103). A recent randomized trial found that increasing fluid 
intake to 1.5 litres above their normal daily intake reduced the mean number 
of UTIs (3.2 in the usual care group versus 1.7 in the hydration group), and 
UTI-related antibiotic prescriptions (3.6 in the usual care group versus 1.9 
in the hydration group) in premenopausal women with recurrent UTI over 
12 months (104).  
In summary, current evidence does not support the use of NSAIDs for 
treatment of acute UTI given the observed increase in cases of 
pyelonephritis. For prevention of recurrent UTI, there is insufficient evidence 
to support the use of cranberry products, but vaginal oestrogens may be 
beneficial for postmenopausal women and increased hydration seems 
promising as a simple and effective preventative measure, although the 
available trial only included premenopausal women.   
2.15 Summary of evidence gaps 
We identified several gaps in the published evidence that could be 
addressed to generate new knowledge that could improve antibiotic 
prescribing for UTI in older people. First, there are no current estimates of 
the incidence of UTI in UK primary care in a generalisable sample of older 
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people to inform service provision. Second, there are no data describing 
trends in antibiotic prescribing for UTI over time in the UK, which are 
necessary to understand whether practice aligns with the available evidence 
and guidance. Third, little is known about the association between different 
antibiotics prescribed for UTI and clinical outcomes. This is important to help 
understand if observed variation is clinically warranted, and related to better 
outcomes. Fourth, there are no data to inform the optimal duration of 
antibiotic treatment for UTI in older men. Could shorter courses be used 
safely? Fifth, currently available research has not fully evaluated outcomes 
following nitrofurantoin use in older people with renal impairment to help 
understand if avoidance of nitrofurantoin is clinically warranted. Finally, it is 
unclear if long-term antibiotic prophylaxis is beneficial for older people with 
recurrent UTI.  
2.16 Aims and objectives of this thesis 
The aim of this thesis was to generate new evidence that could improve 
antibiotic prescribing for UTI in older people. 
Our specific objectives were to: 
1. Describe trends in the incidence of UTI in older people in UK primary 
care over time. 
2. Describe trends in antibiotic prescribing for UTI in older people in UK 
primary care over time. 
3. Investigate associations between choice of empirical antibiotic and 
adverse outcomes in older people with UTI. 
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4. Investigate associations between the duration of antibiotic treatment 
and adverse outcomes in older men with UTI.  
5. Investigate associations between nitrofurantoin prescribing and 
adverse outcomes in older people with UTI and renal impairment. 
6. Systematically review and meta-analyse randomised trials 
comparing antibiotic prophylaxis versus non-antibiotic prophylaxis or 
placebo in older people with recurrent UTI. 
7. Investigate outcomes associated with long-term antibiotic 
prophylaxis versus no antibiotic prophylaxis in older people with 
recurrent UTI
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3 Overview of methods 
 
This chapter provides an overview of the data source used in the 
quantitative primary research that addresses objectives 1-5, and objective 
7. We also summarise the methodological approaches generic to these 
objectives. Methods specific to a single objective are presented in the 
relevant chapter. Strengths and limitations are also discussed in the 
relevant chapters, as these differed depending on the study objective. 
3.1 Data source  
We addressed the aforementioned research objectives through a series of 
retrospective cohort studies using routinely collected healthcare data. The 
strengths of using routinely collected healthcare data for research are 
dependent on the structure, function and coverage of the health system 
involved but include (105):  
 Size and statistical power to address questions in under-studied 
populations and/or about rare exposures and outcomes. 
 Longitudinal data to allow follow-up over time. 
 Ability to address several inter-related questions relatively cheaply 
and efficiently. 
 Ability to link data across health and other (e.g., social care) datasets 
to enable a more holistic understanding of disease determinants and 
outcomes. 
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 Findings may be more generalisable to the population of interest than 
those generated from clinical trials. 
The main limitation of using routinely collected healthcare data is that it is 
not collected for research and is therefore subject to variation in its quality, 
completeness and recording methods (105). Diagnostic codes are open to 
interpretation and partly depend on the clinician’s clinical judgement. 
Therefore, two clinicians could see patients who present with the same 
signs and symptoms but code their presentation differently. Furthermore, 
not all required variables will be measured or coded and therefore it is 
challenging to fully account for all sources of confounding. 
In the UK, 98% of the population are registered with a General Practitioner 
(GP), and GPs are responsible for acute care in the community, long-term 
care for chronic illness, and for referring to and collating information from 
hospital specialists (106). Therefore, GP records are an important source of 
longitudinal data about patients’ healthcare encounters.  
There were four main sources of routinely collected GP data for researchers 
at the start of this project: The Clinical Practice Research Datalink (CPRD) 
(106), The Health Improvement Network database (THIN) (107), the 
QResearch database (108), and the Secure Anonymised Information 
Linkage databank (SAIL) (109). We chose the CPRD because: 
 It had wider coverage and contained a greater number of patient 
records than THIN and SAIL.  
 It was used more extensively than the other three databases, with an 
increasing number of published validation studies. 
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There were also some pragmatic considerations. For example, use of 
CPRD was covered by a Cardiff University license that included access to 
linked hospital admission and mortality data. Furthermore, data could be 
extracted using their online data portal and could be stored and processed 
on an office desktop computer. This was in contrast to SAIL where data 
could only be accessed and analysed in a secure web gateway which could 
increase processing time if using large data-sets. This was also in contrast 
to QResearch where linked hospital and mortality data could only be 
analysed on-site at the University of Nottingham. 
3.2 The CPRD 
The CPRD (formerly known as the General Practice Research Database) is 
a not-for-profit research service funded by the National Institute for Health 
Research and the Medicines and Healthcare products Regulatory Agency. 
It is owned by the UK Department of Health and contains the records of 11 
million patients from 674 general practices across the UK (106). Linked 
hospital and death registration data are available for patients from 
approximately 50% of contributing English practices. A previous study of the 
incidence of lower respiratory tract infections and pneumonia identified 
records for 1,534,443 adults aged 65 and over in CPRD between 1997 and 
2011, with linked data available for 916,128, (110) suggesting a sufficient 
sample for our proposed analyses.  
Practices “opt-in” to contribute data to CPRD and can provide additional 
consent to allow CPRD to link their data at the patient-level with other 
datasets, including hospital and death registry data. Patients registered with 
a practice that contributes data to CPRD can “opt-out”, meaning that their 
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data would not be included in the practices CPRD contribution.  
Approximately 7% of the UK population are included in the CPRD and 
patients are broadly representative of the wider UK population in terms of 
age, gender and ethnicity (106). The CPRD holds data on demographics, 
clinical encounters and diagnoses, drug prescriptions, laboratory tests and 
referrals to specialists.  
CPRD GP data are coded using the Read code system. Read codes were 
developed by Dr James Read and Abies Informatics Ltd in the early 1980s 
and recommended for national adoption across UK General Practice by the 
British Medical Association and the Royal College of General Practitioners 
in 1988 (111). Read codes are organised in three categories;  
 Diagnoses – codes all begin with a uppercase letter, e.g., H33 
(Asthma) 
 Processes of care – codes all begin with a number, e.g., 65E 
(Influenza vaccination) 
 Medication – codes all begin with a lowercase letter, e.g., bu25 
(Aspirin 75mg tablets). 
The coding system is hierarchical, with greater detail as you descend 
through the hierarchy (Table 3.1) (112). 
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Table 3.1. Example of the Read code hierarchy. 
Read code Description 
In
c
re
a
s
in
g
 d
e
ta
il 
C Endocrine, nutritional, metabolic and immunity disorders 
C1 Other endocrine gland diseases 
C10 Diabetes mellitus 
C10E Type 1 diabetes mellitus 
C10E7 Type 1 diabetes mellitus with retinopathy 
 
CPRD provides participating practices guidelines that describe how to 
record significant clinical events in a patient's medical history. The raw data 
provided by each practice undergo extensive quality control and validity 
checks by a research team based at the Medicines and Healthcare products 
Regulatory Agency before release. These data are assessed by an ‘up to 
standard’ audit, confirming the reliability and accuracy of data recording in 
several key areas. Practices meeting this standard are included in the 
CPRD data warehouse. Patient-level data are also assessed, with patients 
considered ‘acceptable’ for inclusion in the CPRD if recorded data are 
internally consistent in four areas: age, sex, registration details, and event 
recording (106). Data are only available to researchers once they have met 
these quality checks on completeness and reliability and the CPRD deems 
them to be of the standard required for research purposes. Linked hospital 
and death registration data are available for patients from approximately 
50% of contributing English practices. Of patients with linked data, around 
67% are matched exactly on NHS number, gender, date of birth and 
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postcode, and a further 28% are matched exactly on NHS number, gender, 
and date of birth (113). Hospital diagnoses and causes of death are 
recorded using version 10 of the International Classification of Disease 
(ICD-10). 
Although CPRD’s size, longitudinal data, and linkage capabilities made it an 
appropriate and valuable resource for the objectives of this thesis, we 
identified several limitations with its use. First, we required linked data which 
restricted us to data from English practices only, potentially reducing the 
generalisability of the findings to other parts of the UK. Second, CPRD was 
subject to the same limitations and variations in data coding that apply to all 
routinely collected healthcare data as discussed earlier in this chapter. 
Third, CPRD recorded prescribed medication, not dispensed or consumed 
medication and there no data to inform us of what proportion of medication 
prescribed in CPRD practices is dispensed or consumed. Fourth, CPRD 
does not record medication bought over the counter, important for some of 
the studies in this thesis where outcomes could differ if over the counter 
symptomatic treatments were used. Fifth, CPRD does not contain any 
microbiological data. This was an important limitation and warrants further 
discussion. Without microbiology data, we would not be able to: 
1. Determine who had a laboratory-confirmed UTI. 
2. Determine any antibiotic resistance-related outcomes. 
Therefore, our cohort actually consisted of people presenting with 
suspected UTI. In some ways, this is more clinically relevant, as most 
people who present to primary care with urinary tract symptoms are 
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diagnosed with a UTI based on their clinical presentation. If we had 
microbiology data and restricted to those with a urine sample sent for 
culture, we would be restricting to a select group as urine sampling is only 
recommended for men, women with atypical symptoms, and those who 
have failed a course of treatment (29), and even within these groups there 
is variation amongst practitioners (114). However, the lack of microbiology 
data meant that we did not know if differences in outcomes between studied 
groups related to differences in accuracy of the diagnosis, or reflected 
differences in resistance rates of the presenting infection. Furthermore, we 
were unable to determine whether differences in treatment choices had an 
impact on future resistance – especially important for exposures like 
antibiotic duration where evidence for an impact on resistance is limited 
(115). 
On balance, we decided that the strengths of using CPRD outweighed the 
limitations but were clear about the limitations in our interpretation and 
reporting. 
3.3 CPRD data extraction 
We submitted prospective study protocols and analysis plans to the CPRD 
Independent Scientific Advisory Committee for approval. Approvals were 
requested at three time-points over the course of the project: 
January 2015: Trends in UTI incidence and antibiotic prescribing (chapter 
4) 
October 2015: Antibiotic prophylaxis for recurrent UTI (chapter 9) 
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June 2017: Outcomes following different antibiotic treatment strategies for 
UTI (chapters 5-7). 
Due to the sequence above and the time-lag between each approval 
process, our analysis of UTI incidence (chapter 4) and our study of UTI 
prophylaxis (chapter 9), uses CPRD data from 2004-2014, and our analysis 
of UTI outcomes (chapters 5-7) uses data from 2010-2016. 
We extracted CPRD GP data using the CPRD Gold web portal. For our 
analysis of UTI incidence (chapter 4) and our study of UTI prophylaxis 
(chapter 9), we extracted data on all CPRD patients who, between 2004 and 
2014, were aged ≥65, had data deemed as “acceptable”, were registered 
with a practice whose data were deemed “up-to-standard”, and were eligible 
for data-linkage. Only patients registered with practices who had consented 
to data-linkage were eligible for linkage to hospital and death registry data. 
Previous research found that patients from practices who had consented to 
data-linkage were similar to those from practices without data-linkage in 
terms of age, gender, follow-up time and socioeconomic deprivation (110). 
The analyses presented in chapters 5-7 used data from 2010 to 2016, but 
all other data specifications were as above. CPRD provided linked hospital 
and death registry data for each study once the study specific protocol and 
analysis plans were approved. 
3.4 Data processing 
CPRD provides data in several separate tables. For example, the “Patient” 
table contains basic demographic data that includes year of birth, start of 
CPRD follow-up, and end of CPRD follow-up for patients who have died or 
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left their practice. The “clinical” table contains data on all patient-practice 
encounters, with date of encounter and a Read code describing the reason 
for the encounter. Some encounters relate to multiple Read codes, as the 
patients may have discussed several different issues and/or had several 
different examinations. Some encounters may not have an associated Read 
code if no data were entered. The “therapy” table contains data on all 
prescriptions issued and includes date of issue, a code to differentiate 
between repeat and acute prescriptions, and data about quantity and dose 
prescribed. The same patient can be identified across the different tables 
by their unique patient identifier. Tables were cleaned by systematically 
identifying implausible or missing values for each variable. Variables 
required for analysis were then generated and the tables were combined 
using merge functions in R as required for each analysis. 
3.5 Identifying episodes of UTI in CPRD 
The first task was to develop a method for identifying UTI episodes in CPRD 
data. CPRD does not contain microbiology data. Therefore, UTIs were 
identified using clinical codes and drug prescriptions only. To identify 
relevant codes, we firstly reviewed code lists from published studies that 
used a primary care database to investigate antibiotic prescribing or urinary 
tract infections in primary care (25, 116).  Secondly, we used the CPRD 
data browser to identify all UTI-related codes. The data browser identifies 
all codes within CPRD that match a given search term, which can be a word 
or part of a word. For example, searching for “*urinary tract infection*” would 
identify “urinary tract infection”, and “recurrent urinary tract infection”, and 
“urinary tract infection – site not specified”. Thirdly, we identified all acute 
45 
 
trimethoprim prescriptions in CPRD issued between 2004 and 2014 and 
reviewed the clinical Read codes relating to the prescribing indication. In the 
UK, during this period, trimethoprim was used almost exclusively for 
treatment of UTI. We found that 10% of trimethoprim prescriptions were not 
associated with a clinical code, i.e., no indication was recorded, and 25% 
were associated with a non-specific code, e.g., “telephone encounter”, or 
“had a chat to patient”. The remaining 65% of prescriptions were associated 
with codes we had already identified using the code lists from published 
studies and the CPRD data browser. The final code list was checked by 
three practicing GPs to ensure codes were clinically relevant and sensible. 
However, we accepted that we may miss around a third of UTIs because of 
coding issues. This proportion was similar to research from the THIN 
database that found no clinical code associated with 13% of antibiotic 
prescriptions, and a non-specific code associated with 18%, resulting in the 
prescribing indication being present for only 69% of antibiotic prescriptions 
(17).  
Whilst Read codes enabled identification of UTI-related consultations, we 
still needed to define distinct UTI episodes, based on incident UTIs, 
because codes occurring within a short time-frame of one another could 
represent multiple consultations for the same UTI-related episode. To the 
best of our knowledge, there are no widely accepted time points to define 
when re-presentation following UTI treatment should be regarded as a 
“relapse”, due to failed treatment and ongoing symptoms secondary to the 
initial infection, or “recurrence”, due to infection with a new or different 
organism. Previous observational research regarded codes occurring within 
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28 days of one another as belonging to the same illness episode and those 
occurring greater than 28 days apart as representing separate or distinct 
infections (25, 73, 110). We followed this approach to define UTI episodes. 
For the study of UTI incidence (chapter 4), we wanted to maximise the 
chances of identifying episodes of UTI and reduce the chances of identifying 
asymptomatic bacteriuria. We therefore identified UTI episodes as follows: 
All potential episodes needed a record of a primary care consultation with 
Read codes indicating either a diagnosis of UTI or a clearly relevant 
symptom of UTI, for example, dysuria or urinary frequency. They then 
needed at least one of the following:  
1. A same-day antibiotic prescription, suggesting a primary care 
clinically diagnosed and empirically treated UTI.  
2. A same-day emergency hospital admission with an ICD-10 code for 
UTI, suggesting a primary care clinically diagnosed UTI confirmed in 
secondary care.  
3. A same-day Read code indicating urine was sent for culture, and an 
antibiotic prescription within seven days, suggesting a primary care 
clinically suspected UTI, confirmed and treated following culture 
Figure 3.1 shows the flowchart and Read and ICD-10 codes used for case 
ascertainment via the above method. 
For studies where we investigated outcomes of different antibiotic treatment 
strategies for UTI, UTI episodes were identified as those with a Read code 
indicating a diagnosis or clearly relevant symptom of UTI, (using the codes 
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in code list 1 in Figure 3.1), and a same-day antibiotic prescription, 
suggesting a primary care clinically diagnosed and empirically treated UTI.  
We chose these definitions for UTI because clinical experience suggested 
that most older people presenting with suspected UTI would be prescribed 
antibiotics on the same day. This was partly supported by a study of the 
THIN database where 92% of patients aged over 14 presenting with 
symptoms suggestive of UTI received a same-day antibiotic (17). This study 
excluded patients with co-morbidities. Therefore, we felt the same-day 
prescribing rate would be higher in a sample of unselected older patients 
with comorbidities in whom the uncertainty around sepsis or poor prognosis 
would be greater. There were no data describing the prevalence of delayed 
prescribing in the older population and therefore we did not factor this in to 
our definitions as we felt its use was minimal during the study period. 
For all studies, we excluded UTI episodes recorded within six months of 
registering at the practice, as these may represent historical events 
recorded at registration. We also excluded UTI episodes recorded within 14 
days of a hospital discharge (identified from linked hospital data), as these 
may represent hospital-acquired infection, and the focus of our research 
was community-acquired UTI. 
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Figure 3.1. Flowchart and code lists used to ascertain UTI episodes for the UTI incidence 
study. 
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3.6 Estimating incidence of clinically diagnosed UTI 
We calculated age and gender specific incidence rates and 95% confidence 
intervals (CIs) for clinically diagnosed community-acquired UTI each month 
from March 2004 to April 2014 by dividing the number of incident UTIs 
presenting to primary care by person-time at risk. Individuals were 
considered not at risk of an incident community acquired UTI if they were in 
hospital, for 14 days following a hospital discharge, and for periods of time 
following an incident UTI until they had 28 days without a UTI-related code. 
We multiplied calculated incident rates by 365 X 100 to transform from 
incidence per person-days at risk to incidence per 100 person-years at risk. 
Incidence rates were calculated for three age groups: 65-74, 75-84 and 85+ 
years.  
We used joinpoint regression  to model trends in incidence rates over time 
and identify the estimated location of any statistically significant change in 
the slope of a trend line (117).  Joinpoint analysis identifies the best fit for 
inflexion points (“joinpoints”) at which there is a significant change in trends 
using a series of permutation tests (118).  In the UTI incidence study, 
joinpoint analysis was used to identify months (as the explanatory variable) 
at which significant changes in incidence rates occurred over the study 
period, and the size of these changes (as the percentage change in rate per 
year). A maximum of two joinpoints were allowed for each model we 
considered. This was the default value according to the number of 
observations in each model. We estimated the annual percentage change 
and 95% confidence intervals for each trend line. 
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3.7 Comparing outcomes following antibiotic treatment for UTI 
In chapters 5-7 we report outcomes of different antibiotic treatment 
strategies for acute and recurrent UTI. The exposure variable in these 
studies was the antibiotic prescription (for example, the choice of antibiotic, 
or the prescription duration). The outcomes were adverse events that could 
be reliably ascertained from CPRD data and therefore were: 
1. A record in the GP data of another UTI-related consultation 
(identified using the codes in code list 1 in Figure 3.1) with a same-
day antibiotic prescription in the 14 days following the index event. 
This was regarded as a proxy for “treatment non-response” or 
“treatment failure”, that is, that the patient re-presented because of 
ongoing symptoms of UTI that had persisted despite the initial 
treatment, and were severe enough to warrant another course of 
treatment.  
2. A record in the linked hospital data of a UTI-related hospitalisation in 
the 14 days following the index event. This included hospitalisations 
with ICD-10 codes for UTI or sepsis, and were regarded as an 
indication of worsening infection despite the initial treatment. The 
included codes were: 
N30  Cystitis 
N30.0  Acute cystitis 
N30.8   Other cystitis 
N30.9  Cystitis unspecified  
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N39.0  Urinary tract infection, site not specified 
A41.5  Gram-negative sepsis NOS 
A41.8  Other specified sepsis 
A41.9  Sepsis, unspecified 
A49.9  Bacteraemia NOS 
R57.2  septic shock 
3. A record in the linked hospital data of a hospitalisation with an acute 
kidney injury (AKI). AKI was ascertained from the following ICD-10 
codes:  
N17  Acute renal failure 
N17.0  Acute renal failure with tubular necrosis 
N17.1  Acute renal failure with acute cortical necrosis 
N17.2  Acute renal failure with medullary necrosis 
N17.8  Other acute renal failure 
N17.9  Acute renal failure, unspecified 
N19  Unspecified kidney failure
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Hospitalisation for AKI was regarded as an indication of worsening 
systemic illness despite the initial treatment. 
4. A record in the linked death registry data of death in the 28 days 
following the index event. 
We chose to study a “treatment failure” related outcome as primary care 
clinicians had cited prevention of treatment failure as a reason for 
prescribing non-recommended antibiotics (77). We chose UTI-related 
hospitalisations because of the recently observed increase in 
hospitalisations for UTI (119) and for E.coli bacteraemia (7), with treatment 
failure of community-acquired UTI thought to be a contributory factor.  
Hospitalisation for AKI was chosen for several reasons. AKI is more 
common in older adults, with around 5% of those aged over 70 experiencing 
an AKI hospitalisation each year in the UK, compared to around 1% of those 
aged 40-69 (120). AKI costs the NHS between £434 and £620 million each 
year (120). NICE defines AKI as a rise in serum creatinine of 26 
micromols/litre or more within 48 hours, or a 50% or greater rise in serum 
creatinine occurring within 7 days (121).  
NICE specifically recommends investigating for the presence of AKI in older 
people with acute illness, especially if suspected to have sepsis, a well-
recognised risk factor for AKI (122, 123). In the context of UTI, AKI could be 
caused by the systemic effects of the infection (e.g., confusion or fever could 
disrupt fluid balance leading to dehydration), or by worsening infection and 
subsequent sepsis.  
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We chose 14 days for the treatment failure and hospitalisation outcomes to 
increase the likelihood that these events were related to the initial UTI. 
Longer time periods increase the likelihood that the outcome may have 
been influenced by an intervening event, e.g., if a 28 day period was used, 
a patient could have a UTI, recover, have a cardiac event and be 
hospitalised with AKI. We chose 28 days for the death outcome as the UTI 
could precipitate events (e.g., sepsis) which take some time to evolve before 
death.  
3.8 Confounding variables 
We considered multiple confounding variables that could be causes of both 
the antibiotic prescription (exposure) and outcome. We included age, 
gender, and Index of Multiple Deprivation score quintile. The Index of 
Multiple Deprivation is an area-level measure of deprivation covering 
different aspects of material deprivation including housing, employment, 
income, access to services, education, crime, and living environment (124). 
We also included a Charlson score - a weighted summary measure of 
comorbidity (125). To calculate a Charlson score, we used each included 
patients clinical data to identify whether they had a history of myocardial 
infarction, congestive heart failure, peripheral vascular disease, dementia, 
cerebrovascular disease, chronic lung disease, connective tissue disease, 
peptic ulcer disease, chronic liver disease, diabetes, AIDS, or cancer prior 
to their entry into the cohort, using a previously published list of Read codes 
(125). Absence of a relevent code was taken to mean absence of the 
condition of interest. The presence and severity of each condition was 
scored according pre-defined Charlson score methodology (125) resulting 
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in an overall summary score. We also adjusted for a recorded history of  
coronary heart disease, renal disease, and respiratory disease,  as these 
variables were previously found to be associated with antibiotic prescribing 
(78, 79).  
The presence or absence of prescriptions for angiotensin converting 
enzyme inhibitors, angiotensin receptor blockers and potassium-sparing 
diuretics were also included as confounders as these were previously 
shown to be associated with AKI hospitalisation in adults with UTI (83, 84, 
126).  
We also adjusted for potential confounders that we thought could influence 
the clinical decision about antibiotic prescribing and the outcomes under 
investigation. These included: 
 Whether the patient was housebound,  
 Whether the patient had a recorded diagnosis of dementia, liver 
disease, rheumatoid arthritis, or cancer, 
 Whether the patient had urinary incontinence or an indwelling urinary 
catheter,  
 An estimated glomerular filtration rate (eGFR) calculated using the 
modification of diet in renal disease study equation (127),  
 Polypharmacy, defined as records indicating ≥5 long-term 
medications per month in the year prior to the incident UTI. 
To determine polypharmacy, we identified each included patients repeat 
prescriptions for the 12 months prior to cohort entry. All medications were 
included as long as they were prescribed at least 3 times in the past 12 
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months and coded as a repeat prescription and not as an acute prescription. 
We divided the number of different medications prescribed over the 12 
month period by 12 to get an estimate for the number of medications 
prescribed per month and defined those with ≥5 medications per month as 
polypharmacy, the most commonly used numerical definition of 
polypharmacy in the healthcare literature (128). 
We can consider the potential impact of the described confounding 
variables on exposure and outcome using rheumatoid arthritis as an 
example. A patient with rheumatoid arthritis may be using 
immunosuppressant drugs and therefore be at greater risk of an adverse 
outcome such as sepsis. The prescribing clinician may recognise that the 
patients is at increased risk of an adverse outcome, and this may influence 
the choice or duration of antibiotic treatment prescribed This could also 
occur in patients with cancer. Similarly, patients with a reduced eGFR are 
at greater risk of an infection-related adverse outcome (129) and reduced 
eGFR could influence a prescriber’s choice of antibiotic due to, for example, 
the contraindications described in section 2.10 relating to kidney disease 
and nitrofurantoin.  
CPRD records sociodemographic variables and drug prescriptions with a 
high degree of reliability and completeness (106). However, recording of co-
morbidities varies, with better recording of those for which GPs received 
financial incentives during the study period. A systematic review of 49 
studies that investigated the accuracy of diagnostic coding in the CPRD by 
comparing CPRD diagnostic codes with a review of the patient’s medical 
records found that CPRD diagnostic codes had a positive predictive value 
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of over 90% for conditions such as cerebrovascular disease, diabetes, or 
hip fracture (130). Overall, most long-term conditions were recorded 
accurately with positive predictive values of over 80%. However, there were 
no data validating confounding variables such as urinary incontinence or the 
presence of an indwelling urinary catheter, meaning that it was unclear as 
to how reliably we could ascertain them in the CPRD. 
3.9 Methods to adjust for measured confounders 
We adjusted for confounders in two ways. We included all potential 
confounders in mixed effects multivariable logistic regression models using 
the lme4 package in R (131). In these models, we included the general 
practice as a random effect to account for clustering by practice (132). We 
also used the confounding variables to generate a propensity-score and 
then did propensity-score matched analyses. The propensity score was the 
probability of receiving the exposure variable given the confounding 
variables. The aim of propensity score matching is to improve balance of 
baseline characteristics in comparison groups (133). We used nearest 
neighbour matching with no replacement using the MatchIt package in R 
(134). Nearest neighbour matching previously showed consistently good 
performance in simulation studies that compared it to full matching and 
inverse probability of treatment weighting in scenarios that varied the 
prevalence of the treatment and the strength of association between the 
covariates and treatment assignment (135). We assessed balance in 
measured baseline covariates between matched groups by visually 
inspecting jitter plots and histograms of covariate distribution before and 
after matching, and by calculating standardised mean differences for 
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covariates between groups. We regarded standardised mean differences of 
<0.1 as reflecting adequate balance (136). 
We used other methods to better understand the impact of confounding in 
specific analyses, and describe these in the relevant chapters. All analyses 
were conducted in R version  3.2.1. 
3.10 Patient and Public Involvement 
This project had two patient and public involvement representatives from 
inception to completion. Both were recruited through Health and Care 
Research Wales’ INVOLVE network and expressed an interest in a project 
about UTIs. They had personal experience of UTIs. One had a neurological 
condition that predisposed her to recurrent infections, and the other was a 
carer for someone with recurrent UTIs. They were involved in discussions 
about the research questions that formed this project and provided advice 
on all aspects of the project. We met at six-monthly intervals to discuss 
progress and obtain their feedback on project findings. 
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4 Trends in UTI incidence and antibiotic prescribing  
 
This is the first empirical study in this thesis and presents data on incidence 
and antibiotic prescribing for UTI in older adults in primary care. 
4.1 Background 
UTI is an important cause of morbidity and antibiotic use in older adults. In 
the UK, most episodes of suspected UTI are managed in primary care. 
Despite the associated morbidity, there are few recent, robust, externally 
valid data describing trends in the incidence of UTI in UK primary care. A 
large prospective observational study with systematic urine sampling would 
provide estimates of the incidence of microbiologically confirmed UTI, but 
would be expensive and pose several challenges including recruitment, 
retention and collection of uncontaminated urine samples. It would also not 
reflect the true burden of UTI in primary care as many episodes are 
diagnosed and treated clinically, based on symptoms and signs, without 
microbiological confirmation. Therefore, we used the CPRD to estimate 
incidence rates of clinically diagnosed UTI in UK primary care and examine 
associated antibiotic prescribing. We investigated trends in the proportion 
of older adults prescribed a UTI-specific antibiotic (nitrofurantoin or 
trimethoprim), and the proportion prescribed antibiotics for durations 
recommended in clinical guidelines.  
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4.2 Methods 
This was a retrospective cohort study. Patients were eligible for inclusion if, 
between 1st March 2004 and 31st March 2014, they were ≥65 years old, had 
linked hospital data and more than one day of CPRD follow-up. We 
excluded patients with temporary registrations or gaps in their data 
coverage. Patient follow-up began on the latest of study start date, the 
patient’s 65th birthday or 28 weeks after the patient first registered at the 
practice. Follow-up ended at the earliest of study end date, death, or last 
day of available CPRD data. We identified UTI episodes using the flowchart 
and code lists in Figure 3.1. We used joinpoint regression to model trends 
in incidence rates over time and identify the estimated location of any 
significant change in the slope of a trend line. For individuals prescribed a 
same-day empirical antibiotic, we investigated gender-specific trends for 
antibiotic choice and duration. We used multilevel logistic regression to 
account for clustering within practices and modelled trends in:  
1. The proportion of older adults prescribed a UTI-specific antibiotic 
(trimethoprim or nitrofurantoin).  
2. The proportion of older adults prescribed antibiotics for the duration 
recommended by clinical guidelines (three days for women, seven 
days for men).   
4.3 Results 
There were 966,454 adults aged ≥65 with data of acceptable standard, 
linked hospital data, and at least one day of follow-up between 2004 and 
2014, in the database. We excluded 34,509 (3.6%), resulting in a final study 
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population of 931,945 older adults (Figure 4.1). Table 4.1 shows the study 
population characteristics. 
 
 
Figure 4.1. Flow of patients from initial identification in the database to final cohort. 
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Table 4.1. Characteristics of the study population. 
 Number (%) 
Total study population 931,945 
Male 417,190 (45) 
Female 514,755 (55) 
Median (IQR) age at start of follow-up (years) 70.2 (65.0-78.2) 
Median (IQR) age at end of follow-up (years) 77.1 (70.3-84.4) 
Median (IQR) follow-up time (years)  5.0 (2.2-8.5) 
Total follow-up time (person years) 4,857,433 
4.3.1 Incidence by age and gender 
Of 931,945 older adults, 196,358 (21%) had at least one UTI between 1st 
March 2004 and 31st March 2014. In this cohort of 196,358 patients, we 
identified 450,080 episodes of community-acquired UTI. Median number of 
episodes per person was 2 (IQR 1-4). Over 96% of episodes were identified 
by the presence of a diagnostic (e.g., “Urinary tract infection”) or 
symptomatic (e.g., “dysuria”) Read code and a same-day antibiotic 
prescription. Incidence of UTI increased with age and was higher in women. 
There was marked monthly variation in incidence for both men and women, 
but with no clear pattern or seasonal distribution.  
The incidence of UTI in older men (episodes per 100 person-years at risk), 
increased between March 2004 and April 2014 from 2.81 (95% CI 2.48-
3.15) to 3.05 (95% CI 2.56-3.54) in those aged 65-74, and 5.90 (95% CI 
5.28-6.53) to 6.13 (95% CI 5.25-7.00) in those aged 75-84. The increase 
was most marked in those aged 85+, from 8.08 (95% CI 6.64-9.52) to 10.54 
(95% CI 8.61-12.48). Joinpoint analyses showed an annual percentage 
63 
 
increase (APC) in incidence rates of 1.4% (95% CI 0.7-2.1) in those aged 
65-74 (Figure 4.2).  The APC for those aged 75-84 was 5.5% (95% CI 1.6-
9.5) between March 2004 and September 2007, followed by a change in 
trend in September 2007 (95% CI May 2006 to January 2009), and then an 
APC of 1.1% (95% CI 0.0-2.2) between October 2007 and April 2014. The 
APC for those aged 85+ was 3.3% (95% CI 2.8-3.9). 
The incidence of UTI in older women (episodes per 100 person-years at 
risk), increased between March 2004 and April 2014 from 9.03 (95% CI 
8.44-9.61) to 10.96 (95% CI 10.05-11.87) in those aged 65-74, 11.35 (95% 
CI 10.62-12.07) to 14.34 (95% CI 13.13-15.54) in those aged 75-84, and 
14.65 (95% CI 13.39-15.91) to 19.80 (95% CI 17.86-21.73) in those aged 
85+. The APC for those aged 65-74 was 6.1% (95% CI 3.8-8.5) between 
March 2004 and November 2007, and 1.1% (95% CI 0.4-1.7) between 
December 2007 and April 2014 (Figure 4.3).  The APC for those aged 75-
84 was 8.8% (95% CI 6.6-11.2) between March 2004 and November 2006, 
and 3.2% (95% CI 2.7-3.6) between December 2006 and April 2014. The 
APC for those aged 85+ was 6.9% (95% CI 3.5-10.4) between March 2004 
and February 2007, and 3.1% (95% CI 1.3-4.8) between March 2007 and 
April 2014. Estimated changes in trend for the 65-74, 75-84 and 85+ age 
groups occurred in December 2007 (95% CI May 2006 to April 2009), 
November 2006 (95% CI February 2006 to January 2008), and February 
2007 (95% CI January 2006 to April 2009) respectively. 
64 
 
 
 
 
 
 
 
 
0
5
10
15
In
c
id
e
n
c
e
 r
a
te
 p
e
r 
1
0
0
 p
e
rs
o
n
 y
e
a
rs
 
a
t 
ri
s
k
0
5
10
15
In
c
id
e
n
c
e
 r
a
te
 p
e
r 
1
0
0
 p
e
rs
o
n
 y
e
a
rs
 
a
t 
ri
s
k
0
5
10
15
In
c
id
e
n
c
e
 r
a
te
 p
e
r 
1
0
0
 p
e
rs
o
n
 y
e
a
rs
 
a
t 
ri
s
k
Figure 4.2a: Men aged 
65-74. Statistically 
significant increase in 
incidence rate over time. 
The APC between 2004 
and 2014 was 1.4% 
(95% CI 0.7-2.1).  
 
Figure 4.2b: Men aged 
75-84. Estimated change 
in trend in September 
2007. Statistically 
significant increase in 
incidence rate between 
2004 and 2014. The APC 
between March 2004 and 
September 2007 was 
5.5% (95% CI 1.6-9.5), 
and between October 
2007 and April 2014 was 
1.1% (95% CI 0.0-2.2). 
 
Figure 4.2c: Men aged 
85+. Statistically 
significant increase in 
incidence rate between 
2004 and 2014. The APC 
between 2004 and 2014 
was 3.3% (95% CI 2.8-
3.9). 
APC = Annual Percentage 
Change. Observed monthly 
incidence represented by blue 
line. Joinpoint regression 
represented by red and black 
lines. 
 
 
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Figure 4.2. Joinpoint analyses of monthly age-specific community acquired urinary tract infection 
incidence rates for older men in UK primary care March 2004 – April 2014. 
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2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2004 
Figure 4.3a: Women 
aged 65-74. Estimated 
change in trend in 
November 2007. 
Statistically significant 
increase in incidence 
rate between 2004 and 
2014. The APC between 
March 2004 and 
November 2007 was 
6.1% (95% CI 3.8-8.5), 
and between December 
2007 and April 2014 was 
1.1% (95% CI 0.4-1.7).  
 
Figure 4.3c: Women 
aged 85+. Estimated 
change in trend in 
February 2007.   
Statistically significant 
increase in incidence 
rate between 2004 and 
2014. The APC between 
March 2004 and 
February 2007 was 6.9% 
(95% CI 3.5-10.4), and 
between March 2007 
and April 2014 was 3.1% 
(95% CI 1.3-4.8). 
APC = Annual Percentage 
Change. Observed monthly 
incidence represented by blue 
line. Joinpoint regression 
represented by red and black 
lines. 
 
Figure 4.3b: Women 
aged 75-84. Estimated 
change in trend in 
November 2006. 
Statistically significant 
increase in incidence 
rate between 2004 and 
2014. The APC between 
March 2004 and 
November 2006 was 
8.8% (95% CI 6.6-11.2), 
and between December 
2006 and April 2014 was 
3.2% (95% CI 2.7-3.6).  
 
Figure 4.3. Joinpoint analyses of monthly age-specific community acquired urinary tract infection 
incidence rates for older women in UK primary care March 2004 – April 2014. 
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4.3.2 Antibiotic choice 
Trends in antibiotic choice were similar for older men and women (Figure 
4.4 and Figure 4.5). Trimethoprim was consistently the most commonly 
prescribed antibiotic for community-acquired UTI, accounting for about 50% 
of all prescriptions. Prescriptions of broad-spectrum cephalosporins for UTI 
decreased markedly in men from 23.7% in 2004 to 4.1% in 2014, and 
women from 24.6% in 2004 to 5.5% in 2014. Quinolone use also decreased; 
in men from 12.2% in 2004 to 6% in 2014 and in women, from 6.2% in 2004 
to 2.7% in 2014. Prescriptions of nitrofurantoin for community-acquired UTI 
increased markedly during the study period, rising from 5.5% of 
prescriptions for male UTI in 2004, to 22.3% in 2014, and from 6.2% of 
prescriptions for female UTI in 2004 to 27.9% in 2014. Use of other antibiotic 
groups remained relatively stable. 
There was an increase in the proportion of older men prescribed a UTI-
specific antibiotic (nitrofurantoin or trimethoprim) between March 2004 and 
April 2014, from 45% to 74%. Multi-level logistic regression model estimates 
suggest that a practice with UTI-specific prescribing one standard deviation 
below the mean would show an increase across the 10-year study period 
from 24% to 75%, and a practice with prescribing one standard deviation 
above the mean would show an increase from 67% to 95% (Table 4.2). 
Across the same period, there was also an increase in the proportion of 
older women prescribed a UTI-specific antibiotic, from 55% to 82%.  
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Model estimates suggest that a practice with UTI specific antibiotic 
prescribing one standard deviation below the mean would show an increase 
from 31% to 85% and a practice with prescribing one standard deviation 
above the mean would show an increase from 76% to 97% (Table 4.3). 
 
 
Figure 4.4. Antibiotic prescribing for community acquired UTI for older men by year and 
antibiotic group. 
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Figure 4.5. Antibiotic prescribing for community acquired UTI for older women by year and 
antibiotic group. 
 
Table 4.2. Mixed multilevel model estimates for change in the proportion of older men 
prescribed a UTI-specific antibiotic between 2004-2014 
Fixed effects Coefficient Standard Error z-value p-value 
Intercept 
Time since 2004 (days) 
-0.2024 
0.0003368 
0.05251 
0.00001695 
-3.854 
19.870 
<0.001 
<0.001 
Random effects Standard Deviation    
Practice 
Time since 2004 (days) 
0.9317832 
0.0002745 
   
*Generalised linear mixed model fit by maximum likelihood (Laplace approximation) 
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Table 4.3. Mixed multilevel model estimates for change in the proportion of older women 
prescribed a UTI-specific antibiotic between 2004-2014 
Fixed effects Coefficient Standard Error z-value p-value 
Intercept 
Time since 2004 (days) 
0.1893026 
0.0003631 
0.0519098 
0.0000172 
3.647 
21.110 
<0.001 
<0.001 
Random effects Standard Deviation    
Practice 
Time since 2004 (days) 
0.9704797 
0.0003106 
   
*Generalised linear mixed model fit by maximum likelihood (Laplace approximation) 
 
4.3.3 Antibiotic duration 
There was an increase in the proportion of older men prescribed seven-day 
antibiotic therapy between 2004 and 2014, from 42% to 69% (Figure 4.6). 
This was accompanied by a reduction in the proportion of older men 
prescribed five-day antibiotic therapy, from 32% in 2004 to 14% in 2014. 
There was little change over time in the proportion of older men prescribed 
three-day or >7 day antibiotic therapy. Multi-level logistic regression model 
estimates suggest a practice with seven-day therapy prescribing one 
standard deviation below the mean would show an increase from 23% to 
74%, and a practice with seven-day therapy prescribing one standard 
deviation above the mean would show a change from 64% to 94% (Table 
4.4). Across the same period, there was also an increase in the proportion 
of older women prescribed three-day antibiotic therapy, from 15% to 26% 
(Figure 4.7). This was accompanied by a small reduction in the proportion 
of older women prescribed five-day therapy, from 29% in 2004 to 20% in 
2014. There was little change over time in the proportion of women 
prescribed ≥7 day antibiotic therapy. Model estimates suggest that a 
practice with three-day therapy prescribing one standard deviation below 
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the mean would show a change from 4% to 31% and a practice with three-
day therapy prescribing one standard deviation above the mean would show 
a change from 43% to 90% (Table 4.5). 
 
 
Figure 4.6. Duration of antibiotic prescription for community acquired UTI in older men. 
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Figure 4.7. Duration of antibiotic prescription for community acquired UTI in older women. 
 
Table 4.4.Mixed multilevel model estimates for change in the proportion of older men 
prescribed 7-day antibiotic treatment between 2004-2014 
Fixed effects Coefficient Standard Error z-value p-value 
Intercept 
Time since 2004 (days) 
-0.3361 
0.0003066 
0.05087 
0.00001847 
-6.608 
16.6 
<0.001 
<0.001 
Random effects Standard Deviation    
Practice 
Time since 2004 (days) 
0.896207 
0.000306 
   
*Generalised linear mixed model fit by maximum likelihood (Laplace approximation) 
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Table 4.5.Mixed multilevel model estimates for change in the proportion of older women 
prescribed 3-day antibiotic treatment between 2004-2014 
Fixed effects Coefficient Standard Error z-value p-value 
Intercept 
Time since 2004 (days) 
-1.751 
0.0001947 
0.07912 
0.00002557 
-22.135 
7.615 
<0.001 
<0.001 
Random effects Standard Deviation    
Practice 
Time since 2004 (days) 
1.4830682 
0.0004632 
   
*Generalised linear mixed model fit by maximum likelihood (Laplace approximation) 
 
4.3.4 Additional analysis 
Following peer-review of the above analyses by Reviewers at PLoS ONE, 
we examined whether the changing incidence of UTI was related to 
increasing age within each age-group.  The Reviewers commented that 
although we reported age-specific incidence rates for UTI by 10-year age-
groups, the mean age within these age-groups may have increased over 
time, and consequently the observed changes in incidence may be the 
result of increasing age. They requested that we calculate the mean age in 
each age-group at the start and end of the study period to examine whether 
this had changed (Table 4.6).  
We found no evidence for a change in the mean age in any age-group 
across the study period, therefore decreasing the likelihood of increases in 
incidence being related to increasing age within our sample. 
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Table 4.6. Mean age in each age-group for each study year. 
 
 
4.4 Discussion 
This study is the first to provide age and gender-specific monthly incidence 
estimates of clinically diagnosed UTI derived from a large population-based 
sample. We identified monthly variation in incidence rates with an overall 
increasing incidence rate that was most marked for men over 85 and women 
over 75. About 20% of nearly one million older adults in our sample had at 
least one clinically diagnosed UTI in primary care over a 10-year period. 
The proportion of older adults prescribed nitrofurantoin or trimethoprim 
increased, as did the proportion of older men prescribed seven-day 
antibiotic therapy. The proportion of older women prescribed three-day 
antibiotic therapy also increased but three in four older women still received 
longer than three-day therapy suggesting on-going clinical uncertainty in 
this area. However, overall, these changes are encouraging and 
demonstrate improvements in guideline congruent prescribing.  
4.4.1 Findings in context 
Our incidence estimates are broadly consistent with those of the Pittsburgh 
Good Health Study (23) and the Leiden 85-plus study (24).  In contrast to 
two previous studies, (137, 138) we did not identify any clear evidence of 
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seasonality. However, both previous studies included women of all ages. A 
more recent study examined UTI seasonality by age-group and found that 
UTI consultation incidence peaks between September and November for 
ages 14-69, but this seasonality progressively fades in older age groups, 
with no seasonality found in individuals aged 85+ (139).   
We identified a change in incidence trend for older women occurring around 
2007, with a reduction in the APC for incidence rates that followed this 
period. Reasons for this could include publication of the first two UK clinical 
guidelines on management of bacterial UTI in adults in 2006 and 2007. The 
SIGN guidelines provided evidence-based recommendations for diagnosis 
and treatment of UTI in adults (29). They did not provide recommendations 
specifically for older people, but they did highlight the prevalence of 
asymptomatic bacteriuria, and the evidence to show that antibiotic treatment 
for asymptomatic bacteriuria was more likely to cause harm than benefit. 
The Public Health England guidelines focussed on UTI diagnosis and made 
recommendations around urine sampling in older people (30). They 
discussed the importance of diagnosis based on combinations of specific 
signs and symptoms. This push towards criteria based diagnosis of UTI in 
older people was supported by a clinical trial published in 2005 that found 
UTI diagnosis based on a set of clinical criteria reduced antibiotic use (140, 
141). Together, these publications may have had enough reach and impact 
to persuade clinicians to modify their approach towards UTI diagnosis in 
older people. 
Our analyses demonstrated increasing incidence of UTI, especially in men 
over 85 and women over 75. This may represent over-diagnosis, reflecting 
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the increasing challenge of accurately diagnosing UTI in this population, or 
may represent an increase in true bacterial UTI, possibly due to the 
increasing prevalence of elderly multi-morbid individuals with greater 
susceptibility to infections. Further investigation is required to ascertain the 
reasons for this increase and to assess whether preventative or diagnostic 
interventions could effectively and safely reduce incidence and associated 
antibiotic use. 
Guideline congruent antibiotic prescribing for community acquired UTI is 
improving, with increasing use of UTI-specific antibiotics. Prescribing of 
trimethoprim or nitrofurantoin for older men with UTI increased from 45% in 
2004, to 74% in 2014. For older women, this increase was from 55% to 
82%. The observed increases in trimethoprim and nitrofurantoin prescribing 
were accompanied by decreases in prescribing of cephalosporins, 
quinolones and co-amoxiclav.  Despite limited empirical evidence for 
optimal antibiotic duration in older men, we observed  greater adherence to 
prescribing of seven-day antibiotic therapy, which increased from 42% in 
2004 to 69% in 2014. Three-day antibiotic prescribing for older women also 
increased, although not as dramatically, from 15% in 2004 to 26% in 2014. 
This was a surprising finding given that there is empirical trial evidence for 
optimal antibiotic duration for UTI in older women, with meta-analysis 
showing no difference in short (3 trials, N=431) or long-term (3 trials, N=470) 
outcomes between those treated with three days of antibiotics versus those 
treated with seven days (62). These results may be explained by findings 
from previous studies that report reasons for why clinician adherence to 
evidence based guidance for UTI is sub-optimal (142). This may be partly 
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due to conflicting recommendations in guidelines, (75) and partly due to 
clinical complexity and prognostic uncertainty associated with UTI in older 
adults (143, 144). Better understanding of these uncertainties around 
recovery and prognosis may help to improve adherence to three-day 
antibiotic therapy for older women. However, overall, these findings 
demonstrate improvements in evidence-based antibiotic prescribing for UTI 
in older adults and are an encouraging indicator of practice change. 
4.4.2 Strengths and limitations 
Our study used a large population-based sample to estimate UTI incidence 
trends. We sought to optimise the accuracy of our estimates by calculating 
days at risk for included individuals, and subtracted time at risk of hospital 
acquired infection from the denominator.  We distinguished repeat 
consultations for the same infection from new incident infection by 
attributing codes within 28 days of one another to the same episode. This 
may have underestimated the incidence of UTI if some of these episodes 
were actually new incident UTIs. We did not have access to linked 
microbiological data and thus the UTI episodes are clinically diagnosed 
episodes rather than microbiologically confirmed, but as over 98% of these 
episodes were associated with a same-day antibiotic prescription, they are 
more likely to reflect the true burden of clinically diagnosed and empirically 
treated UTI in a primary care population. However, data used were recorded 
for clinical purposes and thus are prone to a degree of coding error, 
differential coding between clinicians, and confounding by indication.  We 
also would not have captured incident UTIs where the antibiotic prescription 
was associated with a non-specific code (e.g., “patient reviewed”). 
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4.5 Conclusions 
This population-based analysis of clinical records from nearly one million 
older adults has shown an increase in the incidence of clinically diagnosed 
UTI between 2004 and 2014. There is a clear need to better understand the 
reasons for the increasing incidence, and for interventions that improve 
prevention and diagnosis of UTI. Although antibiotic choice for UTI in 
primary care has improved, further improvements could arise through better 
understanding and addressing the reasons for the relatively low uptake of 
short-course therapy for older women.
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5 Association between choice of empirical antibiotic 
prescription and adverse outcomes 
 
In chapter 4, we described trends in antibiotic prescribing for UTI in older 
people in primary care. We found that the proportion of older patients with 
UTI prescribed nitrofurantoin or trimethoprim increased between 2004 and 
2014. However, in 2014, 24% of older men and 19% of older women still 
received a prescription for an antibiotic other than nitrofurantoin or 
trimethoprim. In this chapter, we present analyses on whether prescribing 
these alternative antibiotics had an impact on the risk of treatment failure, 
UTI-related hospitalisation, or death, in the 14-28 days following the incident 
UTI. 
5.1 Background 
Nitrofurantoin and trimethoprim are narrow-spectrum antibiotics widely 
recommended for the treatment of UTI (18, 19). However, GPs may 
prescribe broad-spectrum antibiotics for some patients, especially if they are 
older or frail, have co-morbidities, or present with symptoms or signs of 
more severe illness (71). The perceived aim of broad-spectrum antibiotic 
prescribing is to prevent treatment failure, worsening illness, and 
hospitalisation, events thought to be more likely if narrow-spectrum 
antibiotics are prescribed for that clinical scenario (77).  
Although randomised trials showed similar clinical cure rates between 
patients with UTI treated with nitrofurantoin or trimethoprim versus 
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flouroquinolones or cephalosporins (145-147), these trials only included 
young, healthy women and were underpowered to assess risk of important 
but rare outcomes such as UTI-related hospitalisation or death (58, 148). 
Previous observational studies compared trimethoprim-sulfamethoxazole 
with flouroquinolones, and sulfamethiazole with pivmecillinam and were 
either restricted to younger females, assessed treatment failure alone, or 
lacked clinical coding data to ascertain the indication for the antibiotic 
prescription (149, 150). Furthermore, trimethoprim-sulfamethoxazole, and 
sulfamethiazole are rarely used in UK primary care.   
We therefore used the CPRD to investigate the risk of adverse outcomes in 
adults aged ≥65 prescribed empirical nitrofurantoin or trimethoprim versus 
other antibiotics commonly prescribed for suspected UTI in UK primary 
care. We had two aims. First, to Identify sociodemographic and clinical 
variables associated with broad-spectrum antibiotic prescribing (amoxicillin, 
cefalexin, ciprofloxacin or co-amoxiclav). Second, to assess whether 
amoxicillin, cefalexin, ciprofloxacin or co-amoxiclav were associated with a 
reduced risk of treatment failure, hospitalisation for UTI, sepsis or acute 
kidney injury (AKI), or death. If these antibiotics were associated with risks 
that were similar or higher than those of nitrofurantoin or trimethoprim, then 
this would support further reductions in their use, even in older, frailer, 
comorbid patients with more severe presenting features.  
5.2 Methods 
This was a retrospective cohort study. Patients were eligible for inclusion if, 
between 1st January 2010 and 31st December 2016, they were ≥65 years 
old, had linked hospital data and more than one day of CPRD follow-up. We 
80 
 
excluded patients with temporary registrations or gaps in their data 
coverage. Patient follow-up began on the latest of study start date, the 
patient’s 65th birthday or 28 weeks after the patient first registered at the 
practice. Follow-up ended at the earliest of study end date, death, last day 
of available CPRD data, or 28 days after an incident UTI event. We identified 
eligible patients with a Read code indicating an incident primary care 
presentation with a suspected UTI (Code list 1 in Figure 3.1) and a same-
day prescription code indicating empirical prescribing of a relevant 
antibiotic. We defined ‘incident’ as a consultation occurring in a patient 
without a UTI-related Read code or trimethoprim or nitrofurantoin 
prescription in the preceding 90 days. We used the first incident episode 
during each patient’s follow-up period.  
We used the recorded empirical antibiotic prescription as the exposure 
variable and used primary care demographic and clinical codes to describe 
baseline characteristics for each exposure group. We used multivariable 
logistic regression to estimate odds ratios (ORs) and 95% CIs for 
associations between demographic and clinical variables and broad-
spectrum antibiotic prescribing for UTI. We then used mixed effects 
multivariable logistic regression to estimate ORs and 95% CIs for the risk of 
each adverse outcome with the general practice included as a random effect 
to account for clustering. The outcomes were re-consultation and re-
prescription within 14 days following the incident UTI (proxy for treatment 
failure), hospitalisation for UTI, sepsis or AKI within 14 days following the 
incident UTI, and death within 28 days following the incident UTI. More 
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detail on the justification and ascertainment of these outcomes is provided 
in section 3.7. 
We repeated the analyses using propensity-score matching to improve 
balance of baseline characteristics across the comparison groups. We first 
matched three patients with nitrofurantoin prescriptions to one patient with 
an amoxicillin prescription, and then repeated the process to compare 
nitrofurantoin with cefalexin, ciprofloxacin and co-amoxiclav.  We then 
matched three patients with trimethoprim prescriptions to one patient with 
an amoxicillin prescription, and again repeated the process to compare 
trimethoprim with cefalexin, ciprofloxacin and co-amoxiclav.  
5.3 Results 
From a cohort of 795,484 patients aged 65 and over, we identified 123,607 
(16%) with an incident UTI empirically treated with a relevant antibiotic 
(Figure 5.1). In this final cohort, 33,745 (27%) patients were male and the 
median age at time of incident UTI was 76 years (IQR 70-83). Trimethoprim 
was the most commonly prescribed antibiotic, accounting for 61% of all 
prescriptions, followed by nitrofurantoin (21%), cefalexin (6%), amoxicillin 
(5%), co-amoxiclav (4%) and ciprofloxacin (3%).  
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Figure 5.1. Flow of patients from initial identification in the database through to final cohort. 
 
5.3.1 Baseline characteristics 
There were differences in baseline characteristics across the antibiotic 
groups. For example, 55% of the ciprofloxacin group were male compared 
to 23% of the nitrofurantoin group and 26% of the trimethoprim group (Table 
5.1). Compared to the nitrofurantoin and trimethoprim groups, greater 
proportions of the amoxicillin, cefalexin, ciprofloxacin and co-amoxiclav 
groups had co-morbidities, particularly ischaemic heart disease, heart 
failure, and renal disease. Around 3% of the nitrofurantoin and trimethoprim 
groups had a Charlson score of ≥6, compared to 5-6% of the other groups. 
The presence of rheumatoid arthritis (adjusted OR 1.34, 95% CI 1.23-1.46), 
a urinary catheter (adjusted OR 1.32, 95% CI 1.23-1.43), urinary 
incontinence (adjusted OR 1.10, 95% CI 1.06-1.15), liver disease (adjusted 
OR 1.30, 95% CI 1.08-1.55), and polypharmacy (adjusted OR 1.17, 95% CI 
1.13-1.21), were all strongly associated with increased odds of a broad-
795,484 patients ≥65 years old between 1st January 2010 and 31st December 2016 
with data of the required quality and eligible for data linkage. 
769,574 patients eligible for inclusion 
123,607 patients had a record indicating an empirically treated UTI and were 
entered into the final cohort. 
Patients with temporary registrations or gaps in their data 
coverage (25,908) 
Patients with gender recorded as “indeterminate” (2) 
Patients without a record indicating a UTI (645,967) 
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spectrum antibiotic prescription (amoxicillin, cefalexin, ciprofloxacin or co-
amoxiclav, compared to nitrofurantoin or trimethoprim) (Table 5.2). Odds of 
a broad-spectrum antibiotic prescription also increased in a graded manner 
relative to increasing Charlson score and decreasing eGFR. Women had 
lower odds of a broad-spectrum antibiotic prescription than men, (adjusted 
OR 0.58, 95% CI 0.56-0.60), as did patients with dementia (compared to 
those without dementia; adjusted OR 0.91, 95% CI 0.85-0.97). 
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Table 5.1. Baseline characteristics by prescribed antibiotic. Values are numbers (%) unless otherwise stated. 
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Table 5.2. Association between baseline variables and broad-spectrum antibiotic 
prescribing. 
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5.3.2 Re-consultation and re-prescription 
In the 14 days following the incident UTI, 7598 (6.1%) patients re-consulted 
and were re-prescribed an antibiotic. Compared to nitrofurantoin, patients 
prescribed ciprofloxacin or co-amoxiclav had lower odds of re-consultation 
and re-prescription (adjusted OR for ciprofloxacin; 0.58, 95% CI 0.48-0.70, 
adjusted OR for co-amoxiclav; 0.86, 95% CI 0.74-0.99) (Table 5.3). 
Similarly, compared to trimethoprim, patients prescribed ciprofloxacin or co-
amoxiclav had lower odds of re-consultation and re-prescription (adjusted 
OR for ciprofloxacin; 0.55, 95% CI 0.46-0.65, adjusted OR for co-amoxiclav; 
0.81, 95% CI 0.71-0.93) (Table 5.4). Propensity-score matched analyses 
produced similar estimates, and also found a reduction in odds of re-
consultation and re-prescription in patients prescribed cefalexin (OR 
compared to nitrofurantoin; 0.85, 95% CI 0.75-0.98, OR compared to 
trimethoprim; 0.80, 95% CI 0.70-0.91) (Table 5.5). 
5.3.3 Hospitalisation for UTI 
In the 14 days following the incident UTI, 2057 (1.7%) patients were 
hospitalised for a UTI. We found no significant difference in the odds of UTI 
hospitalisation between nitrofurantoin or trimethoprim and the other 
antibiotics.  
5.3.4 Hospitalisation for sepsis 
In the 14 days following the incident UTI, 179 (0.1%) patients were 
hospitalised for sepsis. Patients prescribed ciprofloxacin had greater odds 
of hospitalisation for sepsis compared to nitrofurantoin (adjusted OR 3.12, 
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95% CI 1.65 - 5.92), and trimethoprim (adjusted OR 2.60, 95% CI 1.51 - 
4.49). Propensity-score matched analysis produced similar estimates. 
5.3.5 Hospitalisation for AKI 
In the 14 days following the incident UTI, 889 (0.7%) patients were 
hospitalised for AKI.  Compared to nitrofurantoin, patients prescribed 
ciprofloxacin had greater odds of hospitalisation for AKI (adjusted OR 1.71 
95% CI 1.18 - 2.48). We found a similar estimate in the propensity-score 
matched analyses but the OR was non-significant due to the smaller sample 
size that resulted from matching.  Compared to trimethoprim, patients 
prescribed amoxicillin, cefalexin or co-amoxiclav had lower odds of 
hospitalisation for AKI. Adjusted ORs were 0.69 (95% CI 0.50-0.95) for 
amoxicillin, 0.50 (95% CI 0.36-0.70) for cefalexin, and 0.63 (95% CI 0.45-
0.88) for co-amoxiclav. We found no significant difference in the odds of AKI 
hospitalisation between trimethoprim and ciprofloxacin. Propensity-score 
matched analyses produced similar estimates. 
5.3.6 Death 
In the 28 days following the incident UTI, 1029 patients (1.2%) died. 
Compared to nitrofurantoin, patients prescribed amoxicillin, cefalexin or co-
amoxiclav were more likely to die, with ORs of 1.51 (95% CI 1.16-1.97) for 
amoxicillin, 1.41 (95% CI 1.10-1.82) for cefalexin, and 1.63 (95% CI 1.24-
2.14) for co-amoxiclav. Patients prescribed amoxicillin, cefalexin or co-
amoxiclav were also more likely to die when compared to trimethoprim, with 
ORs of 1.37 (95% CI 1.09-1.73) for amoxicillin, 1.28 (95% CI 1.02-1.60) for 
cefalexin, and 1.48 (95% CI 1.16-1.88) for co-amoxiclav. There was again 
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consistency between estimates from multivariable regression and 
propensity-score matching. 
5.3.7 Sensitivity analyses 
The association between patients prescribed ciprofloxacin or co-amoxiclav 
and lower odds of re-consultation and re-prescription could be due to the 
significantly increased rates of sepsis hospitalisation (ciprofloxacin) and 
death (co-amoxiclav) in these group, preventing patients’ re-presenting to 
primary care. We therefore combined these three outcomes and found that 
7.3% of patients prescribed nitrofurantoin or trimethoprim re-consulted or 
were hospitalised for sepsis or died, compared to 6.4% of patients 
prescribed ciprofloxacin or co-amoxiclav, with an adjusted OR for the 
combined outcome of 0.82 (95% CI 0.74-0.90). 
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Table 5.3. ORs and 95% CIs for outcomes in patients prescribed nitrofurantoin versus amoxicillin, cefalexin, ciprofloxacin or co-amoxiclav.
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Table 5.4. ORs and 95% CIs for outcomes in patients prescribed trimethoprim versus amoxicillin, cefalexin, ciprofloxacin or co-amoxiclav. 
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Table 5.5. Propensity-score matched analyses comparing outcomes between nitrofurantoin, trimethoprim and other antibiotics. 
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5.4 Discussion 
Our results show that 6% of older adults empirically treated in primary care 
for a UTI re-consulted and were re-prescribed antibiotics, 2.5% were 
hospitalised for UTI, sepsis, or AKI, and 1% died. Patients with co-morbid 
conditions, polypharmacy and renal impairment had greater odds of broad-
spectrum antibiotic prescribing. Patients prescribed ciprofloxacin or co-
amoxiclav had lower odds of re-consultation and re-prescription. Patients 
prescribed ciprofloxacin had greater odds of sepsis hospitalisation, and 
those prescribed amoxicillin, cefalexin or co-amoxiclav had greater odds of 
death. These associations persisted in propensity-score matched analyses. 
Patients prescribed amoxicillin, cefalexin or co-amoxiclav had lower odds of 
hospitalisation for AKI when compared to trimethoprim, but not compared to 
nitrofurantoin. Overall, compared to nitrofurantoin, we found no evidence 
that amoxicillin, cefalexin, ciprofloxacin or co-amoxiclav were associated 
with a reduction in the risk of UTI-related hospitalisation or death. 
5.4.1 Results in context 
Previous research showed that age, gender, social deprivation and co-
morbid conditions were associated with increased rates of overall antibiotic 
prescribing, and age, insurance status, clinical setting, and clinician 
specialty were associated with increased rates of broad-spectrum antibiotic 
prescribing (78, 79). We add to previous work by identifying other co-morbid 
conditions that are associated with broad-spectrum antibiotic prescribing for 
UTI. We found that generally worsening health, reflected by increasing 
Charlson score or lower eGFR, had a relatively graded association with the 
odds of broad-spectrum antibiotic prescribing for UTI. This confirms the 
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hypothesis generated from previous qualitative work that suggested primary 
care clinicians were more likely to prescribe broad-spectrum antibiotics to 
sicker, frailer patients, and furthers our understanding of prescribing 
behaviour in clinical practice (77). 
Our findings suggest that patients prescribed ciprofloxacin or co-amoxiclav 
had lower odds of re-consultation and re-prescription, which may reflect 
lower odds of treatment failure. This was in contrast to previous trials that 
generally showed similar clinical cure rates between narrow and broad-
spectrum agents (145-147). This association remained significant when we 
combined the re-consultation and re-prescription outcome with 
hospitalisation for sepsis or death, suggesting that, despite the higher rates 
of sepsis and death in the ciprofloxacin and co-amoxiclav group, there 
remain a group of patients who were less likely to experience treatment 
failure with these agents. However, patients in the nitrofurantoin and 
trimethoprim groups who re-consulted and received another antibiotic 
prescription may have done so because of an adverse event or intolerance, 
rather than for treatment failure. 
Amoxicillin, cefalexin and co-amoxiclav were associated with lower odds of 
AKI hospitalisation compared to trimethoprim. There is a mechanistic 
explanation for this finding. Trimethoprim (and trimethoprim-
sulfamethoxazole) increases the risk of hyperkalaemia in patients co-
prescribed renin-angiotensin system drugs (84) and in older adults in 
general,(80) and thus, it is the hyperkalaemia that likely leads to an AKI-
coded hospital admission. Ciprofloxacin was associated with an increased 
risk of AKI hospitalisation compared to nitrofurantoin, which supports 
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previous findings of a two-fold increase in the risk of AKI associated with 
fluoroquinolone use (151). 
We found an increase in the odds of sepsis in patients prescribed 
ciprofloxacin. Almost 6% of the ciprofloxacin group had a Charlson score of 
≥6 and 55% were male, compared to 3% and 24% of the nitrofurantoin 
group. Therefore, this finding may be because these patients were sicker or 
had more complicated infection that resulted in a degree of residual 
confounding. It may also relate to higher levels of prior fluoroquinolone 
exposure, previously shown to be associated with increased sepsis risk, 
possibly due to disruption of the gut microbiome and subsequent 
dysregulation of the immune response to infection (152). 
Our finding of an increased risk of death in patients prescribed amoxicillin, 
cefalexin or co-amoxiclav is intriguing. There are several possible 
explanations. The antibiotics themselves may increase the risk of death, 
particularly in this cohort, many of whom had multiple co-morbidities and 
were prescribed multiple other drugs. This is not implausible; co-amoxiclav 
use is associated with acute liver injury, which may result in serious and 
protracted illness in elderly co-morbid patients (153).  It may also be due to 
antimicrobial resistance. For example, the 2017 English Surveillance 
Programme for Antimicrobial Utilisation and Resistance report showed that 
15% of community-acquired E.coli UTIs were resistant to co-amoxiclav, 
10% to cefalexin, but only 2% to nitrofurantoin (Amoxicillin resistance was 
not reported) (14).  However, this does not explain why co-amoxiclav or 
cefalexin had greater odds of death than trimethoprim, where resistance 
rates in England are around 30%. Therefore, some of these findings could 
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be due to residual confounding. Patients prescribed co-amoxiclav or 
cefalexin may have been less healthy, presented with more severe illness, 
and were therefore more likely to experience an adverse outcome 
irrespective of the prescribed antibiotic. Thus, it may be more appropriate to 
regard the exposure as a combination of patient and prescription factors, 
which is why we have related associations to the “patients prescribed 
cefalexin”, rather than the prescription alone.  
5.4.2 Strengths and limitations 
We used data from a general practice database that is broadly 
representative of the UK population (106). Cohort entry was dependent on 
presentation and empirical treatment of UTI in primary care, and thus 
reduced indication bias. We also reduced indication bias by repeating the 
analyses with propensity-score matching and achieving adequate balance 
of baseline characteristics across the groups. 
Our study has some limitations. We attempted to capture patients 
presenting with UTI but had no microbiological data to support this. 
However, whilst a limitation, this may be more representative of clinical 
practice as highlighted by a survey of women in the UK that found that only 
around 25% of those who presented to their GP with urinary symptoms had 
urine sent for laboratory analysis (15). Our outcomes, particularly sepsis 
and AKI, relied on coding and were not microbiologically or biochemically 
confirmed. We were unable to determine precise reasons for re-consultation 
and re-prescription and acknowledge that not all of these events may have 
been due to treatment failure. Based on current definitions (18), some 
patients may have presented with ‘complicated’ UTI, for which the 
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recommended treatment includes some of the alternative antibiotics 
assessed. Therefore, we have not commented on the appropriateness (or 
not) of the prescribed agent. Our findings are based on prescriptions and 
not on dispensed or ingested drugs.  Finally, despite our design, differential 
coding, indication bias and residual confounding may have affected our 
findings. 
5.5 Implications  
Our findings demonstrate the clinical burden and workload associated with 
UTI in older people. Around 16% of our cohort had at least one empirically 
treated UTI over a median follow-up of five years. There are around 12 
million people aged 65 and over in the UK. Therefore, over 5 years, around 
two million may present with a UTI and receive an antibiotic prescription, of 
whom 115,000 may re-consult and receive another antibiotic prescription, 
58,000 may be hospitalised for a UTI-related cause, and 20,000 may die. 
These estimates of UTI burden highlight the need for interventions that 
improve prevention and management in older people. The estimates for 
hospitalisation and mortality suggest that presenting to primary care with a 
suspected UTI may be an indicator of an increased risk of a short-term 
adverse event. This highlights the need for better diagnostic tests and 
processes that enable UTI to be reliably ruled in or out at the point of care, 
and, if ruled out, prompt assessment for other causes of the clinical 
presentation.    
Our findings also highlight the challenges associated with selecting 
antibiotics for older patients with suspected UTI. Given the association with 
increased risk of AKI, we suggest trimethoprim prescribing is reduced in 
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older adults. Compared to nitrofurantoin, we found no evidence that 
prescribing amoxicillin, cefalexin, ciprofloxacin or co-amoxiclav reduced the 
risk of hospitalisation or death, suggesting that the perceived aim expressed 
by clinicians in previous qualitative work was not being achieved, and thus 
supporting further reductions in prescribing of these agents, even in frailer, 
sicker patients.  
Future research should use qualitative methods to explore and understand 
reasons for continued use of broad-spectrum antibiotics for UTI in primary 
care. There is also a need for research that provides clinicians with 
information on which patients are most likely to benefit from broad-spectrum 
antibiotic use. This would ideally require a large-scale prognostic study with 
prospective data collected on structured case-report forms to ensure 
capture of variables that may had resulted in residual confounding in our 
study, for example, temperature, heart rate, self-reported severity of 
symptoms. A well-conducted prognostic study would widen understanding 
of which variables (either alone or in combination) best predict pre-specified 
adverse outcomes in patients with microbiologically confirmed UTI and help 
target antibiotics more appropriately. 
5.6 Conclusions 
A consistent finding in this study was that, compared to nitrofurantoin, 
patients prescribed ciprofloxacin or co-amoxiclav were less likely to re-
consult and receive a further antibiotic prescription. This may reflect a 
reduced risk of treatment failure. Our analyses also suggested that patients 
prescribed ciprofloxacin were more likely to be hospitalised for sepsis and 
patients prescribed co-amoxiclav were more likely to die. Combining the re-
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consultation and re-prescription outcome with hospitalisation for sepsis or 
death found that despite the higher rates of sepsis and death in the 
ciprofloxacin and co-amoxiclav group, some patients were still less likely to 
experience treatment failure with these agents. However, residual 
confounding, and the lack of microbiology data with which to ascertain 
resistance-related outcomes, significantly limit the conclusions that can be 
drawn from these findings.
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6 Association between antibiotic prescription duration 
and adverse outcomes in older men 
 
In chapter 4, we described trends in the duration of antibiotic treatment for 
UTI in older men in primary care. We found that the proportion of older men 
with UTI prescribed guideline congruent 7-day antibiotic treatment 
increased between 2004 and 2014. However, in 2014, 30% of older men 
with UTI received a prescription for a different duration. In this chapter, we 
present analyses on whether these different durations of antibiotic treatment 
had an impact on the risk of treatment failure, UTI-related hospitalisation, or 
death, in the 14-28 days following the incident UTI. We restricted these 
analyses to older men as this is where the evidence is lacking, unlike in 
older women, where meta-analyses of randomised trials support the 
recommended 3-day treatment period and thus, make it unlikely that 
observational data would add significantly to the current evidence base. 
6.1 Background 
Around 20% of all UTIs occur in men (154). The optimal duration of antibiotic 
treatment for UTI in older men is not known (155).  Most clinical guidelines 
recommend seven days of antibiotic therapy (19, 49, 67) but this 
recommendation is largely based on expert consensus due to the lack of 
data in this area. Previous randomised trials investigating different antibiotic 
durations for UTI in men have focussed on febrile (68, 69) or complicated 
UTI (70, 71), or men with spinal cord injury (72), and are not generalizable 
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to the majority of men with community-acquired UTI seen and treated in 
primary care.  
Antimicrobial stewardship policies and guidelines recommend prescribing 
the minimum duration of antibiotic therapy required for clinical resolution 
(115, 156). A recent observational study found no difference in the rate of 
clinical recurrence between US male Veterans with UTI prescribed long 
course (≥7 days) versus short course therapy (<7 days) (73). However, this 
study uses outpatient data alone, and may have missed men who were 
subsequently hospitalised with UTI-related emergencies such as sepsis or 
acute kidney injury. 
We therefore used the CPRD to estimate risk of adverse outcomes in older 
men prescribed different durations of antibiotic treatment for UTI in primary 
care. Our aim was to assess whether short course therapy was associated 
with an increased risk of treatment failure, hospitalisation for UTI, sepsis or 
acute kidney injury (AKI), or death, to determine the potential for safe and 
effective reduction of antibiotic treatment duration.  
6.2 Methods 
This was a retrospective cohort study. Men were eligible for inclusion if, 
between 1st January 2010 and 31st December 2016, they were ≥65 years 
old, had linked hospital data and more than one day of CPRD follow-up. We 
excluded men with temporary registrations or gaps in their data coverage. 
Follow-up began on the latest of study start date, the patient’s 65th birthday 
or 28 weeks after the patient first registered at the practice. Follow-up ended 
at the earliest of study end date, death, last day of available CPRD data, or 
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28 days after an incident UTI event. We identified eligible men with a Read 
code indicating an incident primary care presentation with a suspected UTI 
(code list 1 in Figure 3.1) and a same-day prescription code indicating 
empirical prescribing of a relevant antibiotic. We defined ‘incident’ as a 
consultation occurring in a patient without a UTI-related Read code or 
trimethoprim or nitrofurantoin prescription in the preceding 90 days. We 
used the first incident episode during each patient’s follow-up period.  
We used prescription data for daily dosing and total quantity prescribed to 
calculate duration of antibiotic prescriptions as a proxy for duration of 
treatment. We excluded prescriptions with durations >14 days as it is 
unlikely that these were prescribed for an acute UTI, and more likely that 
they reflected treatment for prostatitis. We also excluded prescription 
durations of 1, 2, 4, and 6 days, as together these represented <1% of all 
calculated durations and were potentially unreliable. The final exposure 
groups were 3, 5, 7 and 8-14 days. 
We used primary care demographic and clinical codes to describe baseline 
characteristics for patients by prescription duration. First, we assessed the 
impact of different prescription durations by using multivariable logistic 
regression to estimate ORs and 95% CIs for the risk of each outcome in 
those prescribed 7-day therapy, compared to those prescribed 3, 5 or 8-14 
days therapy. Outcomes were re-consultation and re-prescription within 14 
days following the incident UTI (proxy for treatment failure), hospitalisation 
for UTI, sepsis or AKI within 14 days following the incident UTI, and death 
within 28 days following the incident UTI. More detail on the justification and 
ascertainment of these outcomes is provided in section 3.7. 
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Second, we compared outcomes in men prescribed 3-day versus 7-day 
therapy using propensity score matching to improve balance of baseline 
characteristics across comparison groups. We chose 7 days as the 
reference standard as it is currently the recommended treatment duration 
for male UTI in the UK, and 3 days as the comparator as it is a potentially 
acceptable and feasible shorter duration of therapy, given that 3-day 
therapy is widely used to treat UTI in women. Prescriptions for duration of 5 
days or 8-14 days were not included in this analysis. 
We used mixed effects models in in the multivariable logistic regression 
analysis and the propensity score matched analysis, with the general 
practice included as a random effect to account for clustering. We repeated 
the analyses restricting to men prescribed trimethoprim, the most commonly 
used antibiotic for UTI in the UK during the study period. Finally, we 
calculated an E-value for our estimated associations  (157). The E-value is 
defined as the minimum strength of association, on the risk ratio scale, that 
an unmeasured confounder would need to have with both the exposure and 
the outcome to fully explain away a specific exposure-outcome association, 
conditional on the measured covariates. A large E-value implies that 
considerable unmeasured confounding would be needed to explain away 
an effect estimate. A small E-value implies little unmeasured confounding 
would be needed to explain away an effect estimate. 
6.3 Results   
From a cohort of 360,640 men aged 65 and over with a median follow-up of 
4.9 years (IQR 3.1-6.4), we identified 33,745 (9.4%) with an incident UTI 
treated with a relevant antibiotic (Figure 6.1). Of these, we were able to 
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assign an antibiotic prescription duration to 32,593 (96.6%) incident UTIs. 
The median age at the time of incident UTI was 77 years (IQR 70 - 83). In 
total, 1966 (6.0%) men were prescribed amoxicillin, 2002 (6.1%) 
ciprofloxacin, 2060 (6.3%) cefalexin, 2143 (6.6%) co-amoxiclav, 5724 
(17.6%) nitrofurantoin, and 18,698 (57.4%) trimethoprim. Guideline 
concordant 7-day therapy was prescribed to 20,729 (63.6%) men, 3-day 
therapy to 2498 (7.7%), 5-day therapy to 6254 (19.2%), and 8-14 days to 
3112 (9.5%). Baseline characteristics were broadly similar across the 
groups (Table 6.1).   
 
 
Figure 6.1. Flow of men from initial identification in the database to final cohort 
360,640 men ≥65 years old between 1st January 2010 and 31st December 2016 with 
data of the required quality and eligible for data linkage. 
348,981 men eligible for inclusion. 
33,745 men had a record indicating a UTI 
32,593 men entered into the final cohort. 
UTI events where antibiotic duration missing (29), >14 days 
(750), or unreliable (373).  
Men with temporary registrations or gaps in their data 
coverage (11,659). 
Men without a record indicating a UTI (315,236) 
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Table 6.1. Baseline characteristics according to antibiotic prescription duration. Values are 
numbers (%) unless otherwise stated 
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6.3.1 Outcomes according to treatment duration 
A total of 2007 (6.2%) men re-consulted and received another antibiotic 
prescription within 14 days following the incident UTI. Compared to 7-day 
therapy, there was a graded association between prescription duration and 
odds of re-consultation and re-prescription with adjusted ORs of 1.48 (95% 
CI 1.25-1.74) for 3-day therapy, 1.18 (95% CI 1.04-1.33) for 5-day therapy, 
and 0.80 (95% CI 0.67-0.96) for 8-14 day therapy (Table 6.2). 
A total of 817 (2.5%) men were hospitalised for UTI, 89 (0.3%) hospitalised 
for sepsis, and 449 (1.4%) hospitalised for AKI within 14 days following the 
incident UTI. There were no significant associations between antibiotic 
prescription duration and hospitalisation for UTI or sepsis. Compared to 7-
days, 3 and 8-14 day prescriptions were associated with reduced odds of 
hospitalisation for AKI (adjusted OR for 3-days 0.66, 95% CI 0.45-0.97, 
adjusted OR for 8-14 days 0.63, 95% CI 0.40-0.99). A total of 419 (1.3%) 
men died within 28 days of the incident UTI. There were no significant 
associations between antibiotic prescription duration and odds of death. 
6.3.2 Propensity score matched comparison of 7-day versus 3-day 
therapy 
We matched 2392 men prescribed 3-day therapy to 7182 men prescribed 
7-day therapy. Inspection of jitter plots and histograms suggested matching 
had improved balance of covariates across the two groups. Standardised 
mean differences were all less than 0.1 (Table 6.3). 3-day therapy was 
associated with increased odds of re-consultation and re-prescription (OR 
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1.52, 95% CI 1.25-1.85) and reduced odds of hospitalisation for AKI (OR 
0.62, 95% CI 0.42-0.93) (Table 6.4).   
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Table 6.2. Adjusted ORs and 95% CIs for each outcome by antibiotic prescription duration 
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Table 6.3. Baseline characteristics before and after propensity-score matching of men 
prescribed three versus seven days of antibiotics. Values are numbers (%) unless 
otherwise stated 
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Table 6.4. Odds ratios and 95% CIs for each outcome in men matched on their propensity to receive a seven-day antibiotic prescription 
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6.3.3 Sensitivity analyses 
We repeated both analyses restricting to men who received trimethoprim 
and found that all ORs were consistent with our main analyses. We 
calculated E-values for the two significant associations in our propensity 
score matched analysis. The E-value was 2.4 for re-consultation and re-
prescription, and 2.6 for AKI hospitalisation, suggesting any unmeasured 
confounder would require an OR of at least 2.4 for its association with 
antibiotic prescription duration and outcome, independent of measured 
confounders, to explain away the observed associations.  
6.4 Discussion 
We showed, for the first time, that in older men presenting to primary care 
with a UTI, 3-day antibiotic therapy was associated with a 52% increase in 
odds of re-consultation and re-prescription that could indicate treatment 
failure, but was not associated with increased odds of UTI-related 
hospitalisation or death. We also showed for the first time, an association 
between 3-day therapy and a 38% reduction in the odds of hospitalisation 
for AKI. 
6.4.1 Results in context 
A retrospective observational study of 33,336 index UTIs in US male 
Veterans found no difference in recurrence rates at 30 days between short 
and long duration antibiotic therapy (73). Similar to our study, inclusion was 
based on patients having a relevant diagnostic code and antibiotic 
prescription, without microbiological confirmation of UTI. However, this 
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study defined ‘short duration’ as ≤7 days, and 77% of the short duration 
group received 7-day therapy. Thus, their comparison was ≤7 days versus 
>7 days, and explains the discrepancy between our finding of increased 
odds of re-consulting and receiving another antibiotic prescription in short 
duration (3 or 5-day) versus long duration (7-day) therapy.  
Our finding of an association between 3-day antibiotic therapy and reduced 
odds of AKI could be explained by trimethoprim prescribing. Trimethoprim 
is associated with hyperkalaemia and AKI in older adults (80), and was 
prescribed to 85% of men in our matched analysis. Therefore, reduced 
exposure in the 3-day group may have resulted in reduced rates of AKI.   
Few randomised trials have investigated the potential for shorter duration of 
antibiotic treatment in men with UTI, and those that have focussed on more 
severe UTI. A Swedish trial of 114 men with febrile UTI showed similar 
clinical and microbiological cure rates between 14-day and 28-day antibiotic 
treatment (69). A randomised placebo controlled non-inferiority trial 
recruited men with febrile UTI from Dutch primary care and emergency 
departments, and showed 7-day antibiotic treatment was inferior to 14-day 
treatment in terms of clinical cure rates 10-18 days post UTI (68). In 
contrast, a US trial of men and women (39% men) with complicated UTI or 
acute pyelonephritis showed no difference in outcomes between those 
receiving 5-day versus 10-day antibiotic therapy (70). However, these trials 
recruited men with more severe UTI than that normally seen in a primary 
care setting. To the best of our knowledge, no trials have investigated the 
effect of short duration antibiotic therapy for men presenting to primary care 
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with symptoms suggestive of UTI, but without fever or other signs of 
ascending infection. 
6.4.2 Strengths and limitations 
We used data from a general practice database that is broadly 
representative of the UK population (106). Cohort entry was dependent on 
presentation and empirical treatment of UTI in primary care, and thus 
reduced indication bias. We also reduced indication bias by matching 
patients on their propensity to receive a 7-day prescription, and achieving 
adequate balance of covariates across treatment groups.  
Our study has important limitations. We attempted to capture patients 
presenting with UTI but had no microbiological data to support this. 
However, whilst a limitation, this may also be more representative of clinical 
practice. Our estimates are based on prescription duration and may 
overestimate actual antibiotic consumption because prescriptions may not 
have been collected, and if collected, consumed antibiotics may have been 
less than the prescribed amount.  Despite careful selection of codes used 
to identify eligible men, differential use of codes amongst clinicians means 
we may have included some men who had more complicated UTI or 
pyelonephritis. Although we found an increase in the rate of UTI-related re-
consultation and re-prescription among men prescribed 3-day therapy, we 
were not able to assess the appropriateness of these events. Some of these 
events may represent ‘treatment failure’, but others may reflect unrealistic 
expectations about the speed of symptom resolution. Therefore, even if 
symptoms were recovering at a similar rate in those receiving short versus 
longer duration antibiotic therapy, a higher rate of re-consultation (and 
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further prescriptions) in those receiving shorter duration therapy may reflect 
an unrealistic belief that symptoms should have fully resolved by the end of 
the treatment course. A related limitation is that patients with seemingly 
“milder” symptoms may have been prescribed three-day therapy with 
planned follow-up, therefore introducing a degree of “detection bias” if 
symptoms were not completely resolved. Finally, despite our design, 
differential coding, indication bias and residual confounding may still have 
affected our findings. However, our E-values suggest residual confounders 
would need relatively strong associations between antibiotic duration and 
outcomes to alter the conclusions from our effect estimates. 
6.5 Implications 
Our findings suggest it may be possible to safely reduce the duration of 
antibiotic treatment to 3 days for older men presenting to primary care with 
a UTI. For patients, shorter duration treatment could mean better adherence 
and less side effects but a higher rate of treatment failure. Using the 
propensity score matched event rates and ORs in table 4, we estimate that 
treating 150 older men with 3-day instead of 7-day therapy, could result in 
four extra re-consultation and re-prescriptions (numbers needed to harm = 
37) and one less AKI hospital admission (numbers needed to treat = 148) 
(158).  For health services, there is potential for significant cost savings from 
prescription costs alone. The analysis in chapter 4 found that around 7% of 
a sample of roughly 400,000 men ≥65 were prescribed an antibiotic in 
primary care for UTI in 2014. Current UK population estimates suggest there 
are around 5.2 million men aged ≥65 (159). A 7% annual UTI rate equates 
to around 364,000 UTI events. Based on current prescribing costs reported 
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in the British National Formulary (3-day trimethoprim = £3.60, 7-day 
trimethoprim = £10.00, 7-day nitrofurantoin = £9.50), if all men were 
prescribed 3-days of trimethoprim instead of 7 days, and men who re-
consulted were prescribed 7 days of nitrofurantoin, the UK health service 
could save around £2.2 million a year.  
Future research should focus on an adequately powered randomised 
placebo controlled trial of 3 versus 7 day antibiotic treatment for older men 
presenting to primary care with a UTI. In line with recent thinking on trials of 
antibiotic stewardship interventions, the trial should include an efficacy and 
safety related co-primary outcome (160). Secondary outcomes should 
include patient reported outcome measures and measures of antibiotic 
resistance, especially as there is little evidence on whether shorter antibiotic 
courses affect the risk of subsequent antibiotic resistance. The trial may also 
offer an opportunity to include a third arm and test the recently debated 
strategy of symptom guided treatment versus 3 days versus 7 days, to see 
if antibiotic treatment is effective in those who stop once symptoms have 
resolved rather than completing the prescribed course (161).  
6.6 Conclusions 
Our findings suggest that there may be potential to safely reduce the 
antibiotic treatment duration for older men with UTI in primary care to three 
days. These findings should be interpreted with caution given the potential 
for residual confounding and other biases inherent in retrospective studies 
of routinely collected healthcare data. However, reducing antibiotic 
treatment duration to three days may reduce antibiotic burden and 
prescription costs but may also increase the risk of treatment failure. A 
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definitive randomised trial of short versus standard duration treatment is 
urgently needed to better understand the benefits and harms of this 
approach.  
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7 Association between nitrofurantoin prescribing and 
adverse outcomes in older people with renal 
impairment 
 
In this chapter, we report analyses on whether nitrofurantoin is associated 
with increased risk of treatment failure, UTI-related hospitalisation, or death, 
in older people with UTI and a history of renal impairment. 
7.1 Background 
Nitrofurantoin and trimethoprim (alone or with sulfamethoxazole) are the two 
most commonly prescribed antibiotics for empirical treatment of UTIs and 
are recommended by clinical guidelines in the UK, USA, and Europe (18, 
19). Nitrofurantoin use was initially limited to those with an eGFR 
≥60mls/min/1.73m2, due to concerns about poorer efficacy in patients with 
lower eGFRs. In 2014, a review of the evidence (87)  and a retrospective 
cohort study (88) prompted the UK Medicines and Healthcare products 
Regulation Authority to lower the threshold for nitrofurantoin use to an 
eGFR≥45 mls/min/1.73m2. However, outcomes following empirical 
nitrofurantoin prescribing in older adults with a UTI and an eGFR <60 
mls/min/1.73m2 are yet to be fully evaluated. We used data from the CPRD 
to estimate the risk of treatment failure, hospitalisation for UTI, sepsis or 
acute kidney injury (AKI), or death, in older patients with an eGFR<60 
mls/min/1.73m2 who were prescribed empirical nitrofurantoin versus 
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trimethoprim, to inform prescribing decisions and explore if nitrofurantoin 
prescribing is safe in patients with renal impairment. 
7.2 Methods 
This was a retrospective cohort study. Patients were eligible for inclusion if, 
between 1st January 2010 and 31st December 2016, they were ≥65 years 
old, had linked hospital data and more than one day of CPRD follow-up. We 
excluded patients with temporary registrations or gaps in their data 
coverage. Patient follow-up began on the latest of study start date, the 
patient’s 65th birthday or 28 weeks after the patient first registered at the 
practice. Follow-up ended at the earliest of study end date, death, last day 
of available CPRD data, or 28 days after an incident UTI event. We identified 
eligible patients with a Read code indicating an incident primary care 
presentation with a suspected UTI (code list 1 in Figure 3.1), a same-day 
prescription code indicating empirical prescribing of nitrofurantoin or 
trimethoprim, and a creatinine record in the preceding 24 months. We 
defined ‘incident’ as a consultation occurring in a patient without a UTI-
related Read code or trimethoprim or nitrofurantoin prescription in the 
preceding 90 days. We used the first incident episode during each patient’s 
follow-up period.  
We used the most recent serum creatinine value recorded in the 24 months 
preceding the incident UTI and data for patient age, gender and ethnicity to 
calculate an eGFR as per the Modification of Diet in Renal Disease (MDRD) 
Study equation (127). The choice of 24 months was pragmatic. We judged 
this to be a long enough period for a sufficient number of our cohort to have 
a creatinine measurement, but also short enough to reasonably represent a 
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patient’s renal function at time of the index UTI. We categorised eGFRs as 
45-59mls/min/1.73m2, 30-44mls/min/1.73m2, and <30mls/min/1.73m2. To 
assess the impact of empirical trimethoprim versus nitrofurantoin 
prescribing, we used a range of demographic and clinical variables to match 
patients on their propensity to receive a trimethoprim prescription. We used 
nearest neighbour matching and matched three patients receiving 
trimethoprim with one patient receiving nitrofurantoin. We used mixed 
effects logistic regression to estimate ORs and 95% CIs for the risk of each 
adverse outcome, accounting for clustering within practices. Outcomes 
were re-consultation and re-prescription within 14 days following the 
incident UTI (proxy for treatment failure), hospitalisation for UTI, sepsis or 
AKI within 14 days following the incident UTI, and death within 28 days 
following the incident UTI. More detail on the justification and ascertainment 
of these outcomes is provided in section 3.7. 
7.3 Results 
From a cohort of 795,484 patients aged 65 and over, we identified 123,607 
with an incident UTI empirically treated with a relevant antibiotic (Figure 
7.1). Of these, 116,945 (95%) patients had a creatinine measurement 
recorded in the 24 months prior to the incident UTI, of whom 32,428 (28%) 
were male. The median age at time of incident UTI was 76 years (IQR 70-
83). Almost one third of creatinine measurements were in the 90 days prior 
to the incident UTI. Median duration between most recent creatinine and 
UTI was 169 days (IQR 65-285). We excluded 76,112 patients with an 
eGFR ≥60. Of the remaining 40,833 patients with an eGFR <60,   26,970 
(66.1%) had an eGFR of 45-59, 10,854 (26.6%) an eGFR of 30-44, and 
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3009 (7.3%) an eGFR of <15. In this cohort, 24,471 (60%) were prescribed 
trimethoprim and 7484 (18%) were prescribed nitrofurantoin. We matched 
20,948 patients with an eGFR of 45-60 (15,711 prescribed trimethoprim, 
5237 prescribed nitrofurantoin), 7260 with an eGFR of 30-44 (5445 
prescribed trimethoprim, 1815 prescribed nitrofurantoin), and 1728 with an 
eGFR <30 (1296 prescribed trimethoprim, 432 prescribed nitrofurantoin). 
Inspection of jitter plots and histograms suggested matching had improved 
balance of covariates across trimethoprim versus nitrofurantoin groups. 
Standardised mean differences were all less than 0.1 (Table 7.1).   
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Figure 7.1. Flow of patients from initial identification in the database through to final cohort 
795,484 patients ≥65 years old between 1st January 2010 and 31st December 2016 
with data of the required quality and eligible for data linkage. 
769,574 patients eligible for inclusion 
123,607 patients had a record indicating an empirically treated UTI 
116,945 patients with a creatinine recorded in the prior 2 years 
Patients with no record of a creatinine measurement in the 
prior 2 years (6662) 
Patients with temporary registrations or gaps in their data 
coverage (25,908) 
Patients with gender recorded as “indeterminate” (2) 
Patients without a record indicating a UTI (645,976) 
40,833 patients with an eGFR <60mls/min/1.73m2  
Patients with an eGFR ≥60mls/min/1.73m2 (76,112) 
Patients not prescribed nitrofurantoin or trimethoprim  (8878) 
31,955 patients with an eGFR <60mls/min/1.73m
2
 prescribed empirical 
nitrofurantoin or trimethoprim 
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Table 7.1. Balance of baseline characteristics across trimethoprim and nitrofurantoin groups following propensity score matching for patients with renal impairment. 
Numbers are values (%) unless otherwise stated 
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7.3.1 Re-consultation and re-prescription 
In the 14 days following the incident UTI, 1334 (5.9%) patients prescribed 
trimethoprim and 436 (5.8%) patients prescribed nitrofurantoin re-consulted 
and received another antibiotic prescription. These proportions were similar 
across the three eGFR groups; 6.0% v 5.5% in those with an eGFR of 45-
59, 5.8% v 6.4% in those with an eGFR of 30-44, and 5.7% v 6.7% in those 
with an eGFR of <30. Nitrofurantoin prescribing was associated with 
significantly lower odds of re-consultation and re-prescription in patients 
with eGFRs of 45-59 (OR 0.74, 95% CI 0.61-0.91), but no significant 
differences were found for the other eGFR groups (Table 7.2).  
7.3.2 Hospitalisation for UTI 
In the 14 days following the incident UTI, 529 (2.4%) patients prescribed 
trimethoprim and 185 (2.5%) patients prescribed nitrofurantoin were 
hospitalised for UTI. There were no significant differences between 
trimethoprim and nitrofurantoin for the odds of hospitalisation for UTI across 
the three eGFR groups. 
7.3.3 Hospitalisation for sepsis 
In the 14 days following the incident UTI, 47 (0.2%) patients prescribed 
trimethoprim and 10 (0.1%) patients prescribed nitrofurantoin were 
hospitalised for sepsis. There were no significant differences between 
trimethoprim and nitrofurantoin for the odds of hospitalisation for sepsis 
across the three eGFR groups. 
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7.3.4 Hospitalisation for AKI 
In the 14 days following the incident UTI, 356 (1.6%) patients prescribed 
trimethoprim and 62 (0.8%) patients prescribed nitrofurantoin were 
hospitalised for AKI. Nitrofurantoin prescribing was consistently associated 
with reduced odds of hospitalisation for AKI across the three eGFR groups.  
The proportions of patients hospitalised for AKI in the trimethoprim versus 
nitrofurantoin groups were 0.8% v 0.5% in those with an eGFR of 45-59 (OR 
0.62, 95% CI 0.40-0.94), 2.7% v 1.3% in those with an eGFR of 30-44 (OR 
0.47, 95% CI 0.30-0.73), and 6.5% v 3.0% in those with an eGFR of <30 
(OR 0.45, 95% CI 0.25-0.81). 
7.3.5 Death 
In the 28 days following the incident UTI, 321 (1.4%) patients prescribed 
trimethoprim and 91 (1.2%) patients prescribed nitrofurantoin died. 
Nitrofurantoin prescribing was associated with significantly lower odds of 
death in patients with eGFRs of 30-44 (OR 0.61, 95% CI 0.31-0.95), but no 
significant differences were found for the other eGFR groups.  
7.3.6 Sensitivity analysis 
We combined the hospitalisation and death outcomes to increase statistical 
power to detect these adverse outcomes but our findings were consistent 
with our main analysis (Table 7.3). Importantly, we did not detect any 
increase in odds of adverse outcomes in patients prescribed nitrofurantoin.  
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Table 7.2. Odds ratios and 95% confidence intervals for each outcome in propensity-score  matched trimethoprim versus nitrofurantoin groups, across three 
eGFR categories. 
 
125 
 
Table 7.3. Odds ratios and 95% confidence intervals for a combined “hospitalisation or 
death” outcome in propensity-score matched trimethoprim versus nitrofurantoin groups, 
across three eGFR categories. 
 
7.4 Discussion 
Our results show that compared to trimethoprim, nitrofurantoin was 
associated with reduced odds of hospitalisation for AKI across all eGFR 
groups. We found no evidence of an association between nitrofurantoin and 
increased risk of any adverse event evaluated in our study.   
7.4.1 Results in context 
Two previous studies assessed trimethoprim and nitrofurantoin prescribing 
in patients with renal impairment. The first compared treatment failure rates 
in women with UTI prescribed nitrofurantoin according to renal function and 
found no difference across the eGFR groups (88). This study lacked a 
comparator group prescribed an alternative antibiotic, which makes it 
difficult to interpret their findings. The second compared outcomes in older 
women with a median eGFR of 38mls/min/1.73m2, prescribed either 
nitrofurantoin or trimethoprim, and found no difference in risk of treatment 
failure or UTI hospitalisation (162). We compared nitrofurantoin with 
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trimethoprim across three eGFR groups, and found that nitrofurantoin was 
associated with lower odds of re-consultation and re-prescription in patients 
with eGFRs of 45-59. This difference could be explained by recent data 
showing that 34% of community-acquired E.coli UTIs in England are 
resistant to trimethoprim, compared to only 2.7% resistant to nitrofurantoin 
(14). However, rates of trimethoprim and nitrofurantoin resistance should be 
similar across eGFR groups, and therefore, why did we not find statistically 
significant differences between re-consultation and re-prescription rates in 
people with eGFRs <45? This could be due to less statistical power, as 
nitrofurantoin use was less common in these patients due to the advice to 
use with care in patients with eGFRs of 30-44 and to avoid in eGFRs <30. 
It may also be due to the possibility that nitrofurantoin efficacy was reduced 
in those with lower eGFRs but was offset by the high rates of trimethoprim 
resistance and thus resulted in apparent similar rates of re-consultation and 
re-prescription. However, it should be noted that the evidence for reduced 
nitrofurantoin efficacy in patients with renal impairment comes from several 
small studies that assessed urinary nitrofurantoin excretion, not clinical 
outcomes (87).  
Our finding that nitrofurantoin was associated with a reduced risk of death 
in those with moderate renal impairment is consistent with previously 
reported estimates in studies that compared nitrofurantoin with amoxicillin 
in the general population (80, 126). We also found a previously unreported 
lower risk of AKI associated with nitrofurantoin use across all three eGFR 
groups of our cohort, that aligns with previous studies that found 
trimethoprim (with or without sulfamethoxazole) prescribing was associated 
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with an increased risk of hyperkalaemia, AKI and death compared to 
amoxicillin (80, 81, 83, 126). However, previous studies did not investigate 
associations by degree of renal impairment, providing little information to 
guide prescribing in this population.   
7.4.2 Strengths and limitations 
We used data from a general practice database that is broadly 
representative of the UK population, increasing the generalisability of our 
findings. This is the first study to investigate trimethoprim versus 
nitrofurantoin prescribing in renal impairment, using clinically relevant eGFR 
groups analogous to stages of CKD, and without excluding men. We also 
reduced indication bias by matching patients on their propensity to receive 
trimethoprim, and achieving adequate balance of covariates across the two 
groups.  
Our study has important limitations. We attempted to capture patients 
presenting with UTI but had no microbiological data to support this. 
However, whilst a limitation, this may also be more representative of clinical 
practice. We were unable to investigate pulmonary/hepatic toxicity related 
to nitrofurantoin use due to the lack of reliable codes, and differential use of 
these codes by clinicians. However, two systematic reviews have shown 
that these toxicities are rare with short-term use (59, 163). We relied on a 
creatinine measurement from the 24 months prior to the UTI to estimate an 
eGFR, but this may not fully represent patients’ current renal function. 
Finally, despite our design, differential coding, indication bias and residual 
confounding may still have affected our findings. 
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7.5 Implications 
Current guidelines and the British National Formulary limit nitrofurantoin use 
to those with an eGFR >45mls/min/1.73m2, although short courses can be 
used with care in those with eGFRs >30mls/min/1.73m2 (19). We found no 
evidence to support this limitation, and actually found nitrofurantoin to be 
associated with a reduced risk of AKI compared to trimethoprim.  
7.6 Conclusion 
The recommendation to avoid nitrofurantoin in patients with an eGFR of 
<45mls/min/1.73m2 has meant clinicians have to choose between 
trimethoprim or broad-spectrum agents to treat UTI in this patient group. 
However, previous work has shown increasing rates of bacterial resistance 
to trimethoprim and highlighted the need to avoid broad-spectrum antibiotics 
to help contain resistance. Our data suggest nitrofurantoin may be a suitable 
narrow spectrum treatment option in older patients with eGFRs 
<45mls/min/1.73m2. We found no associated increase in the risk of adverse 
outcomes but our findings are limited by the potential for residual 
confounding and the lack of data on nitrofurantoin-related lung and liver 
toxicity, and therefore should be interpreted with a degree of caution.  
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8 Antibiotic prophylaxis versus non-antibiotic 
prophylaxis or placebo for prevention of recurrent 
UTI in older people: systematic review and meta-
analysis of randomised controlled trials 
 
In chapters 5 to 7, we focussed on antibiotic treatment for acute UTI. In 
chapters 8 and 9, we will focus on long-term antibiotic prophylaxis for 
recurrent UTI. This chapter presents a systematic review and meta-analysis 
of randomised trials of antibiotic versus non-antibiotic prophylaxis for 
recurrent UTI in older people to widen understanding of the evidence base 
for this practice.  
8.1 Background 
Older men and women are commonly prescribed long-term antibiotic 
prophylaxis to prevent recurrent UTI (2, 3). The prevalence of prophylaxis 
use in community dwelling older adults is not known but the HALT-2 point 
prevalence survey of 1181 long-term care facilities in 19 European countries 
found that, between April and May 2013, 22% of 77,264 surveyed residents 
were prescribed antibiotic prophylaxis for UTI (164). Figures for the UK are 
higher. For example, in Northern Ireland, point prevalence surveys of care 
home residents found that 39.3% were prescribed antibiotic prophylaxis for 
UTI in November 2010 (n=585), and 46% in April 2011 (n=578) (2). 
Antibiotic use is a key driver of antibiotic resistance (12). Therefore, 
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antibiotic use must be justified by robust evidence, where the estimated 
benefit outweighs estimated harm.  
Previous meta-analyses of 10 trials of 410 women showed antibiotic 
prophylaxis conferred a relative risk reduction of 79% in the proportion of 
women experiencing a microbiologically confirmed UTI, compared to 
placebo (93). However, these analyses included data from mostly small 
trials (sample sizes ranged from 27 to 60) of younger women (only 4 trials 
of 144 women included those aged over 65) without co-morbidities. There 
is uncertainty around the generalisability of these findings to older adults.  
There are several important clinical uncertainties relating to long-term 
antibiotic prophylaxis in older adults with recurrent UTI, including effect on 
frequency of infective episodes, optimal duration of prophylaxis, adverse 
effects, risk of relapse following cessation of prophylaxis and effect on 
urinary antibiotic resistance. We therefore systematically reviewed 
randomised controlled trials comparing long-term antibiotic prophylaxis with 
placebo or non-antibiotic prophylaxis for preventing further episodes of UTI 
in older people. Our aim was to quantify the benefits and harms of long-term 
antibiotic prophylaxis for older adults, to better inform patients and clinicians 
during clinical decision-making.  
8.2 Methods 
We conducted a systematic review following guidance from the Cochrane 
handbook for systematic reviews of interventions for conduct and PRISMA 
guidelines for reporting (165).  
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The review protocol was prospectively registered on PROSPERO: 
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD4201
5016628) registration number: PROSPERO 2015:CRD42015016628).  
8.2.1 Data sources  
We initially did a systematic search of Medline, Embase, CINAHL and the 
Cochrane Central Register of Controlled Trials from inception to March 2016 
for English language randomised controlled trials. Our search strategy 
consisted of keywords and MESH terms for urinary tract infection and 
randomised trials (Figure 8.1). The search was repeated in April 2018 to 
identify any recently published eligible studies.  
I conducted the first screening of potentially relevant records based on titles 
and abstracts. Due to time and resource constraints, these records were not 
screened by a second reviewer. The Cochrane Handbook for systematic 
reviews of interventions states in section 7.2.4 that “authors must first 
decide if more than one of them will assess the titles and abstracts of 
records retrieved from the search. Using at least two authors may reduce 
the possibility that relevant reports will be discarded” (166). We therefore 
acknowledge this issue in our limitations. The handbook also states that “It 
is most important that the final selection of studies into the review is 
undertaken by more than one author” and therefore I and another 
researcher independently performed the final selection of included trials 
based on full text evaluation. Reference lists of included studies and 
relevant systematic reviews were screened for further potentially relevant 
studies. Disagreements on which studies should or should not be included 
were resolved through discussion with the rest of the review team. 
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          Figure 8.1. Medline search strategy 
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8.2.2 Study selection 
We included only randomised controlled trials published in full (i.e., not 
abstracts) in English, comparing the effect of long-term antibiotic 
prophylaxis versus placebo or non-antibiotic prophylaxis on the rate of UTI 
in older adults with recurrent UTI. We defined “long-term antibiotics” as daily 
antibiotic dosing for at least six months, as clinical guidelines recommend 
reviewing patients after six-months of antibiotic prophylaxis to assess 
benefit (33).  We defined “older adults” as women who were 
postmenopausal or over the age of 65, and men aged over 65. We used the 
National Institute of Health and Care Excellence clinical guideline definition 
of “recurrent UTI” -  self-reported or clinically recorded history of two or more 
UTIs in six months, or three or more in 12 months (33). 
We included studies recruiting adults of all ages and screened relevant 
results to assess whether reported data allowed estimates of effect size in 
our specified population of older adults. For data not presented in this 
format, we contacted authors if the study was published in the last ten years 
and if the mean or median age in any arm was greater than 50 years. 
We excluded studies evaluating the effect of antibiotic prophylaxis in 
specific situations, e.g., post-catheterisation, post-surgery, in patients with 
spinal injuries or in those with structural renal tract abnormalities. 
135 
 
8.2.3 Outcome measures 
Our primary outcome was the number of urinary tract infection recurrences 
per patient year during the prophylaxis period, defined microbiologically 
(>100,000 colony forming units of bacteria/ml of urine) and/or clinically (for 
example, dysuria, polyuria, loin pain, fever), or other measure of change in 
the frequency of UTI events during prophylaxis.  We also aimed to assess 
the proportion of patients with severe (requiring withdrawal of treatment) 
and mild (not requiring withdrawal of treatment) adverse effects. Secondary 
outcomes included the proportion of patients who experienced at least one 
recurrence after the prophylaxis period, time to first recurrence, proportion 
of patients with antibiotic resistant micro-organisms in future urine samples, 
and quality of life. 
8.2.4 Data extraction and quality assessment 
We extracted study characteristics (setting, participants, intervention, 
control, funding source) and outcome data from included trials. We 
contacted two authors for sub-group data on postmenopausal women. One 
author replied and provided relevant outcome data. I and another member 
of the review team independently assessed the risk of bias of the included 
studies using the Cochrane Collaboration’s risk of bias tool (167). 
Disagreements were resolved through discussion. We used RevMan 
version 5.3 to meta-analyse the data and generate forest plots.  
8.2.5 Data synthesis and analysis 
Outcomes measured in only one trial were reported narratively. Outcomes 
measured in more than one trial were synthesised quantitatively. We 
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estimated between trial heterogeneity using the I2 statistic (168) and used 
random effects meta-analyses to estimate pooled risk ratios and 95% CIs 
(169). We undertook sensitivity analyses to examine treatment effects 
according to study quality and assessed the impact of including data from a 
potentially eligible trial where the study author did not reply to our request 
for data on older participants.  
8.3 Results 
From 6645 records, we identified 53 studies for full-text review (Figure 8.2). 
Four studies were eligible for inclusion (94-97). Two studies recruited only 
postmenopausal women (94, 95). Two studies recruited women of all ages 
but the median age was >50 years (96, 97). For these studies, we contacted 
authors requesting data for postmenopausal women, or if menopausal 
status not ascertained, for women aged over 65. We received data from one 
author and hence included three trials consisting of 594 postmenopausal 
women in our review (Table 8.1) (94-96).  We did not identify any studies 
that included older men.  
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Figure 8.2. PRISMA flowchart
Potentially relevant records after excluding duplicates (n=6645) 
 Medline (n=2273) Embase (n=4133) CINAHL (n=53) CENTRAL (n=196) 
 
Excluded after screening titles and abstracts (n=5992) 
 
Potentially relevant studies identified for full text evaluation (n=53) 
Studies excluded (n=50) 
Not randomised controlled trial (n=10) 
Not appropriate population (n=13)* 
Not appropriate disease (n=4) 
Not appropriate intervention (n=11) 
Not appropriate control group (n=11) 
Not addressing relevant outcome (n=1) 
*studies excluded if presented data did not allow calculation of outcomes for relevant age group. 
We wrote to authors of studies published in the last ten years to request outcome data stratified by 
age-group and menopausal status, and received data for one trial.  
 
 Included studies (n=3 randomised controlled trials) 
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Table 8.1. Characteristics of included studies. 
Study ID Setting N Population Intervention Control Confirmation of 
UTI 
Outcomes 
Raz 2003 Outpatient 
infection 
disease clinics 
in Northern 
Israel 
150 Community 
dwelling 
postmenopa
usal women 
with 
recurrent 
UTI┼ 
 
Nitrofurantoin 
100mg capsule 
at night for 9 
months, with 
placebo vaginal 
pessary to 
mimic control 
group 
Vaginal pessary 
containing 0.5mg 
Estriol daily for two 
weeks, then once a 
fortnight for nine 
months, with oral 
placebo capsules at 
night to mimic the 
intervention group 
>103 colony forming 
units/mL bacteria in 
midstream urine 
1.Number of women experiencing a 
recurrence during the prophylaxis period 
2.Mean number of UTIs per woman 
during the prophylaxis period 
3.Effects of oestrogens and antibiotics 
on vaginal mucosa, flora and pH 
4.Mild and serious adverse events 
 
Beerepoot 
2012 
Community 
setting in 
Amsterdam 
238 Community 
dwelling 
postmenopa
usal women 
with a self-
reported 
history of at 
least 3 UTIs 
in the 
preceding 
year 
Trimethoprim-
sulfamethoxazo
le 480mg tablet 
at night for 12 
months, with 
placebo 
capsule twice 
daily 
One capsule 
containing at least 
109 colony forming 
units of L rhamnosus 
GR-1 and L reuteri 
RC-14 twice daily for 
12 months, with 
placebo capsule at 
night 
Symptoms +/- >103 
colony forming 
units/mL bacteria in 
midstream urine 
1.Number of women experiencing a 
recurrence during, and three months 
after the prophylaxis period 
2.Mean number of UTIs per woman 
during the prophylaxis period 
3.Median time to first recurrence during 
and after the prophylaxis period 
4.Effects of lactobacilli and antibiotics on 
vaginal flora  
5.Effects of lactobacilli and antibiotics on 
urinary and faecal antibiotic resistance 
6.Mild and serious adverse events 
 
Kranjcec 
2014 
Outpatients 
and primary 
care in Zabok, 
Croatia 
206 Community 
dwelling 
women with 
self-reported 
recurrent 
UTI┼ 
Nitrofurantoin 
50mg at night 
for six months 
Two grams D-
mannose powder 
diluted in 200mls 
water at night for six 
months 
OR 
No treatment 
Symptoms and 
>103 colony forming 
units/mL bacteria in 
midstream urine 
1.Number of women experiencing a 
recurrence during the prophylaxis period 
2.Median time to first recurrence during 
the prophylaxis period 
3.Adverse events 
 
 
┼ defined as two confirmed episodes of uncomplicated UTI in six months, or three in twelve months. 
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Trials were conducted in community and outpatient settings in Israel, 
Netherlands and Croatia. Only one trial included individuals with diabetes 
(94) and only one trial included individuals with renal impairment (96). 
Intervention arms consisted of 6 to 12 months of antibiotic prophylaxis. 
Control arms consisted of non-antibiotic prophylaxis with vaginal oestrogen 
pessaries (95), oral lactobacilli capsules (94), and D-mannose powder (96). 
One trial reported the number of urinary tract infection recurrences per 
patient year during the prophylaxis period (94). All trials reported the number 
of women experiencing a UTI during the prophylaxis period and frequency 
of adverse events. Only one trial assessed recurrence of UTI after the 
prophylaxis period (3 months) (89). One trial assessed effect on urinary and 
faecal bacterial resistance (89). 
8.3.1 Risk of bias 
Figure 8.3 summarises the risk of bias assessment. Allocation and 
randomisation details were poorly reported in two trials (95, 96). One trial 
was assessed as high risk for performance and detection bias; trial arms 
consisted of an oral antibiotic capsule or D-mannose powder diluted in 
200mls water or no treatment with no use of placebo and did not report on 
blinding of outcome assessors (96). Only one trial reported a sample size 
calculation (95) . Overall, one trial was judged to be low risk of bias (94)  and 
two trials unclear risk due to limited reporting of methods (95, 96). 
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Figure 8.3. Summary of risk of bias assessment 
8.3.2 Effect of long-term antibiotic prophylaxis on recurrent UTI 
Compared to a capsule of Lactobacilli, prophylaxis with 480mg of 
trimethoprim-sulfamethoxazole for 12 months led to fewer  microbiologically 
confirmed UTI episodes per patient year ( mean number of episodes per 
year = 1.2 versus 1.8, mean difference 0.6, 95% CI 0.0-1.4, p=0.02). 
Prophylaxis with trimethoprim-sulfamethoxazole also led to less women 
experiencing a microbiologically confirmed UTI during prophylaxis (49.4% 
versus 62.9%; RR 0.79, 95% CI 0.63-1.0), and an increase in time to first 
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UTI (six months versus three months; log-rank p=0.02). There was no 
difference between arms in the mean number of microbiologically confirmed 
UTI episodes three months after cessation of prophylaxis (mean number of 
episodes = 0.1 versus 0.2, mean difference 0.0, 95% CI -0.1-0.3, p=0.64) 
(94) .  
Compared to vaginal oestrogen pessaries, prophylaxis with 100mg of 
nitrofurantoin for nine months led to fewer women experiencing a UTI during 
prophylaxis (42.3% versus 64.6%; RR 0.65, 95% CI 0.8-0.90), and a lower 
mean number of UTIs per woman (0.6 episodes per woman versus 1.6 
episodes per woman) (95).  
Compared to D-mannose powder, prophylaxis with 50mg of nitrofurantoin 
for six months led to more postmenopausal women experiencing a UTI 
during prophylaxis (24% versus 19%, RR 1.24, 95% CI 0.57-2.69) (96).  
Random effects meta-analysis (Figure 8.4) found that long-term antibiotic 
prophylaxis reduced the risk of a woman experiencing a UTI during the 
prophylaxis period (pooled RR 0.76, 95% CI 0.61-0.95) with about eight 
post-menopausal women needing treatment with long-term antibiotics to 
prevent one woman experiencing a UTI during the prophylaxis period 
(NNT=8.5).
 
Figure 8.4. Forest plot showing results of meta-analysis for proportion of women 
experiencing a UTI during the prophylaxis period 
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8.3.3 Adverse events 
Commonly reported side effects across the three trials included skin rash, 
gastrointestinal disturbance and vaginal symptoms. There were no 
statistically significant difference between odds of adverse events between 
trimethoprim-sulfamethoxazole and lactobacilli (94), or between 
nitrofurantoin and vaginal oestrogens (95). Risk of side effects with D-
mannose powder were significantly lower than with nitrofurantoin (RR 0.28, 
95% CI 0.13-0.57) (96). Overall, absolute numbers of serious adverse 
events or events resulting in treatment withdrawal were small.  
We had data on mild adverse events (not resulting in treatment withdrawal) 
for all three trials. There was marked heterogeneity between trials for 
adverse events (I2 = 86%). 
Meta-analyses showed no statistically significant difference between 
antibiotics and control for overall risk of mild adverse events (RR 1.52, 95% 
CI 0.76-3.03) (Figure 8.5).   
 
Figure 8.5. Forest plot showing results of meta-analysis for proportion of women 
experiencing mild side effect (treatment not withdrawn) during the prophylaxis period 
We extracted data for serious adverse events (resulting in treatment 
withdrawal) for two trials. Meta-analyses showed no statistically significant 
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difference between antibiotics and control for overall risk of serious adverse 
events (RR 0.90, 95% confidence interval 0.31-2.66) (Figure 8.6). 
 
Figure 8.6. Forest plot showing results of meta-analysis for proportion of women 
experiencing a serious side effect (resulting in treatment withdrawal) during the prophylaxis 
period 
8.3.4   Effect of long-term antibiotic prophylaxis on bacterial resistance 
Compared with lactobacilli, women receiving 12 months prophylaxis with 
trimethoprim-sulfamethoxazole showed dramatic increases in the 
proportion of antibiotic resistant bacteria isolated from urine and faeces. For 
example, 20-40% of urinary and faecal E coli isolates were resistant to 
trimethoprim-sulfamethoxazole, trimethoprim and amoxicillin at baseline, 
increasing to 80-95% after one month of treatment. Over the 15 month 
follow-up period, resistance levels decreased following cessation of 
prophylaxis but remained above baseline levels (94). 
8.3.5 Sensitivity analyses 
We assessed the impact of removing the study at high risk of bias on the 
pooled effect size and direction (96). Removal made little difference to the 
meta-analysis for proportion of women experiencing a UTI during the 
prophylaxis period (RR 0.74, 95% CI 0.61-0.89). Removal did impact on the 
meta-analysis for proportion of women experiencing mild side effects during 
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the prophylaxis period, but overall difference between antibiotics and 
placebo did not reach statistical significance (RR 0.99, 95% CI 0.82-1.20). 
We also pooled aggregate data from another potentially relevant study 
where authors did not respond to our request for data regarding 
postmenopausal women or women over 65 (97). This study compared 
500mg of cranberry extract to 100mg trimethoprim taken at night for six 
months. However, adding aggregate data for the whole study population 
(women aged 45 and above) to our meta-analysis for the proportion of 
women experiencing a UTI during the prophylaxis period made little 
difference to risk estimates (RR 0.74, 95% CI 0.61-0.90). 
8.4 Discussion 
This systematic review assessed evidence from three European 
randomised trials reported between 2003 and 2014. Trials only included 
women. Compared to controls, long-term antibiotic prophylaxis reduced the 
risk of postmenopausal women experiencing a recurrent UTI during the 
prophylaxis period, without a statistically significant increase in risk of 
adverse events. Data from one trial found that long-term antibiotic 
prophylaxis led to a dramatic increase in urinary and faecal antibiotic 
resistance, and resulted in a reduction in UTI recurrence only during the 
treatment period, with no benefit apparent three months after cessation of 
prophylaxis (94). However, trials were small with relatively short follow-up 
and had limitations in design and reporting, with one trial judged high risk of 
bias. 
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8.4.1 Results in context 
Meta-analysis of 10 randomised trials of women aged 18 and older found 
long-term antibiotics reduced the risk of UTI recurrence during the 
prophylaxis period by almost 80% (RR 0.21, 95% CI 0.13-0.34, NNT = 1.85) 
(93). Our analyses showed a smaller effect size and greater NNT for 
postmenopausal women, possibly due to more complex pathophysiology of 
recurrent UTI in this population. We did not identify a statistically significant 
increase in risk of adverse events associated with use of antibiotics. 
Adverse events are often poorly reported in trials (170), and we found  
heterogeneity for adverse events between trials. In addition, the studies 
included in this review compared long-term antibiotic prophylaxis with 
various non-antibiotic treatments and not placebo, and this may have 
influenced effect sizes for adverse events towards the null. We found small 
absolute numbers of serious adverse events, and cannot exclude the 
possibility of important effects being missed in these relatively small studies. 
During two point prevalence surveys, almost half of all adults residing in a 
sample of care homes were prescribed antibiotics for prevention of recurrent 
UTI (2, 3). Based on three small trials, with relatively short follow-up periods 
and design limitations, our meta-analyses suggest that this widely practiced 
use of prophylaxis reduces risk of recurrence in older women. However, it 
is still unclear if these benefits extend to older men or frailer care home 
populations. These are important gaps in current evidence, especially given 
large-scale observational data showing 10% of older men who experience 
an acute UTI go on to have at least one recurrence (73). 
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Only one study followed up participants after cessation of prophylaxis and 
found that beneficial effects had ceased after 3 months (94). Previous 
studies of younger women have reported similar findings suggesting that 
prophylaxis only confers protection from recurrence during the active 
prophylaxis phase (93). 
We found little data on the impact of long-term antibiotic prophylaxis on 
antibiotic resistance. Antibiotic use is associated with increased risk of 
resistance (12). Given the potential harms from acquiring an antibiotic 
resistant infection, the risk inferred by long-term antibiotic use is an 
important factor to consider with patients when making decisions about 
antibiotic prophylaxis.  
8.4.2 Strengths and limitations 
We conducted this review following prospective registration of a review 
protocol and in line with guidance from the Cochrane handbook for 
systematic reviews of interventions. The search strategies were 
comprehensive and supplemented with reviews of reference lists of relevant 
trials (94-97), systematic reviews (93, 103, 171) and clinical guidelines (18, 
19, 92). Only one reviewer screened the initially identified records, raising 
the possibility of relevant records being missed. However, two reviewers 
independently performed final selection of studies into the review. We 
contacted authors where additional data were required for study inclusion. 
Due to resource constraints, we limited searches to English language and 
may have missed potentially relevant studies. 
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8.5 Implications  
Based on the data analysed, a pragmatic approach is required when 
considering prescribing long-term antibiotic prophylaxis for older patients 
with recurrent UTI. Although long-term antibiotics may reduce the risk of UTI 
recurrence in women, this benefit diminishes upon cessation of treatment. 
Little is known about optimal prophylaxis period, long-term effects on health, 
risk of antibiotic resistant infections, effect in older men, effect in frail care 
home residents, or impact on important patient centred outcomes. These 
unknowns must be balanced against benefits and patient preferences. 
Future research efforts on recurrent UTI should focus on improving the 
design and reporting of trials and developing a core set of outcomes to allow 
better synthesis of trial data.  Antibiotic prophylaxis should be compared 
with non-antibiotic prophylaxis with some evidence of efficacy (such as 
vaginal oestrogens) rather than those with little or poor evidence of efficacy. 
Researchers should address unanswered questions regarding long-term 
effects, duration of use, adverse effects and antibiotic resistance. 
8.6 Conclusion 
There is ongoing uncertainty around the benefits and harms of long-term 
antibiotic prophylaxis in older men and frail care home residents with 
recurrent UTI. The effect of long-term antibiotic prophylaxis for older women 
with recurrent UTI was only assessed in three trials with a total of 594 
women. Two of these trials had important limitations in their design. 
Therefore, prescribing long-term antibiotic prophylaxis to older women with 
recurrent UTI needs careful discussion between patient and clinician of the 
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ongoing uncertainties in the evidence. Although the existing evidence 
suggests that antibiotic prophylaxis reduces the risk of relapse, it also 
suggests a potential increase in urinary and faecal antibiotic resistance and 
rapidly diminished benefit once prophylaxis stops.    
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9 Association between long-term antibiotic prophylaxis 
and outcomes in older people with recurrent UTI 
 
In chapter 8, we reported a systematic review and meta-analysis of the 
effect of antibiotic prophylaxis on outcomes in older people with recurrent 
UTI. We found that the evidence was limited to three small trials that only 
included postmenopausal women. In this chapter, we report analyses on 
associations between long-term antibiotic prophylaxis and UTI recurrence, 
acute antibiotic prescribing and hospitalisation, in older people with 
recurrent UTI.  
9.1 Background 
Clinical guidelines recommend several methods for preventing recurrent 
UTIs including avoidance of risk factors, vaginal oestrogens, 
immunoprophylaxis, or long-term low-dose antibiotic prophylaxis (67, 92).  
Our systematic review and meta-analysis of randomised trials found that 
long-term antibiotic prophylaxis reduced the risk of UTI recurrence in post-
menopausal women during 6-12 months of follow-up. However, we 
identified several areas of uncertainty that need to be addressed to better 
inform clinical decision making around the use of long-term antibiotic 
prophylaxis in older adults with recurrent UTI. Firstly, there are no robust 
data to inform long-term antibiotic prophylaxis use in men. Secondly, trials 
in post-menopausal women often excluded those with co-morbidities, such 
as diabetes, thus limiting their generalizability to real-world older 
populations. Thirdly, previous studies were underpowered to study 
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important but rare events such as hospitalisation. Fourthly, no high quality 
trials have reported the comparative effects of different antibiotics used for 
prophylaxis of recurrent UTI.  
An adequately powered, pragmatic, long-term randomised trial could 
address some of these uncertainties. However, given the challenges of 
recruitment and retention of older adults into clinical trials (172),  and the 
associated costs and time scales,  a trial may not be feasible. 
Epidemiological analysis of routinely collected large-scale healthcare data 
provides an opportunity to generate clinically useful evidence efficiently and 
cost-effectively. Therefore, we analysed data from anonymised linked 
health records of older adults with recurrent UTI to investigate gender-
specific associations between long-term antibiotic prophylaxis and clinical 
outcomes, including hospitalisation, whilst accounting for comorbidities, and 
compare risk of each outcome by antibiotic class. 
9.2 Methods 
This was a retrospective cohort study using the CPRD. Patients were 
eligible for inclusion if, between 1st March 2004 and 31st December 2015, 
their data were of the quality required by CPRD, they were ≥65 years old, 
eligible for data-linkage with hospital admission data, and met the definition 
of recurrent UTI.  We submitted the protocol and analysis plan for this study 
in 2016 and at that time the main clinical guideline for recurrent UTI was 
written by the Canadian Urological Association, who defined recurrent UTI 
as three or more uncomplicated incident UTIs in 12 months (92). We used 
this definition for our study. The recent NICE guideline for recurrent UTI use 
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a similar definition but also include people with 2 or more UTIs in the past 6 
months (33). 
Incident UTIs were identified using Read codes recorded by primary care 
clinicians or ICD-10 codes recorded in hospital admission data, as 
described in Figure 3.1 in chapter 3. Codes occurring within a short time-
frame of one another could represent multiple consultations for the same 
UTI-related episode. Previous observational research regarded codes 
occurring within 28 days of one another as belonging to the same illness 
episode and those occurring greater than 28 days apart as representing 
separate or distinct infections (25, 73, 110). We therefore used this 
approach to distinguish repeat consultations for the same episode from 
incident episodes.  
We excluded patients if they were temporary residents or had gaps in their 
data coverage. We also excluded those who had commenced a long-term 
antibiotic of interest prior to meeting the definition of recurrent UTI, those 
who met the definition of recurrent UTI but were prescribed long-term 
antibiotics other than those of interest to this study, and those with an 
exposure period of less than three months. 
9.2.1 Exposures 
The exposure of interest was prescription records indicating at least three 
consecutive months prescribing of trimethoprim, nitrofurantoin or cefalexin. 
We chose these antibiotics because: 
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1. Trimethoprim, nitrofurantoin and cefalexin were the only antibiotics 
recommended for long-term low-dose UTI prophylaxis by the British 
National Formulary during the study period.  
2. Previous studies of care home residents in Northern Ireland and 
Wales found that trimethoprim and nitrofurantoin were the most 
common antibiotics prescribed for UTI prophylaxis (2, 173). 
3. Including other long-term antibiotic prescriptions would risk 
assessing outcomes in patients where the prescription indication was 
not recurrent UTI, for example, long-term penicillins prescribed for 
recurrent cellulitis or prevention of infection in patients without a 
spleen. 
To investigate associations between long-term antibiotic prophylaxis and 
outcomes, we partitioned patients’ follow-up times into unexposed and 
exposed periods (Figure 9.1). Unexposed periods began from the day the 
patient met the definition of recurrent UTI to the earliest of, day of their first 
long-term antibiotic prescription, study end date (31st December 2015), 
death, or last day of available CPRD data. We identified long-term antibiotic 
prescriptions by searching for codes for nitrofurantoin, trimethoprim or 
cefalexin and restricting to those issued as a repeat prescription, rather than 
an acute prescription, using the “issueseq” variable in CPRD. These 
antibiotic are recommended to be taken once daily for UTI prophylaxis. 
Therefore, we used data on the quantity supplied to estimate the number of 
days of treatment covered by each prescription. We used these data to 
determine exposure periods and ensure that exposure periods contained at 
least three months of continuous long-term antibiotic prescriptions, allowing 
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up to seven days leeway at the end of each prescription for time to collect 
the next prescription. Exposed periods began from day of the first long-term 
antibiotic prescription to the earliest of, study end date (31st December 
2015), death, or last day of available CPRD data, as a continuous period 
irrespective of whether there were periods when the prescribed long-term 
antibiotic was changed. Therefore, we regarded patients as exposed to 
long-term antibiotic prophylaxis from the day of their first prescription to the 
end of their follow-up. We estimated risk of each outcome during exposed 
versus unexposed periods.  
 
Figure 9.1. Partitioning of patient follow-up time according to exposure status. 
 
To compare outcomes between the three specified antibiotics, we selected 
only those patients with an exposed period and partitioned their exposure 
period by the prescribed antibiotic (Figure 9.2). For example, a patient 
prescribed trimethoprim for six months and then nitrofurantoin for 9 months 
would have two exposure periods. For this analysis, follow-up began on the 
date of the first prescription and ended on the earliest of 90 days after the 
last prescription, date of the next exposure period, death, study end date, 
or last day of available CPRD data. 
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Figure 9.2. Partitioning exposure periods to compare different antibiotics prescribed for UTI 
prophylaxis. 
9.2.2 Outcomes 
The primary outcome was clinical recurrence, defined as a primary care 
record of symptoms or diagnoses indicating a UTI (using codes in code list 
1 in Figure 3.1) and a same-day antibiotic prescription.  
Secondary outcomes were all-cause primary care acute antibiotic 
prescribing, with one prescription equal to one event, UTI-related 
hospitalisation, ascertained from linked hospital data using relevant ICD-10 
codes for UTI and cystitis (codes N30.0, N30.9, N39.0), and all-cause 
(emergency and elective) hospitalisation. 
9.2.3 Statistical Analyses 
We used primary care demographic and clinical codes to describe baseline 
characteristics for patients exposed and not exposed to long-term antibiotic 
prophylaxis, and, for those exposed, further described characteristics by 
antibiotic class. We used random effects Cox recurrent event models to 
estimate hazard ratios (HR) and 95% CIs for each outcome. To reduce 
indication bias, we used a shared frailty term to account for correlated 
multiple events per person. This approach introduces a random covariate 
into the model that induces dependence among the recurrent event times, 
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and describes the excess risk for distinct individuals whilst accounting for 
unmeasured heterogeneity that remains unexplained using observed 
covariates alone (174-176).  
We adjusted for a range of potential confounding variables. These included 
age, Index of Multiple Deprivation score quintile, the presence or absence 
of a record indicating; diabetes, dementia, coronary heart disease, renal 
disease, stroke, cancer, heart failure, urinary incontinence and urinary 
catheter; polypharmacy, (defined as records indicating ≥5 long-term 
medications per months in the year prior to cohort entry), and a Charlson 
comorbidity score (125).  We also used the most recent serum creatinine 
value recorded in the 24 months preceding the incident UTI and data for 
patient age, gender and ethnicity to calculate an eGFR as per the 
Modification of Diet in Renal Disease (MDRD) Study equation (127). We 
measured confounding variables using data inputted prior to the date of 
cohort entry, except for age, which was calculated at the time of each event. 
We did several sensitivity analyses. The first was a pre-specified analysis 
where we selected only those patients with an unexposed and an exposed 
period and estimated risk of outcomes using a self-controlled case series 
design where each patient’s unexposed period acted as their own control, 
thus reducing bias from between person residual confounding. We did a  
post-hoc analysis to assess robustness of associations between long-term 
antibiotic prophylaxis and outcomes, where we used data on time between 
prescriptions, number of tablets issued and prescribed dosage instructions 
to split exposed periods into “consistent exposure”, “inconsistent exposure” 
and “post-exposure” periods and estimated risk of outcome for each period, 
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with the unexposed period as the reference. We also restricted analyses to 
only those prescribed the correct antibiotic dose defined as the dose 
recommended for UTI prophylaxis in adults by the BNF (50-100mg of 
nitrofurantoin at night, 100mg of trimethoprim at night, 125mg of cefalexin 
at night). Sensitivity analyses for the comparison between trimethoprim, 
nitrofurantoin and cefalexin included restricting to those prescribed the 
correct dose and those with only one exposure period.  
9.3 Results 
There were 966,454 patients aged ≥65 between 2004 and 2015 with data 
of the required quality and with linked hospital data, in the database.  Of 
these, 931,945 (96%) met our initial eligibility criteria, and 25,276 (2.7%) 
had clinical records indicating recurrent UTI. Following further exclusions 
(Figure 9.3), we entered 19,696 patients from 393 primary care practices 
into our final cohort. 2737 (13.9%) of these patients had a period of 
exposure to long-term antibiotic prophylaxis, of whom 508 (18.6%) were 
men.   
9.3.1 Baseline characteristics 
Table 9.1 shows characteristics of included patients with recurrent UTI who 
were prescribed long-term antibiotic prophylaxis during their follow-up 
period (i.e., had a period of exposure) versus those who were not (i.e., 
remained unexposed). Characteristics were mostly similar except for higher 
proportions of patients with urinary incontinence and polypharmacy in those 
with a period of exposure. We adjusted for both these characteristics in our 
analyses. Baseline characteristics were also similar according to prescribed 
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antibiotic for those with exposure periods, except for a higher proportion of 
men in exposure periods with trimethoprim (21%) compared to 
nitrofurantoin (17%) or cefalexin (14%) (Table 9.2).   Almost half of those 
exposed were initially prescribed trimethoprim. Over 20% of those exposed 
were prescribed their long-term antibiotic prophylaxis at a dose greater than 
that recommended for UTI prophylaxis by the British National Formulary 
(Table 9.3). Almost 50% of patients were prescribed long-term antibiotic 
prophylaxis for over two years. 
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Figure 9.3. Flow of patients from initial identification in the database through to final cohort 
966,454 patients ≥65 years between 2004 and 2015 with linked hospital data and 
with data quality of the required standard 
931,945 patients eligible for inclusion 
25,276 patients had ≥3 UTIs within 365 days, therefore meeting our definition of 
recurrent UTI 
19,696 patients eligible for entry to cohort 
Patients excluded (5580):  
Exposed to antibiotics other than cefalexin, trimethoprim or 
nitrofurantoin (3141)  
Less than 3 months of exposure (1317)  
Long-term antibiotics initiated before meeting definition of 
recurrent UTI (1122)  
2737 patients were prescribed long-
term antibiotics during their follow-up 
period.  
Men=508, Women=2229 
16,959 patients were not prescribed 
long-term antibiotics during their 
follow-up period.  
Men=3535, Women=13,424 
Patients with temporary registrations or gaps in their data 
coverage (34,506) 
Patients with gender recorded as “indeterminate” (3) 
Patients without recurrent UTIs (906,669) 
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Table 9.1. Characteristics of individuals with recurrent UTI prescribed long-term antibiotic 
prophylaxis versus those not prescribed long-term antibiotic prophylaxis. Values are 
numbers (%) unless otherwise stated 
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Table 9.2. Characteristics of patients according to antibiotic exposure period. Values are 
numbers (%) unless otherwise stated 
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Table 9.3. Initial choice, dose and duration of long-term antibiotic prophylaxis. Values are 
numbers (%) unless otherwise stated 
 
9.3.2 Long-term antibiotic prophylaxis and risk of each outcome 
Of 4043 men, 2750 men had 10,722 clinical recurrences diagnosed and 
treated in primary care. There were 9387 recurrences during unexposed 
periods and 1335 recurrences during exposed periods (Figure 9.4). 
Compared to unexposed periods, there was a statistically significant lower 
risk of clinical recurrence during periods of exposure to long-term antibiotic 
prophylaxis (adjusted HR 0.49, 95% CI 0.45-0.54). There was a 22% 
reduction in risk of UTI-related hospitalisation (adjusted HR 0.78, 95% CI 
0.64-0.94) and a 46% reduction in risk of all-cause acute primary care 
antibiotic prescribing (adjusted HR 0.54, 95% CI 0.51-0.57). We found no 
significant association between long-term antibiotic prophylaxis and all-
cause hospitalisation. Risk estimates were consistent across all sensitivity 
analyses (Table 9.4). 
Of 15,653 women, 11,845 women had 60,124 clinical recurrences, with 
51,748 recurrences during unexposed periods and 8376 recurrences during 
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exposed periods (Figure 9.4). Compared to unexposed periods, there were 
statistically significant lower risks of clinical recurrence (adjusted HR 0.57, 
95% CI 0.55-0.59), and all-cause acute antibiotic prescribing (adjusted HR 
0.61, 95% CI 0.59-0.62), during periods of exposure to long-term antibiotic 
prophylaxis. These estimates were consistent across all sensitivity 
analyses. There was a 19% increase in risk of UTI-related hospitalisation 
during periods of long-term antibiotic prophylaxis (adjusted HR 1.19, 95% 
CI 1.08 -1.31). However, when we re-assessed the risk of UTI-related 
hospitalisation in our sensitivity analysis using a self-controlled case series 
design, the direction of effect reversed, showing an 18% risk reduction, 
(adjusted HR 0.82, 95% CI 0.72-0.94) (Table 9.5). We found no significant 
association between long-term antibiotic prophylaxis and all-cause 
hospitalisation in our main analysis, but found an 8% risk increase in our 
self-controlled case series analysis (adjusted HR 1.08, 95% CI 1.02-1.15).  
9.3.3 Comparing outcomes between trimethoprim, nitrofurantoin and 
cefalexin  
There were 3728 exposure periods among 2737 patients, 1559 for 
trimethoprim, 1359 for nitrofurantoin and 810 for cefalexin. There were 2553 
clinical recurrences among 853 patients during trimethoprim exposure, 
2233 clinical recurrences among 707 patients during nitrofurantoin 
exposure, and 1679 clinical recurrences among 474 patients during 
cefalexin exposure. Compared to trimethoprim, exposure to nitrofurantoin 
or cefalexin was associated with a reduced risk of clinical recurrence 
(adjusted HR for nitrofurantoin 0.87, 95% CI 0.80-0.95, adjusted HR for 
cefalexin 0.70, 95% CI 0.64-0.77). There were no statistically significant 
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differences between trimethoprim and nitrofurantoin for any other outcome. 
Compared to trimethoprim, cefalexin exposure was associated with an 18% 
reduction in all-cause primary care acute antibiotic prescribing (adjusted HR 
0.82, 95%CI 0.77-0.88), but was not statistically significantly associated with 
UTI-related hospitalisation or all-cause hospitalisation. 
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Figure 9.4. Number of events, person years of follow-up, and adjusted hazard ratios for each outcome 
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Table 9.4. Number of events, person years of follow-up and adjusted hazard ratios for main and sensitivity analyses in older men 
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Table 9.5. Number of events, person years of follow-up and adjusted hazard ratios for main and sensitivity analyses in older women 
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9.4 Discussion 
We found reduced risks of clinical recurrence and all-cause acute antibiotic 
prescribing for older men and women with recurrent UTI during periods of long-
term antibiotic prophylaxis. There was also a reduced risk of UTI-related 
hospitalisation in older men. These associations were consistent across several 
sensitivity analyses. We found an unexpected increased risk of UTI-related 
hospitalisation for women associated with exposure to long-term antibiotic 
prophylaxis, although the direction of effect reversed in our analysis that used 
individuals as their own controls. We therefore hypothesise that this inconsistent 
finding is due to residual unmeasured confounding that was unaccounted for in 
the main analyses. For example, women who received prophylaxis may have 
been less healthy than women who did not receive prophylaxis and thus at 
increased risk of hospitalisation irrespective of exposure. This may also explain 
the inconsistencies between findings for antibiotic prophylaxis and all-cause 
hospitalisation in women. Given the observed inconsistencies in risk estimates, 
these findings warrant further investigation. We also found that, compared to 
trimethoprim, nitrofurantoin and cefalexin were associated with a reduced risk of 
clinical recurrence, and cefalexin was associated with a reduced risk of all-cause 
acute antibiotic prescribing. 
9.4.1 Results in context 
To our knowledge, there are no rigorous randomised trials or observational 
studies investigating the effect of antibiotic prophylaxis in older men with recurrent 
UTI.  One previous observational study found that around 13% of older men who 
experienced a UTI had at least one recurrence (73). Our analyses showed that 
only 13% of older men with recurrent UTI were prescribed long-term antibiotic 
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prophylaxis, but those that were had significantly lower rates of clinical 
recurrence, UTI-related hospitalisation and all-cause acute antibiotic prescribing. 
The low prescribing rates are likely due to male UTI being considered a more 
complicated infection and thus reluctance to prescribe until serious causes have 
been excluded, and also due to the dearth of empirical data to inform clinical 
practice.  
Our finding of reduced risk of clinical recurrence for older women exposed to long-
term antibiotic prophylaxis is consistent with findings from meta-analyses of post-
menopausal women (177) and younger women (93). Our finding of an increased 
risk of UTI-related hospitalisation among women exposed to long-term antibiotic 
prophylaxis in our main analysis warrants further investigation. To the best of our 
knowledge, no previous observational research has reported on the association 
between antibiotic prophylaxis for UTI and UTI-related hospitalisation, and clinical 
trials of antibiotic prophylaxis in postmenopausal women did not assess 
hospitalisation as an outcome (177). Reversal of the risk estimates in our self-
controlled analysis suggests that the initial finding was due to residual 
confounding but the study needs to be repeated in an independent data-set to 
address this uncertainty. 
9.4.2 Strengths and limitations 
To our knowledge, this study is the first to; provide robust data to inform the use 
of long-term antibiotic prophylaxis in older men with recurrent UTI; estimate risk 
of important clinical outcomes, including hospitalisation, in an unselected, real-
world cohort of older adults with recurrent UTI; and provide estimates of 
comparative effectiveness of three antibiotics commonly used for UTI 
prophylaxis. This is a large study based on a representative sample of older 
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people with over 60,000 person years of follow-up. We used a strict definition of 
three clinically recorded incident UTI episodes in one year to define eligibility and 
limit indication bias. Clinical trials used self-report (94), primary care records (97), 
or were unclear about how they identified patients with a history of recurrent UTI 
(95, 96). Similar to previous database research on infections, we used Read and 
ICD-10 codes to identify UTI episodes and made allowances to distinguish repeat 
consultations for the same episode from incident episodes (25, 110). We used 
primary care records to ascertain exposure to long-term antibiotic prophylaxis. 
Recording of prescriptions issued in UK primary care has high levels of 
completeness, thus representing an accurate and reliable source of exposure 
data (178). We used clinically recorded diagnoses to adjust for a range of co-
morbid conditions with previous research suggesting these are reliably coded in 
primary care records (130).  
A limitation of our study is the use of clinical recurrence rather than 
microbiologically confirmed recurrence as the primary outcome. The main reason 
for this is that the CPRD does not contain microbiological data but, even if it did, 
urine sampling in UK primary care is highly variable and therefore less useful in 
a retrospective study. The lack of microbiology data also meant we were unable 
to investigate any impact on urinary bacterial antibiotic resistance. Our exposure 
data represented antibiotic prescribing, not antibiotic use. We were unable to 
investigate antibiotic related adverse events. A wide variety of codes could be 
used to record these events and it is difficult to reliably associate these codes 
with the prescribed antibiotic without a more detailed account of the clinical 
scenario.  It is likely that residual confounding affected the findings regarding 
antibiotic prophylaxis and UTI-related hospitalisation in older women. Despite our 
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design, indication bias and residual confounding may also have affected other 
findings.  However, there were few baseline differences between those 
unexposed to long-term antibiotic prophylaxis versus those exposed. 
Furthermore, we carried out several sensitivity analyses and interpreted 
inconsistent risk estimates cautiously, and within the constraints of the limitations 
inherent in observational study designs.  
9.5 Implications  
Clinicians should consider several factors when discussing the risks and benefits 
of long-term antibiotic prophylaxis in older women with recurrent UTI. Firstly, the 
evidence from this study and from previous trials, showing that long-term 
antibiotic prophylaxis reduces the risk of UTI recurrence. Secondly, trial evidence 
showing that long-term antibiotic prophylaxis does not significantly increase the 
risk of adverse events but does significantly increase the rate of urinary and fecal 
antimicrobial resistance. Thirdly, the findings from this study that suggest the 
association between antibiotic prophylaxis and the risk UTI-related hospitalisation 
is not clear. We suggest clinical guidelines make recommendations around 
antibiotic prophylaxis for recurrent UTI clearer, highlighting risks, benefits, and 
ongoing uncertainties, with clear guidance on appropriate patient selection and 
monitoring. We suggest recommending nitrofurantoin first-line for those with no 
contraindication. 
Our analyses suggest older men with recurrent UTI could benefit from long-term 
antibiotic prophylaxis. We suggest clinicians consider long-term nitrofurantoin in 
selected older men with a clear history of recurrent UTI, following appropriate 
assessment for treatable functional or structural causes, and in light of the 
ongoing uncertainty about rates of adverse events and impact on antibiotic 
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resistance. In the absence of an adequately powered randomised trial, these 
study results provide the only robust data currently available to inform clinical 
practice in this area.  
9.6 Conclusions 
Antibiotic prophylaxis may reduce rates of recurrence and all-cause antibiotic 
prescribing in older people with recurrent UTI. They may also reduce UTI-related 
hospitalisations in older men but their effect on hospitalisations in older women 
requires further investigation, as does their impact on antibiotic resistance. 
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10 Main findings and implications for practice, policy 
and future research 
 
The aim of the research reported in this thesis was to generate new 
evidence that could help towards more standardised and prudent antibiotic 
prescribing for UTI in older people. In this chapter, we summarise the main 
findings and discuss how they may inform clinical practice, policy and future 
research, and reflect on the strengths and limitations of the research. 
10.1 Main findings 
The main findings of this research are: 
1. 21% of older people in this CPRD sample were clinically 
diagnosed with at least one UTI between 2004 and 2014, 96% of 
whom received a same-day empirical antibiotic prescription. In 
the 14-28 days following empirical antibiotic prescription for 
suspected UTI, 6% of older people in this sample re-consulted 
and received another antibiotic prescription, 2.5% were 
hospitalised for UTI, sepsis, or AKI, and 1% died.  
 
These findings highlight the impact of UTI-related clinical presentations on 
NHS workload. Population estimates suggest there are almost 12 million 
adults aged over 65 in the UK (159). We estimate that If 21% of adults in 
this age-group present at least once with a suspected UTI over the next 10 
years, this will initially result in 2.5 million GP consultations and 2.4 million 
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antibiotic prescriptions. Following initial presentation, 145,000 older people 
will re-consult their GP and receive another antibiotic prescription, 60,000 
will be hospitalised for UTI, sepsis, or AKI, and 24,000 will die. These may 
be conservative estimates given that the number of adults aged 65 and over 
in the UK are projected to increase to around 18 million, and the median 
number of UTI-related presentations in our sample was 2. However, these 
estimates are based on a sample where 96% were prescribed same-day 
empirical antibiotics. Previous work based on reviews of clinical guidelines 
and expert opinion suggests that ideally, 75-90% of people presenting with 
UTI should receive same-day antibiotics (179). Furthermore, coding issues 
meant our sample did not include about one-third of all possible UTI 
presentations. Therefore, including patients with a higher than expected 
empirical antibiotic prescribing rate, and not including people who were 
prescribed a UTI-specific antibiotic but were not coded accurately enough 
for inclusion, may have introduced bias and affected the generalisability of 
our findings.   
Despite the aforementioned limitations, our work suggests that UTI-related 
presentations are an important source of NHS workload and antibiotic 
prescribing. There are several implications of these findings for clinical 
practice. First, older people need to be supported with evidence-based 
interventions that may safely prevent both UTI, and associated symptoms 
that are commonly mistaken for UTI. For example, recent randomised trial 
evidence found that increasing fluid intake by 1.5 litres of water a day in 
young women with recurrent UTIs, reduced the mean number of cystitis 
episodes from 3.2 to 1.7 per year, and mean number of antibiotic 
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prescriptions for UTI from 3.6 to 1.9 per year. Implementing this intervention 
in community-dwelling older people may be challenging, but implementation 
in care homes may be less difficult and may prevent a sizable proportion of 
UTIs given the high incidence in this population. Measures to prevent 
cystitis symptoms related to non-UTI causes may also help to reduce the 
proportion of patients who present with suspected UTI and consequently 
receive an antibiotic prescription. For example, older women may present 
with cystitis symptoms secondary to oestrogen deficiency. Randomised 
trials found that older women using vaginal oestrogen cream or pessaries 
had a 36-75% reduction in the relative risk of a UTI diagnosis, compared to 
placebo (103). Therefore, prevention of UTI and genitourinary symptoms 
commonly mistaken for UTI may be the most effective method of reducing 
unnecessary antibiotic prescribing for UTI, because once patients consult 
with these symptoms, most will receive an antibiotic prescription. 
Second, there is a need for a shift in the diagnostic approach to UTI in older 
people. A total of 96% of older people who consulted with a suspected UTI 
received an empirical antibiotic prescription, presumably because the 
consulting clinician judged a UTI to be likely. Yet, the POETIC study 
(described in detail in section 2.9) found that of 726 women (mean age 45 
years) presenting to GPs with suspected UTI, all of whom provided a mid-
stream urine sample for microbiological analysis, 702 (88.5%) were 
prescribed antibiotics but only 259 (35.7%) had a microbiologically proven 
UTI (74). The diagnostic yield in older people may be lower because urine 
sampling may occur when they present with non-specific symptoms such 
as change in behaviour or falls. The potential for unnecessary antibiotic 
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prescribing may be greater because urine sampled for a non-specific clinical 
presentation may show bacterial growth that is actually asymptomatic 
bacteriuria but the interpreting clinician judges it as a UTI. Even if diagnostic 
yield in older people is similar to the POETIC study, up to 65% or 1.56 million 
of the projected 2.4 million antibiotic prescriptions for suspected UTI over 
the next 10 years may be unnecessary. Clinicians therefore need to adopt 
a more sceptical approach to UTI diagnosis in older people, with more 
consideration of alternate diagnoses that could explain the presenting 
symptoms, and better use of data that provide some insights into the 
predictive value of different symptoms, signs and bedside tests. However, 
the limitation of these data is that the performance of the symptoms, signs 
and bedside tests were most often assessed against urine culture, which is 
an imperfect reference standard. 
Third, clinicians need to be supported to widen the use of delayed antibiotic 
prescribing as a potential management strategy for selected patients 
presenting with suspected UTI. Current NICE and Public Health England 
guidance suggests considering delayed prescribing for those with milder 
symptoms (32, 49), and previous research in younger women found delayed 
prescribed reduced antibiotic use compared to immediate prescribing 
without any important impact on symptoms severity or duration (50). 
Given our findings, future research should develop and test interventions 
that may prevent UTI. For example, there is interest in immunoprophylaxis 
but its effect is not fully understood and further adequately powered 
randomised trials are needed (171). There is also a need for a programme 
of work around UTI diagnosis. A key limitation for UTI diagnostic accuracy 
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studies is the lack of an ideal reference standard. It may be time for a “back 
to basics” approach, to truly nail down what biochemical and microbiological 
features in urine reflect a UTI. Without addressing the current limitations of 
urine culture as a reference standard, future diagnostic studies will not add 
to the current limited evidence base. Finally, there is a need for randomised 
trials of delayed versus immediate antibiotic prescribing in older adults to 
understand if benefits seen in younger women are applicable to this 
population. 
 
2. Between 2004 and 2014, trimethoprim was prescribed to about 
50% of older people with UTI with little change over time, 
Nitrofurantoin prescribing increased, and broad-spectrum 
antibiotic prescribing decreased. Outcomes were no better for 
patients empirically prescribed broad-spectrum antibiotics 
compared to those empirically prescribed nitrofurantoin. Over 
the same time period, the duration of antibiotic treatment 
prescribed also improved, with increases in guideline adherent 
3-day treatment for older women and seven-day treatment for 
older men. 
 
These findings suggest a positive shift in antibiotic prescribing for UTI. 
Antibiotic stewardship campaigns and policies have encouraged a reduction 
in broad-spectrum antibiotic prescribing to reduce the impact of these 
agents on rates of antibiotic resistance. However, there is scope for further 
improvement given that around 20% of older adults in our sample received 
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a broad-spectrum antibiotic for suspected UTI. The prevalence of 
trimethoprim prescribing and the lack of change over time was an 
unexpected finding, especially given the increasing rates of trimethoprim 
resistance in the UK and concerns that sub-optimal treatment of 
trimethoprim-resistant UTIs may be a contributory factor to increasing rates 
of blood stream infections (7). The changes in antibiotic treatment duration 
were also encouraging, showing positive practice change that aligned with 
clinical guidelines and the antibiotic stewardship agenda.  
The main implication for practice is that there is potential for further 
reductions in broad-spectrum antibiotic prescribing for UTI in older adults, 
especially given that we found no associated benefit compared to 
nitrofurantoin. Implications for policy makers include greater clarity on the 
definition of “complicated” and “uncomplicated” UTI, as perceived 
complicated UTI may be a driver of broad-spectrum antibiotic prescribing 
for UTI in older people. There is also potential to increase the proportion of 
older women prescribed three-day treatment, especially as previous meta-
analyses found no clinically important differences in outcome between three 
and seven-day treatment (62). Policy makers could plan systematic 
antibiotic prescribing audit and feedback that includes choice and duration 
of prescribed antibiotics to allow practices to benchmark their prescribing 
with peers and identify specific outlying prescribing behaviours that may 
need amending. This peer-comparison intervention was found to effectively 
reduce inappropriate antibiotic prescribing for respiratory tract infections in 
a randomised trial set in primary care in the US (180). Open source data 
platforms such as openprescribing.net (https://openprescribing.net/) would 
179 
 
allow policy makers to provide such feedback quickly and inexpensively for 
all-cause antibiotic prescribing, but because these platforms have no data 
on the indication for the antibiotic prescription, other methods (such as 
CPRD data) would be required for UTI-specific prescribing. 
Future research should aim to understand why some patients still receive 
prescriptions for broad-spectrum antibiotics, and develop and test complex 
interventions that further improve prescribing behaviour. Given the volume 
of antibiotics prescribed for UTI and the threat of antimicrobial resistance, 
there is a need for randomised trials of safe and effective non-antibiotic 
treatment for UTI. To date, trials of non-steroidal anti-inflammatory drugs 
have found them to be inferior to antibiotics (99, 101, 181), and trials of other 
agents, such as uva-ursi (182), are ongoing with final results awaited.  
 
3. Patients prescribed trimethoprim had a consistently greater risk 
of hospitalisation for AKI compared to patients prescribed other 
antibiotics.  
 
The analyses in this thesis confirm previous findings of an increased risk of 
acute kidney injury following trimethoprim prescribing. Several 
observational studies found an association between trimethoprim 
prescribing and hyperkalaemia, acute kidney injury, and sudden death, first 
in patients’ co-prescribed medications affecting the renin-angiotensin 
system (81, 83, 84, 126), and more recently, in older patients irrespective 
of other prescribed medication (80). The implication of this finding for clinical 
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practice is that trimethoprim should be avoided in older people using 
medication that increases their risk of hyperkalaemia, for example, 
angiotensin-converting-enzyme inhibitors, aldosterone receptor blockers, 
potassium-sparing diuretics, and in those whose clinical presentation is 
suggestive of acute kidney injury. Implications for policy makers is to raise 
awareness amongst prescribers of this potentially serious adverse event, 
which is not mentioned in the recent NICE guideline on antimicrobial 
prescribing for UTI that recommends trimethoprim as a possible first-line 
therapy in patients at low-risk of resistance (183). Given that numerous 
studies have investigated this association, it is unlikely that further 
observational research will add significantly to the evidence base.  
 
4. Nitrofurantoin prescribing was not associated with worse 
outcomes in older people with renal impairment, and was 
actually associated with a reduction in the risk of AKI compared 
to trimethoprim. 
 
This is an important finding. Nitrofurantoin is a useful drug for UTI treatment. 
Previous research shows that only 1-2% of bacterial pathogens from UK 
community urine samples are resistant to nitrofurantoin (14), and 
nitrofurantoin-related serious adverse effects are rare (59). Concerns about 
poorer efficacy in patients with moderate or severe renal impairment led to 
warnings to avoid nitrofurantoin, resulting in prescriptions of alternate 
antibiotics. The most common antibiotic prescribed to older people with 
moderate or severe renal impairment and suspected UTI in our sample was 
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trimethoprim. However, previous research shows that 20-30% of bacterial 
pathogens from UK community urine samples are resistant to trimethoprim 
(14). Furthermore, as discussed previously, trimethoprim is associated with 
hyperkalaemia, which is more common in patients with renal impairment 
than those with normal renal function (184). Therefore, the lack of any 
evidence in our analyses to suggest reduced efficacy, the finding of a 
reduced rate of AKI hospitalisation, and the finding in previous research of 
low resistance rates, could increase healthcare professionals confidence in 
prescribing nitrofurantoin to older people with moderate or severe renal 
impairment.  Our findings highlight the need for policy makers and guideline 
developers to re-appraise and clarify the evidence around the use of 
nitrofurantoin in older people with renal impairment and further support its 
use in this population. However, a limitation of our findings is the lack of 
microbiology data in our data-source, and therefore our inability to ascertain 
associations between nitrofurantoin and resistance-related outcomes.  
 
5. Only around 20-30% of older women were prescribed the 
recommended 3-day course of antibiotic treatment for UTI, with 
40-50% receiving a prescription for ≥ 7-days. 
 
This was an unexpected finding. The clinical guideline recommendation of 
3-day antibiotic therapy for uncomplicated UTI in women is supported by 
meta-analyses of randomised trials showing similar clinical outcomes 
between women prescribed 3-day versus 7-day antibiotic therapy (62, 185). 
One meta-analysis only included randomised trials in postmenopausal 
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women (62), thus increasing generalisability to the population studied in this 
thesis. However, clinicians may have prescribed 7-day antibiotic therapy 
because of uncertainty about whether the presenting features represented 
“uncomplicated” UTI, and concern about a poor outcome with 3-day 
therapy. Further uncertainty may have arisen from some clinical guidelines 
stating that their recommendations excluded older people (19). Therefore, 
the main implication of this finding for clinical practice is to clarify definitions 
of “uncomplicated” and “complicated” UTI to reduce uncertainty, and to 
include older people in recommendations in clinical guidelines.  Future 
research efforts should aim to understand reasons for prescribing 
unnecessarily long courses of antibiotics and how best to address these to 
promote more prudent prescribing. 
 
6. 3-day antibiotic treatment in older men with suspected UTI was 
associated with an increased risk of possible treatment failure, 
but a reduced risk of AKI hospitalisation compared to 7-day 
treatment. 
 
This finding warrants further investigation. There are potential benefits for 
patients and the NHS from safe and effective shorter treatment of UTI in 
older men. It is unclear from our data whether the higher rate of re-
consultation and re-prescription amongst men receiving 3-day prescriptions 
was due to treatment failure, antibiotic side effects, or planned follow-ups. 
Furthermore, the lower rate of AKI hospitalisation amongst men receiving 
3-day prescriptions may be due to residual confounding. Given the 
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limitations of these data, this finding should not affect clinical practice. 
However, the potential benefits associated with this finding support 
justification for a randomised trial of 3 versus 7-day antibiotic therapy for 
older men presenting to primary care with a UTI. Any such trial also presents 
an opportunity to generate new evidence for other uncertainties related to 
antibiotic prescribing. For example, the trial could include a third arm and 
test the recently debated strategy of symptom guided treatment versus 3 
days versus 7 days, to see if antibiotic treatment is effective in those who 
stop once symptoms have resolved rather than completing the prescribed 
course (161). The trial could also generate new evidence on the effect of 
short versus long durations of antibiotic treatment on subsequent antibiotic 
resistance, highlighted by the National Institute of Health and Care 
Excellence as an area where further research is needed to widen 
understanding (115). 
 
7. Randomised trial evidence for the effect of long-term antibiotic 
prophylaxis for recurrent UTI in older people is limited to three 
small studies of postmenopausal women that lack data to draw 
firm conclusions about the impact of prophylaxis on UTI-related 
hospitalisations or antibiotic resistance. 
 
There is limited high quality randomised trial evidence to support the use of 
antibiotic prophylaxis for recurrent UTI in older people. Despite this, 
prophylaxis for recurrent UTI is the most common reason for antibiotic 
prescribing in care home residents (2, 3, 186). Our findings highlight 
184 
 
ongoing uncertainty around the use of antibiotic prophylaxis for recurrent 
UTI including the lack of evidence for its use in older men and the relatively 
little understanding of the impact on subsequent antibiotic resistant 
infections. The implications for clinical practice are to encourage thoughtful 
consideration of these limitations when discussing the benefits and harms 
or antibiotic prophylaxis with older people. Future research efforts should 
aim to test the effectiveness of antibiotic prophylaxis in adequately powered 
trials that include older men and care home residents, use a co-primary 
endpoint incorporating UTI recurrence rate and the acquisition of antibiotic 
resistant urinary pathogens, and consider long-term follow-up with routinely 
collected data to understand impact on rates of UTI-related hospitalisation, 
especially for bacteraemia.  
 
8. Antibiotic prophylaxis was associated with a reduced risk of UTI 
recurrence, hospitalisation, and all-cause acute antibiotic 
prescribing in older men.  
 
The study reported in chapter 9 was the first to investigate the use of 
antibiotic prophylaxis for recurrent UTI in older men. We found evidence of 
benefit that was consistent across several analyses. This study could inform 
prescribing of prophylaxis for older men, albeit with the normal caveats of 
observational data, and continued uncertainty around the impact of 
prophylaxis on antibiotic resistance.  That said, to the best of our knowledge, 
there are no other data that can be drawn upon for this clinical scenario so 
clinicians could consider antibiotic prophylaxis for select older men with a 
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clear history of recurrent UTI, following appropriate assessment for treatable 
functional or structural causes.  
10.2 Reflecting on the research in this thesis 
This thesis arose from a desire to improve antibiotic prescribing for acute 
and recurrent UTI in older people. We wanted to know whether different 
antibiotic prescription strategies affected patient outcomes. We chose to do 
this using routinely collected healthcare data because this meant we could 
address several objectives efficiently and cost-effectively with adequate 
power to study the under-researched older population.   
Two main limitations of our research were lack of microbiology data and the 
potential for residual confounding. The lack of microbiology data meant all 
comparisons were between patients with suspected UTI. Microbiology 
would have added additional value for two reasons; first, it would have 
allowed better understanding of whether patients with poor outcomes (e.g., 
death) actually had a confirmed UTI or not; second if would allowed study 
of antibiotic resistance related outcomes. Residual confounding is a key 
issue with observational data. We addressed measured confounders by 
adjusting in multivariable regression models and by matching on a 
propensity score. In the studies where we used propensity score matching, 
we achieved adequate balance of measured baseline characteristics. 
However, we were unable to address unmeasured confounders. Two 
patients with the same Read codes, may have presented with different 
symptoms and signs, had unrecorded differences in their general health, 
and therefore received different antibiotic prescriptions. Therefore, 
difference in their outcomes may have related to their general health or 
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presenting features rather than the antibiotic prescription. Potentially 
important unmeasured confounders include: 
 Vital signs (e.g., temperature, heart rate) as indicators of the clinical 
severity of the presentation. More severe presentations may have 
prompted prescribing non-recommended antibiotics (e.g., broad-
spectrum agents), and also contributed to poorer outcomes. 
 Signs of complicated UTI, such as renal angle tenderness. This again 
would reflect a more severe presentation and could affect exposure 
and outcome in the same way as abnormal vital signs. 
 Patient-reported symptom severity, again as an indicator of the 
clinical severity of presentation. 
 A measure of frailty, as an indicator of the patient’s general health. 
Frail patients may both be perceived to be at greater risk of an 
adverse outcome, and have a true greater risk of an adverse 
outcome, therefore potentially affecting the antibiotic prescribing 
decision and UTI-related outcome. 
 Time of day, as antibiotic prescribing decisions may change as the 
day progresses, consistent with the hypothesis that decision fatigue 
progressively impairs clinicians’ ability around ordering tests and 
treatments (187). 
Because of the potential for unmeasured confounding, we were careful with 
the language we used and described associations as being between 
“patients who received a prescription for X”, and the outcomes, rather than 
simply between prescription X and the outcome. We were also cautious with 
our interpretation of any findings. 
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There are potential measured confounders that were not adjusted for. We 
did not adjust for a history of recurrent UTI but this may affect antibiotic 
choice and duration and a patients risk of treatment failure. The relationship 
between antibiotic prescribing and AKI could be affected by non-steroidal 
anti-inflammatory (NSAID) medication use at the time of a UTI. We did not 
have data on over the counter NSAID use but could have adjusted for 
prescribed NSAID use. Other confounders of the relationship between 
antibiotic choice and AKI include metformin use, diarrhoea or vomiting, and 
dehydration, and these should have been appropriately adjusted for. 
Another related limitation is that based on certain definitions, age alone 
would be enough to justify treating the patients in our sample as 
“complicated UTI”, and hence prescribing outside of the recommendations. 
Therefore, we did not comment on the appropriateness (or not) of the 
prescribed antibiotics but instead focussed on the impact of the antibiotic on 
the stated outcomes. 
Given the above limitations, it is important to reflect on whether these data 
were appropriate for the objectives of this thesis. The benefits of these data 
include their size, generalisability, and reliability and completeness of 
recording of the prescriptions used as exposures in this thesis. Furthermore, 
addressing even one of the objectives of this thesis with a randomised trial 
would have been more expensive and taken longer than addressing all 
objectives using routinely collected data, especially given the huge 
challenges of recruiting and retaining older people in trials. The thesis aim 
was to generate new knowledge that could help to standardise antibiotic 
prescribing for UTI in older people and encourage more prudent prescribing, 
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and we believe that we have achieved that aim by showing, for example, 
the relative lack of benefit of broad-spectrum antibiotics compared to 
nitrofurantoin, and that avoiding nitrofurantoin in patients with renal 
impairment is unnecessary.  Therefore, these data were appropriate even 
given the limitations we have acknowledged throughout this thesis.  
Undertaking this thesis has provided several insights into the use of 
routinely collected data for research. The whole process was a huge 
learning curve that presented challenges in epidemiological research 
methods, data management and statistical programming. These data have 
huge potential but are most valuable for the right questions, for example 
estimating incidence or prevalence or comparing treatments where 
randomised trials are genuinely not feasible, or investigating drug safety. 
Although these data were an appropriate approach to the stated research, 
I quickly learnt the importance of understanding their strengths and 
weaknesses and how these affected interpretation of findings. There are 
also hugely valuable portions of CPRD data that are rarely used, for 
example, biochemical and haematological investigation results. Research 
questions that use these more objective variables are likely to be more 
appropriate for these data compared to questions that rely purely on Read 
codes, which can, at times, be subjective.  
In hindsight, two ways in which the research in this thesis could have been 
improved are: 
1. Less comparisons – for example, in chapter 5 (Associations between 
antibiotic choice and adverse outcomes), comparisons between 
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nitrofurantoin and cefalexin, ciprofloxacin and co-amoxiclav may 
have been more relevant, as these are the main broad-spectrum 
antibiotics prescribed in UK primary care and amoxicillin use for UTI 
is relatively rare. 
2. Use of additional methods to account for unmeasured confounders, 
for example instrumental variable analysis. Finding a suitable 
instrument would have been challenging for some analyses but 
possible for others, for example in chapter 5, prior antibiotic 
prescription for UTI could have been used as a proxy instrument for 
physician prescribing preference. 
10.3 Concluding remarks 
This thesis presents new evidence on the burden and antibiotic 
management of acute and recurrent UTI in older people in UK primary care. 
Our findings have potential to contribute to better prescribing and the 
antimicrobial stewardship agenda and ultimately result in better outcomes 
for patients. Antibiotic prescribing for UTI has received far less attention 
than antibiotic prescribing for respiratory tract infection and this is 
highlighted by the observed reductions in prescribing for respiratory tract 
infections, compared with little change in prescribing for UTI (14). To 
improve the diagnosis and management of UTI in older people in the 
antibiotic stewardship era, we need better understanding of what clinical 
and microbiological features define a UTI, a better gold standard diagnostic 
test, trials of different prescription strategies and different non-antibiotic 
treatments, and a better understanding of the prognosis of UTI including the 
impact of UTI and the related inflammatory response on non-infectious 
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events.  The research in this thesis, and the related peer-reviewed 
publications could serve as a stimulus for generating interest and funding 
for further work in this under-researched condition and population.    
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